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ABSTRACT 
Background 
One of the greatest challenges for the development of an effective HIV-1 vaccine is the high 
genetic diversity of this pathogen and the complex escape mechanisms employed by the 
envelope gp120 and gp41 glycoprotein that form the envelope spike. An ideal vaccine would 
elicit the production of broadly neutralizing antibodies (nAb), capable of having potent 
activity against worldwide viral isolates. This thesis encompasses a series of studies on 
characterizing the genetic diversity of envelope genes of subtype G and the neutralization 
antibody responses to these viruses. HIV-1 subtype G accounts for 5% of HIV-1 infection 
worldwide, centered on West Africa, with spread to European countries, primarily Spain and 
Portugal, presumably with immigration of infected individuals. Small satellite subtype G 
epidemics have been documented in Cuba and among Russian intravenous drug users. In 
addition, 80% of the recombinant strains circulating in Cameroon contain segments attributed 
to subtype G. However, until recently, little research has been done on the neutralization 
sensitivity and vulnerabilities of subtype G viruses, particularly those that circulate in its main 
reservoir, Central and West Africa.  
Methods and Objectives 
We studied plasma derived viruses from eight HIV-1 subtype G infected individuals. Five 
samples were collected for donation by the Yaoundé Central Hospital Blood Service from 
individuals who were subsequently found to be HIV-infected. Presumably, these donors were 
unaware of their HIV status. The remaining three samples were collected at the CIRCB 
Research Institute in Yaoundé during testing for antiretroviral resistance. These donors were 
failing therapy, and had sufficiently high viral loads that HIV-1 envelope clones could be 
isolated. 
The objectives of my thesis were: 1) to examine the molecular and functional characteristics 
of the HIV-1 envelope glycoproteins of subtype G viral variants which is crucial to improving 
strategies to prevent transmission; 2) to evaluate the neutralization sensitivity subtype G 
viruses and the neutralizing capacities of antibodies induced by the viruses by determining the 
neutralization antibodies titers against autologous and heterologous HIV-1 viral isolates; 3) to 
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characterize the sensitivity of HIV-1 subtype G viral isolates against  broadly neutralizing 
antibodies, to gain insight into the neutralization vulnerabilities of the subtype G viruses. 
Results and Discussion 
Using the single genome amplification technique (SGA), we characterized 42 full length 
envelope genes (Chapter two) who had been typed subtype G for gag and nef or for pol. We 
found that all our envelope sequences clustered within the expected subtype G and were 
apparently not recombinants. The sequences from our donors were highly diverse within the 
subtype G node of sequences: Sequences from three individuals grouped with sequences 
predominantly from Nigeria with few from Spain and Cameroon, sequences from three other 
individuals fell into a cluster comprising only sequences from Cameroon, that themselves 
appears linked to a major cluster of most of the sequences collected in Europe and Cuba. 
Sequences from two individuals clustered from near the root of the subtype G subtree in a 
poorly populated branch with reference virus from Cameroon, Kenya, Russia, and 
CRF06_cpx. 
The median intra-patient genetic distance samples was high (> 1.5%) in 4 out of 8 subjects, 
including all three patients failing ART Therapy and low (<1.5%) in the naïve ART patients 
perhaps because subjects with higher genetic distance may be infected for a longer period. 
There was a variation in the number and location of Potential N-linked glycosylation sites 
(PNGS) as well as variable domain amino acid lengths between clones. In general, our 
subtype G clones exhibit a shorter V1V2 and V4 region sequences compared to the well 
characterized subtype B. All envelope clones exhibited CCR5 co-receptor usage as measured 
by inhibition of invasion of pseudoviruses by CCR5 binding inhibitor TAK-779. This is 
consistent with the predictions made by web PSSM and geno2pheno. This suggests that 
CCR5 inhibitors may be useful for treatment for subtype G-infected individuals. However, 
conclusions about CCR5.based treatment approaches in West and Central Africa will have to 
also account for more such data from other subtypes that are prevalent in that region, 
In chapter three, we characterized the neutralization sensitivity of subtype G pseudoviruses to 
autologous neutralization (own plasma), and plasma pools. Of particular note, all four 
BS12.derived viruses exhibited substantial sensitivity to neutralization by their own plasma 
(geometric mean ID50= 564). Autologous neutralization from a contemporaneous sample is 
rarely seen, and its significance in study participant BS12 is unclear. We cannot measure virus 
Abstract Page xvii 
 
and anti-HIV-1 antibody evolution in this donor because this donor was an anonymous blood 
bank donor and no subsequent samples can be collected.   
We next evaluated the ability of subtype G plasma to neutralize a panel of 14 HIV-1 env 
pseudoviruses comprising representatives of subtypes A, B, C, and CRF02_AG which were 
from tier 2 (moderately resistant viruses) to tier 3 (highly resistant viruses). Three of the 
samples were from patients undergoing testing for antiretroviral resistance, and thus may have 
antiretroviral drugs in their blood plasma despite having detectable viral loads. However, 
plasma from two of these three patients failed to neutralize negative control pseudovirus 
(Murine Leukemia Virus envelope, MLV) or most other viruses tested, suggesting that levels 
of antiretroviral drugs in these two samples were too low to interfere with the neutralization 
assay. It may be that these donors were not taking their antiretroviral. One donor may have 
antiretroviral drugs in the plasma, and was excluded from the analysis. Blood plasma from 
two out of the remaining seven study participants, including BS12, neutralized more than 
50% of panel virus tested at ID50>50, indicating at least limited neutralization breadth in these 
two samples. Interestingly, BS12 serum, the samples that showed a substantial potent 
autologous activity, also neutralized 3/5 of the tier 3 isolates from the panel viruses (278-50 
and 257-31 not neutralized; 33-7, 253-11, and PV0.4 neutralized). Mapping of the epitope 
targeted by neutralizing antibodies in BS12 plasma indicated that the dominant neutralizing 
antibody for virus CAP45.2.00.G3 in sample BS12 targeted the PG9/16 site. This site is the 
target in the V2 and V3 regions of the mAbs PG9 and PG16. However, these viruses were not 
unusually sensitive to the PG9 and PG16 monoclonal antibodies themselves. BS12 plasma 
also exhibited substantial neutralization of an HIV-2 chimeric virus displaying the MPER of 
253-11, a CRF02_AG virus, although we did not examine if these anti-MPER antibodies are 
capable of neutralizing HIV-1 viruses by recognizing MPER.  
We further characterized (chapter four) the susceptibility of these viruses to neutralization by 
a panel of eleven (11) first and second-generation of broadly neutralizing monoclonal 
antibodies, and three HIV-1 entry inhibitors: TAK-779, a CCR5 inhibitor, soluble CD4 
(sCD4), and T20, a fusion inhibitor. We found that subtype G viruses were highly sensitive to 
the CD4-binding site mAbs NIH45–46G54W and VRC01 as well as MPER mAb 10E8, 
neutralizing all (100%) viral variants. In addition, subtype G viruses showed sensitivity to 
4E10 which was able to neutralized 25 of 27 (92%) of viruses and median IC50 of 0.42ug/ml.  
These viruses were more sensitive to 4E10 than a large panel of worldwide viruses published 
Abstract Page xviii 
 
last year (IC50=1.93ug/ml) and of all subtype G viruses with published sensitivity to 4E10 
(median IC50 =17ug/ml). However, neutralization by the mAbs B12, 2G12, Z13e1 was 
generally poor, while 2F5, PG16, PG9 and VRC03 have moderate activity neutralizing 42%, 
65%, 27%, and 50% of viral variants respectively. Subtype G viruses were highly sensitive to 
TAK-779 and T20 but exhibit more variable sensitivity to sCD4, a phenotype that have been 
observed frequently among freshly isolated viruses because sensitivity to sCD4 protein is 
thought to be associated with exposure of the CD4 binding site. 
Conclusion 
Although there are more than 100 subtype G env sequences in the database, some of our 
sequences showed relatively poor similarity to them. This suggests that the full extent of the 
diversity of Subtype G has not yet been described, and provides additional evidence for the 
hypothesis that subtype G itself may be very old. Within patient diversity corresponded to 
other measures of time since infection. One sample, BS12, was unusual in that the plasma 
sample itself neutralized viruses derived from sequences found in the same sample. Despite 
the mapping hit in BS12 plasma for PG9/PG16 site antibodies against CAP45.2.00.G3, BS12 
derived viruses were not highly sensitive to neutralization against PG9 and PG16. Moreover, 
these viruses were not more sensitive to PG9 and PG16 compared to other viruses. This group 
of subtype G viruses could also be useful for screening T20 and CCR5 inhibitors that are 
being tested as potential microbicides in regions where HIV-1 subtype G predominate. In that 
regard, the relative sensitivity of the viruses examined here to T20 and CCR5 inhibitors is 
encouraging, because freshly isolated viruses will be a critical target for such interventions. 
Last, our characterization of these viruses added detailed information about subtype G, which 
is historically understudied. 
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1. 1 Background 
1.1.1 HIV-1 and the global AIDS pandemic 
The first cases of patients with the acquired immunodeficiency syndrome (AIDS) were 
reported in 1981 in the United States following the observation of opportunistic infections 
that usually occur in strongly immune compromised individuals (Hymes et al., 1981). AIDS is 
caused by infection with Human Immunodeficiency Virus.1 (HIV-1) (Barre-Sinoussi et al., 
1983), and also by HIV-2 (Clavel et al., 1986). AIDS is characterized by a failure of the 
immune system permitting the emergence of any of a variety of opportunistic infections that 
may kill the patient. The transmission of HIV can occur through sexual contact by 
unprotected vaginal, oral or anal intercourse with HIV-1 infected individuals (CDC, 2003), 
through blood transfusion or exposure to HIV-contaminated needles, syringes, and other 
equipment(CDC, 2003), or through mother-to-child transmission (MTCT) during pregnancy, 
labor and delivery, or breastfeeding (McGowan and Shah, 2000). 
HIV infects dendritic cells, macrophages, and CD4
+
 T cells of the immune system (Alimonti 
et al., 2003). During HIV infection, the number of CD4 T cells progressively declines.  When 
the CD4 count falls below 200/mm
3
, the person infected with HIV become vulnerable to 
opportunistic infections caused by bacteria, viruses, fungi and parasites that are normally 
controlled by the immune system (Holmes et al., 2003) .  
Since the discovery in 1983 by the team of Françoise Barré-Sinoussi and Luc Montagnier 
(Pasteur Institute, Paris, and all the two Nobel Prize for Medicine 2008) of the human 
immunodeficiency virus of type I (HIV-1), the scientific community has been mobilized to 
implement a large number of research programs to fight against that disease. Despite 
significant scientific progress such as the development of reliable diagnostic tests, sequencing 
of thousands of viral genomes and the development of highly active antiretroviral therapy 
(HAART), HIV-1 has continued to spread largely unabated. Importantly, the global 
prevalence of HIV infection seems to have been stable since around the end of the 20
 th
 
century (figure 1.1). 
In 2011, UNAIDS and WHO estimated that there were approximately 34 million people 
living with HIV with over 2.5 million people who became infected with HIV-1 and 1.7 
million people who died from HIV (WHO, 2013). The majority of people living with HIV 
live in developing countries. Sub-Saharan Africa supports the greater part of the burden of the 
global epidemic, accounting for 69% of the people living with HIV worldwide (figure 1.2). In 
South and South East Asia, the spread is high with almost 5 million people estimated living 
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with the disease. After Sub-Saharan Africa, regions most heavily affected are the Caribbean, 
Eastern Europe and Central Asia, where 1% of adults were living with HIV in 
2011(UNAIDS, 2012).  
1.1.1.1 HIV in Sub-Saharan Africa 
In Africa, Sub-Saharan Africa is the most affected region in the global AIDS epidemic with 
25% of new infections in 2011 and 70% of all deaths due to AIDS (WHO, 2013). In Southern 
Africa, the prevalence of HIV infection in the general population exceeds 15% and South 
Africa alone has more than 10% of the general population infected with HIV. 
In Cameroon, the HIV prevalence rate is estimated at 5.1%, the highest rate for the West and 
Central Africa Sub-region (NACC/CTG, 2010). The prevalence is higher in urban areas than 
in rural areas and prevalence rates vary from one province to another with highest rates in the 
North-Western, Eastern provinces, and Yaoundé (figure 1.3). HIV transmission is mainly 
heterosexual, and women are more vulnerable. The most vulnerable groups include sex 
workers, truck drivers, mobile populations and military personnel (NACC/CTG, 2010).  
The development of antiretroviral drugs targeting the viral enzymes reverse transcriptase and 
protease, the use of combination of inhibitors targeting these enzymes, and the development 
of new antiretroviral agents targeting not only these two enzymes but novel targets as well 
helped to significantly improve the conditions of life of the HIV-infected individuals, and 
especially to increase their life expectancy (Reeves and Piefer, 2005). However, due to 
poverty-related barriers, access to antiretroviral therapy remains limited in Africa and an 
effective vaccine is hoped to be a practical and cost effective intervention to control the 
spread of the HIV/AIDS pandemic.  
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Figure1.1: Estimated number of people living with HIV globally during 1990.2011. (Figure from 
UNAIDS, 2011) 
 
 
 
 
 
 
 
 
 
Figure1.2: Estimated number of adults and children to be living with HIV in 2011. (Figure from 
WHO, 2013) 
 
 
 
 
 
 
 
 
 
Figure1.3: Adult HIV prevalence by region in Cameroon. (Figure from NACC/CTG, 2010) 
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1.1.2 HIV-1 structure, genome organisation and replication cycle 
1.1.2.1 Viral structure 
HIV-1 is a lentivirus belonging to the retroviridae family. A common feature of all 
retroviruses is that they synthesize DNA from their RNA genome via the reverse transcriptase 
enzyme. The mature HIV virion, as illustrated in figure 1.4, is roughly spherical with a 
diameter of around 120 nanometer (nm). The virion is composed of two identical copies of 
positive single.strand RNA together with the  reverse transcriptase (RT), integrase (IN), 
RNase H and protease (PR) enzymes encapsulated within the viral core (CA; p24), which is 
enclosed within the matrix (MA; p17) (Leis, Baltimore et al. 1988). The HIV virion is 
enveloped by a lipid bilayer that is derived from the membranes of the host cell, into which 
the gp41 is embedded, which noncovalently anchors the gp120 in a trimer of heterodimers. 
 
 
 
 
 
 
 
 
 
 
Figure1.4 : Schematic representation of a mature HIV-1 virion illustrating major viral 
components. Figure from http://commons.wikimedia.org/wiki/File:HIV_Virion.en.png (active April 
2009). 
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Figure1.5: Organization and landmarks of the HIV-1 DNA genome. Open reading frames are 
shown as rectangles. The gene start is indicated by number in the upper left corner of each rectangle 
(ATG start codon). The number in the lower right indicates the position of the stop codon. The tat and 
rev spliced exons are shown in dark grey and grey, respectively. The numbering positions in relative to 
HXB2 strain. (Figure from Los Alamos National Library 
http://www.hiv.lanl.gov/content/sequence/HIV/MAP/landmark.html). 
 
1.1.2.2 Genome organisation 
HIV-1virus consists of three structural genes: gag, pol, and env with flanking long terminal 
repeat (LTR) sequences at each end of the genome. In addition, HIV possesses regulatory 
genes (tat, rev), and accessory genes (vif, vpr, vpu, and nef). The organization and landmarks 
of HIV-1 genome is shown in figure 1.5. 
The gag codes for the internal structural proteins of the virus: matrix (MA, p17), capsid (CA, 
p24), and nucleocapsid (NC, p7). pol codes for the viral enzymes: reverse transcriptase (RT), 
which contains both DNA polymerase and associated ribonuclease H (RNase H) activity, 
integrase (IN), and protease (PR) (Coffin, 1990). env codes for viral envelope glycoproteins 
as a precursor (gp160), which is then processed to a surface glycoprotein, gp120 and a trans-
membrane glycoprotein, gp41. The mature gp120.gp41 proteins are bound by non-covalent 
interactions and are associated as a trimer on the surface of virions. The envelope (Env) 
protein is responsible for recognition of cellular receptors and viral entry into cells. 
The regulatory genes are tat and rev. They modulate transcriptional and post-transcriptional 
steps of virus gene expression and are essential for virus propagation. Tat acts by binding to 
the trans-activation response (TAR) RNA element and activates transcription initiation and 
elongation from the LTR promoter (Roy et al., 1990). Rev acts by binding to Rev response 
element (RRE) and promotes the nuclear export, stabilization, and utilization of the viral 
mRNAs containing RRE (Pollard and Malim, 1998). RRE is located at position 7709-8063 
within the Env coding region of HIV-1 (Cullen, 2003). 
The accessory genes are vif, vpr, vpu, and nef. They are called accessory genes because they 
not always required for viral infection in in vitro cell culture systems. Instead, these proteins 
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enable pathogenesis in vivo by allowing viruses to evade antiviral responses (Collins and 
Collins, 2014). 
Virion infectivity factor (Vif) a 23 kDa accessory protein found in HIV-1 and other 
retroviruses is essential for viral replication either in vivo or in culture for nonpermissive cells 
such as peripheral blood lymphoid cells, macrophages, and H9 T cells (Zhang et al., 2000). 
Vif inactivates the antiretroviral activity of the host APOBEC3 (Apo-lipoprotein B mRNA-
editing enzyme, catalytic polypeptide) cytidine deaminases, including APOBEC3G (A3G) 
and A3F (Chiu and Greene, 2008, Goila-Gaur and Strebel, 2008). APOBEC3G is a human 
enzyme encoded by the APOBEC3G gene that belongs to the APOBEC superfamily of 
proteins (Sheehy et al., 2002). This family of protein has been suggested to play an important 
role in innate anti-viral immunity (Takaori, 2005). A3G (Sheehy et al., 2002) and related 
human APOBEC3 proteins are potent inhibitors of HIV-1 in the absence of viral Vif. 
APOBEC.3G exerts its antiviral effect during reverse transcription to trigger G-to-A hyper-
mutation in the nascent retroviral DNA (Mangeat et al., 2003). Vif hijacks the cellular Cullin5 
E3 ubiquitin ligase, which is composed of ElonginB, ElonginC, Cullin5, and Rbx2 (Stanley et 
al., 2008), in order to target APOBEC3G for degradation. 
Viral protein R (Vpr) is a 14 kDa protein. Vpr plays an important role in regulating nuclear 
import of the HIV-1 pre-integration complex, and is required for virus replication in non-
dividing cells such as macrophages (Miller and Sarver, 1997).Vpr also accelerates the 
production of HIV proteins by arresting infected cells at the G2 phase of the cell cycle, 
inhibiting cell division by mitosis (Kim et al., 2012).  Viral protein U (Vpu) is a 17kDa 
protein which is not present in HIV-2, is involved in the assembly of new virus particles and 
facilitates budding (Deora and Ratner, 2001). The formation of Env-CD4 complexes 
interferes with viral assembly. Vpu down-modulates CD4 in the endoplasmic reticulum 
therefore reducing the likelihood of superinfection and is also involved in Env maturation. 
This reduces the formation of the Env-CD4 complexes (Estrabaud et al., 2007). 
Nef is a small 27–35 kDa myristoylated protein encoded in the genomes of primate 
lentiviruses (HIV-1, HIV-2 and SIV). Nef  localizes primarily to the cytoplasm of infected 
cells and is partially recruited to cellular membranes and expressed from the earliest stage of 
viral  gene expression (Fackler and Baur, 2002). Nef reduces cell surface expression of  
receptors, including CD4, the primary receptor for HIV and SIV and MHC class I and class II 
complex, facilitating HIV immune evasion and thus increases viral pathogenesis (Fackler and 
Baur, 2002). Nef retards HIV replication by downregulation of transcription factors natural 
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factor kappa B (NF-kB) and activator protein one (AP-1) (Abraham et al., 2012). Nef also 
induces downregulation of CD4, the primary receptor for HIV and SIV and MHC class I and 
class II complex which impairs T cell function, thereby facilitating HIV immune evasion and 
thus increases viral pathogenesis (Fackler and Baur, 2002). 
Vpx is found in HIV-2, but not in HIV-1. This accessory gene is a homolog of HIV-1 vpr, 
both are incorporated into virions at levels comparable to gag proteins through interactions 
with Gag p6. Vpx enhances HIV-2 replication in humans by counteracting the host factor 
SAMHD1 (SAM domain and HD domain-containing protein 1) (Laguette et al., 2012). Vpx-
mediated degradation of SAMHD1 therefore decreases deoxynucleoside triphosphate 
hydrolysis, thereby increasing the availability of dNTPs for viral reverse transcription in the 
cytoplasm. Vpx is also involved in the nuclear import of the HIV-2/SIV genomes and 
associated proteins (Bouzar et al., 2003), but the specific mechanisms and interactions are 
currently unknown. 
1.1.2.3 Replication cycle 
The life cycle of HIV can be described in different phases. Figure 1.6 graphically depicts the 
events described below: 
 Virus entry (binding and fusion) 
Entry is the first step in the process of HIV infection and requires binding of HIV gp120 to 
host cells expressing CD4 with extremely high affinity (Hladik and McElrath, 2008). This 
results in conformational changes in gp120, which then exposes co-receptor binding sites. The 
co-receptors required for entry of HIV-1 are CCR5 and CXCR4, depending on the viral 
tropism. Immediately following gp120 and co-receptor binding, further conformational 
changes take place in gp41, which allows it to expose of the fusion peptide. The fusion 
peptide is inserted into the target cell membrane. 
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Figure1.6: Schematic representation of the life cycle of HIV. (Figure from 
http://www.niaid.nih.gov/topics/HIVAIDS/Understanding/Biology/pages/hivreplicationcycle.aspx) 
 
 
 Reverse transcription 
Following membrane fusion the virus core enters and uncoats into the cytoplasm of the target 
cell. The virus RNA genomes are converted into double-stranded DNA. Reverse transcriptase 
has two distinct enzymatic activities: it is a DNA polymerase capable of copying either RNA 
or a DNA template into a complementary DNA sequence; and it is an RNase H, capable of 
degrading the RNA strand of an RNA.DNA duplex into small pieces once it has been used as 
a template for the first DNA strand (Arnold and Sarafianos, 2008). The reverse transcription 
is initiated and viral RNA is converted into proviral DNA by the action of reverse 
transcriptase, followed by the generation of a DNA/RNA hybrid. The template RNA is 
degraded by the RNase H activity, generating a DNA fragment known as the minus-strand 
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strong stop DNA (-sssDNA). The identical sequences known as the repeated (R) sequences 
mediated the -sssDNA jumps from 5’ to the 3’end of the genome. This step is referred to as 
the first strand transfer. Minus-strand DNA synthesis occurs, using 3’end of the -sssDNA as a 
primer, accompanied by RNase H digestion of the template strand. This degradation is not 
complete, because the RNA genome contains a short polypurine tract (PPT) that is relatively 
resistant to RNase H degradation. The PPT serves as a primer for plus-strand DNA synthesis. 
A central PPT serves as an additional primer for plus strand DNA synthesis. The tRNA bound 
to the PBS is removed by RNase H, allowing a second-strand transfer of plus-strand strong 
stop DNA (+sssDNA) to take place between PBS sequences. Elongation continues along both 
DNA strands. A central termination signal (CTS) located at 3’ of the central PPT allows 
termination of plus strand DNA synthesis in the center, resulting in the formation of a DNA 
flap. The final product is a double stranded (ds) HIV-1 proviral DNA that contains the long 
terminal repeats (LTRs), U3-R-U5 sequences, at both end. This entire process utilizes only 
the virion-associated RT without host enzyme. 
 Integration 
The integration of HIV DNA into the host DNA is a critical step in the HIV life cycle. HIV’s 
enzyme for inserting the DNA version of its genome into the host cell DNA is called integrase 
(IN). HIV-1 integrase catalyzes the “cut-and-paste” action of clipping the host DNA and 
joining the proviral genome to the clipped ends. The first step of the integration process 
occurs in the cytoplasm of the host cell following the completion of reverse transcription of 
the HIV RNA into cDNA. This step involves the binding of integrase most likely in the dimer 
form to each end of the newly formed HIV cDNA. The integration process begins when IN 
clips off several nucleotides from the 3’termini of both strands of linear viral DNA. This 
reaction, known as 3’-end processing, generates a molecule of DNA with 3’-recessed ends. 
The preintegration complex is transported into the nucleus of the host cell, entering through 
one of the nuclear pore complexes. This nuclear translocation occurs despite the 
preintegration complex having a size that is more than twice the size of the central channel of 
the nuclear pore complex. In the nucleus, IN makes a staggered cleavage in the cellular target 
DNA. The 3’-recessed ends of viral DNA formed in the 3’end processing reaction are joined 
to the ends of the cleaved cellular DNA. This reaction is known as strand transfer. The sites 
for integration into cellular DNA are random. The integration process is completed when 
cellular repair enzymes fill in the gaps between the integrated viral DNA and the host target 
DNA.  
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 Transcription 
Regulation of HIV gene expression involves a complex interplay between chromatin-
associated proviral DNA, cellular transcription factors and the viral encoded trans-activator of 
transcription, Tat. The process of viral transcription can be divided into two distinct phases 
(Wu, 2004). The first phase occurs early in transcription and is mediated by direct interaction 
between cellular transcription factors and cis-acting elements located in the HIV promoter 
region. The second phase immediately follows the first one, and relies on the accumulation of 
sufficient amounts of Tat from the first phase (Jordan et al., 2003) . Following integration, the 
HIV promoter is under the control of local chromatin environment, which determines the 
basal transcriptional activity. Independent of the site of integration, HIV 5' LTR is assembled 
into three unique nucleosomes: nuc-0, -1 and -2. Nuc-1 is positioned immediately 
downstream of the transcription start site (Steger and Workman, 1997), and is rapidly 
disrupted upon transcriptional activation of the HIV-1 promoter. Interestingly, the region 
between nuc-0 and 1 appears to remain nucleosome-free although it is large enough to 
accommodate an additional nucleosome. The viral core or basal promoter (nt -78 to -1) 
contains a TATAA box and three consensus SP1 binding sites. The enhancer (nt -105 to -79) 
carries a duplication of the 10-bp NF-kB binding sites. Regions upstream from the NF-kB 
sites also influence viral gene expression and are designated the modulatory region (-454 to -
104). This region has been proposed to contain a negative regulatory element (NRE). 
Sequences near the RNA initiation site also contain regulatory elements such as the putative 
inducer of short transcripts (IST) (Sheldon et al., 1993, Ratnasabapathy et al., 1990), the 
initiator and the trans-activation response (TAR) element (nt +1 to +60) which interacts with 
Tat and plays an important role in Tat mediated trans-activation. In the absence of Tat and 
cellular stimulation, the nucleosome packed LTR is almost silent. Low levels of transcription 
are mediated by available cellular transcription factors. Efficient activation of the LTR 
promoter is largely driven by Tat, and is concomitant with an acetylation-dependent 
rearrangement of the nucleosome positioned at the viral transcription start site (Jordan et al., 
2003, Jordan et al., 2001). Additionally, Tat appears to be able to directly interact with some 
transcription factors such as Sp1 (Jeang et al., 1993) to promote transcription. One unique 
feature of Tat mediated trans-activation is the ability of Tat to interact with RNA rather than 
with DNA (Berkhout et al., 1989). This interaction occurs specifically between Tat and a 
specific 59-residue stem-loop structure, TAR, on the RNA leader sequence. In general, the 
current model suggests that Tat causes a dramatic increase in transcriptional levels upon 
binding to TAR. Successful transcription leads to the generation of approximately 30 different 
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viral transcripts from the provirus. All these transcripts are derived from a single full-length 
transcript by alternative splicing, which generates mRNA with common 5' and 3' ends. The 
spliced viral RNA can be grouped into three classes: the multiply spliced mRNA encoding 
early regulatory proteins such as Tat, Nef and Rev; the singly spliced mRNA encoding Vpu, 
Vpr, Vif and Env; the un-spliced, full-length mRNA encoding the Gag-Pol poly protein. HIV 
gene expression is also regulated at a second level by the nuclear export of intron-containing 
transcripts. This process is mediated by the viral encoded Rev protein. Specific interaction 
between REV and RRE permits nuclear export of incompletely spliced viral transcripts in 
infected cells (Malim et al., 1989). 
 Viral assembly, maturation and release  
The HIV Env glycoprotein is synthesized in the rough endoplasmic reticulum (ER) to 
generate the Env precursor protein, gp160 and then transported to the golgi complex, where it 
is cleaved by a host protease (furin) into gp120 and gp41. The Env protein is incorporated in 
the plasma membrane of the cell, while Gag and Gag-Pol are assembling into capsids in the 
cytoplasm. The viral RNA genomes bound by p7 Gag product form a nucleoprotein complex. 
The newly formed nucleoprotein particle migrates to the plasma membrane at the site of Env 
insertion, since each particle has two viral RNA with associated Gag and Gag-Pol precursors. 
Immature virus particles then are assembled at the plasma membrane and are released by 
budding through the plasma membrane, acquiring a portion of the plasma membrane that 
contains gp41 and gp120. Pol, the protease, and the Gag proteins are generated by proteolytic 
cleavage of the precursor polypeptides upon release of the particles from the cell, thereby 
producing mature virus particles. HIV-1 budding and release are essential for spreading viral 
infection, and it is therefore not surprising that innate immune pathways have evolved to 
interfere with these processes. It is now well established that the antiviral protein tetherin 
blocks HIV-1 dissemination by tethering newly budded viral particles to the cell surface (Neil 
et al., 2008). In the absence of Vpu, and the presence of tetherin, HIV-1 particles are 
assembled normally, their lipid envelopes undergo endosomal sorting complexes required for 
transport (ESCRT)-protein-mediated fission from the plasma membrane, and they adopt a 
mature morphology. However, tetherin causes virions to remain trapped at the surface of the 
infected cell from which they are derived and to accumulate thereafter in endosomes 
following internalization (Neil et al., 2006). The HIV-1 Vpu protein is used by HIV-1 strains 
as an antagonist of tetherin by causing cytoplasmic tail domain-dependent sequestration into 
internal compartment and causing downregulation and degradation in only a subset of cell 
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types, even though all cells tested support Vpu activity (Neil et al., 2008, Van Damme et al., 
2008). 
1.2 HIV envelope glycoproteins 
HIV-1 Env glycoproteins are assembled as Env spikes. They are responsible for interacting 
with cellular receptors and initiating the fusion of the viral and cell membranes, and therefore 
are a potential target for drugs aimed at blocking the first step of the viral replication cycle. 
Furthermore, HIV-1 Env spikes are the only viral target available for neutralizing antibodies. 
The functional envelope spike consists of a trimer of heterodimers formed by two 
glycoproteins, gp120 (the exterior envelope glycoprotein) and gp41 (the transmembrane 
glycoprotein). Three gp120 molecules interact non-covalently with three gp41 units forming 
an oligomer, where the trimeric structure is maintained by the interactions between the gp41 
domains.  
1.2.1 The gp120 molecule 
1.2.1.1 Structural domains of gp120 
The gp120 molecule (figure 1.7) consists of five relatively conserved regions (C1.C5), 
interspersed between five variable regions (V1.V5), which are bracketed by cysteine forming 
disulfide bonds (Leonard et al., 1990). Gp120 is a highly glycosylated protein with half of its 
mass being N-linked glycans (Allan et al., 1985) with a small proportion being O-linked 
sugars (Bernstein et al., 1994). X.ray crystallography has solved a certain number of gp120 
structures (Checkley et al., 2011). To obtain crystal structures that diffracted with sufficient 
resolution, HIV-1 and SIV gp120s have been deglycosylated and the N. and C terminals, 
V1/V2 and V3 regions deleted, to generate what is commonly referred to as the “gp120 core” 
(Kwong et al., 1998). The final deglycosylated ΔV3, ΔV1.V2 gp120 core retains 67% of the 
envelope amino acid content of the full-length molecule and has a molecular weight of 35 
kDa. The gp120 core is composed of three general areas: the inner domain, the outer domain, 
and the bridging sheet (figure 1.8). The inner domain is formed mainly by the C1 and C5 
regions which interact with the gp41 trans-membrane unit (Helseth et al., 1991). The inner 
domain surface is devoid of glycosylation (Wyatt et al., 1998). The outer domain is heavily 
glycosylated to shield its antigenic surface, protecting it from antibody recognition. The 
proximal end of the outer domain includes V4 and V5 variable loops, whereas the distal end 
includes the base of the excised V3 loop, which interacts through hydrogen-bonds with the 
V1/V2 stem emanating from the inner domain. In between the outer and inner domains is the 
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bridging sheet region, formed by four antiparallel β-sheets: β2 and β3, which constitute the 
stem of the deleted V1/V2 loop; and the β20 and β21 of the C4 region.  
Many studies have provided information on the structure and the mechanisms by which the 
gp120 interacts with the CD4 and co-receptor, the gp41, as well as neutralizing antibodies. 
These studies include the simian immunodeficiency virus (SIV) “unliganded” gp120 (not 
bound to CD4). This unliganded gp120 structure is presumed to represent the native state 
conformation (Chen et al., 2005). In contrast to the outer domain, which has a similar 
conformation as the liganded form, the inner domain and the bridging sheet revealed a much 
altered structure, suggesting that binding of CD4 induces radical conformational changes in 
these regions. A third gp120 structure was resolved using an HIV-1 gp120 core that included 
the V3 loop, bound to CD4 and the X5 antibody (Huang et al., 2005). More recently, other 
gp120 structures include: the gp120 core stabilized in the CD4 bound state associated with a 
CD4 binding site specific neutralizing antibody (Zhou et al., 2007), the gp120 core in 
complex with two CD4 binding site antibodies F105 and b13 (Chen et al., 2009), and the 
gp120 core bound to the gp120.interacting portion of gp41(Pancera et al., 2010). 
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Figure1.7: Organization of gp120 in linear and two-dimensional diagrams. A) Linear 
representation of the structure of HIV-1 envelope. The gp120 and gp41 domains are indicated in blue 
and violet boxes, respectively. N-linked glycosylation sites are indicated by U-shaped branches. B) 
The gp120 core protein that was crystallized (red). It corresponds to the almost entire gp120 that was 
deleted of the V1.V2 and V3 regions (adapted from Chen et al 2005). C) Diagram of the structure of 
HIV-1 gp120 envelope glycoprotein. The gp120 molecule with the location of the variable regions 
indicated in boxes (V1.V5). The glycosylation sites containing high mannose-type and/or hybrid-type 
oligosaccharide structures are indicated by the branched structures, and glycosylation sites containing 
complex-type oligosaccharide structures are indicated by the U-shaped branches. Epitopes in gp120 
that induce neutralizing antibodies are highlighted in color: the highly conformational CD4-binding 
domain (yellow), the CD4.induced epitope (green), an epitope composed of α1→2 mannose residues 
(purple), the V2 loop (orange) and the V3 loop (blue). [Figure from (Zolla-Pazner, 2004)].  
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Figure1.8: HIV-1 gp120 and gp41 structures. (a) Ribbon diagram of gp120 core containing α-
helices (α1–α5), β-strands (1–25), with relative positions of variable loops (V1–V5) and N. and C-
termini shown. The orientation of gp120 in this diagram places the viral membrane toward the top and 
the cell membrane toward the bottom. When gp120 is bound to CD4, it forms a bridging sheet 
consisting of four β-strands, which separates the inner and outer domains of gp120 relative to their 
orientation in the trimeric complex. (b) Ribbon diagram of gp120 core [as in (a)] with N-terminus 
(red) and gp41 interaction site (blue) shown. The inner domain is shown in red and gray, and the outer 
domain is shown in orange. The bridging sheet, which shares elements from both inner and outer 
domains, is in gray and orange. (c) Trimeric gp120 [same colors as in (b)] bound to three molecules of 
CD4 (yellow) and Fab from neutralizing antibody 17b (brown), used to stabilize the gp120 structure, 
superimposed onto the electron density observed by cryoelectron tomography (light gray). The 
orientation of this structure that is rotated 90°, which places the viral membrane in the plane of the 
page, is also shown on the right. (d) Three-dimensional representation of HIV-1 Env in its CD4.bound 
conformation. (Left) A trimeric Env spike (blue) anchored in the lipid bilayer of the viral membrane 
(gray) is shown. The white arrow indicates the predicted location of gp41. (Right) Ribbon diagram of 
the gp120 core (red) superimposed on the density map (blue) with the V1/V2 loop (yellow) and the V3 
loop (green) shown. (Figure from Checkley et al., 2011). 
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1.2.1.2 Functional sites of gp120 
 CD4 binding site (CD4bs) 
The CD4bs of gp120 constitutes a conformational region suggested to be only apparent in the 
context of the liganded structure of gp120 (figure 1.9). The CD4 binding loop projects away 
from the centre of the outer domain and the β20.β21 segment of bridging sheet. The α-helices 
of the inner domain, the CD4 binding loop and the β20.β21 segment of bridging sheet create a 
long, narrow cavity, lined principally with hydrophobic side chains, in which many of the 
residues that are presumed to contact CD4 are located near or within this long cavity (Chen et 
al., 2005). The binding of CD4 induces large conformational changes in the inner domain, 
which leads to the formation of the bridging sheet and co-receptor binding site (Pancera et al., 
2010). 
 
 
 
 
 
 
 
 
Figure1.9:  The binding sites of CD4 and monoclonal antibody 17b. Molecular surface 
representations of gp120 core structures in liganded HIV (left) and unliganded SIV (right) states are 
shown from similar views. Residues in direct contact with CD4 are in green; residues contacting 
human monocolonal antibody 17b, in red; carbohydrate, in light blue. (Figure from Chen et al., 2005) 
 
 
 Co-receptor binding site 
Neither the receptor (CD4) nor the co-receptor (CXCR4 or CCR5) site is properly formed in 
the unliganded conformation of the gp120 core. In the unliganded conformation, the bridging 
sheet can close up to create the co-receptor binding surface, which is flanked by the V1–V2 
and V3 loops (Chen et al., 2005). The V3 loop has been shown as the major determinant of 
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co-receptor switching, which demonstrates its involvement in the co-receptor-binding site 
(Chen et al., 2005).          
1.2.2 The gp41 molecule 
The gp41 molecule is a transmembrane glycoprotein that is less variable and less glycosylated 
than gp120. It interacts non-covalently with gp120 and is responsible for maintaining the 
trimeric structure of the envelope glycoprotein, although its structure in the native 
conformation is unknown. The HIV-1 envelope glycoprotein gp41 is a homotrimeric structure 
formed by three gp41 monomers, with each monomer non-covalently associated with gp120. 
Each gp41 molecule consists of three domains: an extracellular domain (ectodomain), a 
transmembrane domain (TMD), and a C terminal cytoplasmic tail (figure 1.10.A). 
1.2.2.1 The extracellular domain and the fusion process 
The ectodomain is the primary structure involved in membrane fusion (Figure 1.10.B). At the 
amino end terminus of the ectodomain is a hydrophobic fusion peptide sequence, which has 
been proposed to act as an insertional sequence that penetrates the cell membrane. On the 
carboxyl side of the fusion peptide, there are two hydrophobic heptad repeat sequences: HR1, 
adjacent to the amino terminus and HR2, at the carboxyl terminus and adjacent to the TM 
domain. These HR sequences have a leucine zipper motif suggested to form an alpha-helix, 
and are also known as N-helix (near the amino terminus) and C-helix (near the carboxy 
terminus). Prior to co-receptor binding the N-helices form a central three stranded coiled-coil, 
and are surrounded by three anti-parallel C-helices that bind to conserved grooves on the 
coiled-coil surface. This formation can be blocked by peptides derived from either HR1 or 
HR2 (Baldwin and Berkhout, 2008). One such HR2 derived peptide, known as enfuvirtide (T-
20), is approved for use in HIV-1.infected patients.  
1.2.2.2 The transmembrane domain (TMD) 
The TMD of gp41 consists of approximately 25 highly conserved amino acids suggesting 
that it might play specific roles in envelope function. Mutations in the core region of the TMD 
influence fusion (reviewed by Checkley et al 2011). 
1.2.2.3 The cytoplasmic tail (CT) 
HIV and SIV have very long CT of approximately 150 amino acids compared to other 
members of the Retroviridae family. Several properties of the gp120/ gp41 glycoprotein 
complex are mediated by the CT such as virus infectivity, gp120 shedding, Env incorporation 
into virus particles, and cell-surface Env expression (reviewed by Checkley et al 2011). The 
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HIV and SIV cytoplasmic tails contain a number of functional domains (figure 1.10A) 
including:   the membrane-proximal tyrosine-based motif with the consensus (YxxΦ) and the 
dileucine motif at the C terminus mediate binding to AP2 chains, clathrin-dependent 
endocytosis, alter intracellular localization, and regulate envelope expression and 
incorporation in the virion (Boge et al., 1998, Wyss et al., 2001, Byland et al., 2007, Berlioz-
Torrent et al., 1999). Three conserved amphipathic α-helical segments that are referred to 
“Lentivirus Lytic Peptides” domains (LLP.1, LLP.2, and LLP.3) are present in the central and 
C-terminal regions of the gp41 CT. LLP domains have been implicated in interacting with 
the plasma membrane, decreasing bilayer stability, altering membrane ionic 
permeability, and mediating cell killing (Chen et al., 2001, Chernomordik et al., 1994, 
Eisenberg and Wesson, 1990, Kalia et al., 2003, Miller et al., 1993). 
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Figure1.10 : Organization of gp41 and fusion process. A) Schematic representation of the 
functional domains of gp41. Gp41 is formed by three domains: an extracellular domain, containing the 
fusion peptide (FP), heptad repeats (HR1 and HR2), and the MPER; a TMD and a CT. An enlarged 
representation of the gp41 CT is shown to highlight several motifs: the internalization signal YSPL; 
the Kennedy sequence (ks); the amphipathic α-helices LLP.1, LLP.2, and LLP.3; and a C-terminal 
dileucine motif (LL) (Figure from Checkley et al., 2011).  B) Schematic representation of a model of 
HIV entry. The gp120 binds to the CD4 receptor on a target cell to initiate viral entry resulting in a 
conformation change which exposes the co-receptor binding site, allowing binding to a co-receptor. 
Following co-receptor binding gp41 undergoes conformational changes which expose an N-terminal 
hydrophobic peptide. This peptide inserts into the membrane of the target cell and following 
subsequent conformational changes causes fusion of cell and viral membranes. The stages of entry at 
which three HIV-1 entry inhibitors are believed to act are indicated. Figure adapted from (Moore and 
Doms, 2003). 
 
 
 
Chapter1: Introduction Page 21 
 
1.3 HIV co-receptor usage and tropism 
1.3.1 HIV co-receptor usage 
Soon after the discovery of the CD4 molecule as the major receptor for HIV (Dalgleish et al., 
1984), new evidence started to accumulate indicating that CD4 alone was not sufficient for 
HIV to enter the target cells. In 1986, a study showed that CD4 expressed on mouse cells 
allowed virus to bind but did not confer virus entry (Maddon et al., 1986). These results 
supported the conclusion that this restriction was due to the requirement for a cofactor of 
unknown identity that was specific to human cells (Berger et al., 1999). The second 
conclusion of great importance was the observations that HIV-1 isolates fell into two distinct 
groups depending on their phenotypes. Some HIV-1 isolates showed efficient infectivity for 
continuous CD4+ T cell lines, but poor infectivity for primary macrophages. Thus, such 
viruses were designated as T-cell line-tropic (or T-tropic) and they were generally syncytium-
inducing l (SI) in assays using a highly permissive T-cell line. Other HIV-1 isolates showed 
the ability to infect primary macrophages much more efficiently than those T-cell lines. They 
were designated as macrophage-tropic (-) or non-syncytium-inducing l (NSI) isolates. Asjo et 
al. (1986) described the two groups as rapid-high (SI) and slow-low (NSI) depending on their 
replication rates in PBMCs. The first HIV-1 co-receptor was identified in 1996 and was 
named fusin, because it mediated HIV-1 fusion (Alkhatib et al., 1996) and was thereafter 
renamed CXCR4 (Moriuchi et al., 1997).The second HIV-1 co-receptor was identified based 
on the finding that the CC-chemokines (i.e. RANTES, MIP.1α, and MIP.1β) that are the 
natural ligands of CCR5 could block the infection of NSI HIV-1 isolate. Several groups 
reported CCR5 as the co-receptor for NSI viruses (Alkhatib et al., 1996, Deng et al., 1996, 
Dragic et al., 1996), while HIV-1 strains able to use both co-receptors were termed dual-
tropic (D-tropic). Both CCR5 and CXCR4 belong to the superfamily of seven transmembrane 
(7TM) G protein-coupled receptors. More than fourteen other 7TM receptors or structural-
related molecules have been identified to act as co-receptors for entry of HIV-1 in vitro 
(Dejucq et al., 1999). Currently, there is little evidence to suggest that co-receptors other than 
CCR5 and CXCR4 are used significantly in vivo. 
1.3.2 HIV tropism 
HIV tropism is now commonly defined based on the co-receptor usage which is defined as the 
ability of a particular HIV-1 virus to infect a target cell using a specific co-receptor, either 
CCR5, or CXCR4 or both. The HIV-1 viruses can be characterized into three classifications:  
R5, X4, and R5X4 viruses based on the type of co-receptor that they bind. After the 
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identification of the co-receptors, CCR5 and CXCR4, it became clear that the NSI/M-tropic 
and SI/T-tropic phenotypes were linked to their differential use of chemokine receptors for 
HIV-1 entry. NSI/M-tropic viruses preferentially use CCR5, while SI/T-tropic viruses use 
CXCR4. Therefore, NSI/M-tropic virus has been classified as R5, SI/T-tropic virus as X4, 
and dual-tropic virus as R5X4. The major genotypic determinant for HIV-1 co-receptor usage 
is the V3 variable loops of the gp120 envelope glycoprotein (Hwang et al., 1991). Different 
bioinformatics tools have been developed to predict HIV-1 co-receptor usage from the amino 
acid sequence of V3, taking into account the key amino acids at positions 11 and 25, plus 
other sites in V3 that differ between CCR5. and CXCR4.using strains (Briggs et al., 2000). 
 
1.4 HIV genetic diversity 
1.4.1 HIV classification 
HIV is a member of the lentivirus genus of the Retroviridae family. The name lentivirus 
refers to slowly replicating viruses, because these viruses take a long time before it induces 
the full-blown disease. Two types of HIV have been characterized: HIV-1 and HIV-2 and 
both share 40% to 50% genetic homology, with the greatest sequence divergence localized in 
the envelope gene (De Cock et al., 1991). HIV-1 is thought to be the result of cross-species 
transmission of simian immunodeficiency viruses (SIVs) isolated from chimpanzees (SIVcpz) 
(Peeters et al., 1989, Gao et al., 1999), while HIV-2 is most closely related to a virus found in 
sooty mangabeys (SIVsm) (Chen et al., 1997). 
HIV-1 is divided into group M (main), the group O (outlier), the group N (non-M/ non-O), 
and the recently identify group P. A phylogenetic tree representing the HIV-1 genetic 
diversity is shown in Figure 1.11. Group M is responsible for the worldwide HIV-1 epidemic 
and Group O has been endemic in Cameroon and neighboring countries in West Central 
Africa, but even there the group O represents a minority of HIV-1 strain, with prevalence less 
than 10% of HIV-1 infections in Cameroon (Yamaguchi et al., 2004). Group N has been also 
identified in Cameroonian patients and it is only represented by a limited number of isolates 
from Cameroonian patients (Ayouba et al., 2000, Simon et al., 1998). HIV group M is 
classified into 9 recognized subtypes: A, B, C, D, F, G, H, J and K and presumed 
recombination of those subtypes (McCutchan, 2006).  
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Figure1.11: Phylogenetic tree illustrating comparative relationship between SIV, HIV-1 (group 
M, N and O) and HIV-2. Figure constructed utilizing pol gene sequences with small arrows 
indicating where sequences would branch in env gene reconstruction. (Figure from 
http://www.hiv.lanl.gov/content/sequence/HIV/COMPENDIUM/99compendium.html) 
 
Studies have shown that intra-subtype genetic distance can differ by up to 30% in the env 
gene and inter-subtype genetic distances can reach up to 42% (Robertson et al., 2000, Korber 
et al., 2001, Gaschen et al., 2002). Sequencing full-length genomes have led to the 
identification of inter-subtype recombinants know as circulating recombinant forms (CRFs). 
These are presumed to be the result of recombination between different subtypes within an 
individual patient concurrently infected with HIV-1 of two or more subtypes. The inter-
subtype recombinant genomes become designated as CRFs, if; i) the identical recombinant 
viruses are identified in at least three epidemiologically unlinked people, ii) are characterized 
by full-length genome sequencing that share the same recombinant structure, and iii) form a 
monophyletic cluster in all regions of the genome; and as URFs, if only a single or two 
sequences are available (Robertson et al., 2000). Recombinants are currently estimated to be 
responsible for at least 20% of HIV-1 infections worldwide (Hemelaar et al., 2011a).The 
CRFs are named with a number sequential in the order in which they are reported in the 
literature and followed by the letters of the subtype involved, starting with CRF01_AE 
(Figure 1.12). If the recombinants consist of more than two subtypes involved, they are 
therefore replaced by designation “cpx”, meaning complex, e.g. CRF04_cpx (A, G, H, K, and 
U). Taxonomically, the CRFs are at the same level as the subtype. Currently, 55 CRFs for 
HIV-1 (CRF01 to CRF55) are found in the HIV database at Los Alamos National Laboratory 
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(www.hiv.lanl.gov), most of them having been described in Africa. Some CRFs are major 
strains circulating in certain regions and responsible of newly emerging epidemics. For 
example CRF0l_AE and CRF02_AG are dominant in Thailand, Asia (Xiridou et al., 2007) 
and West Africa respectively (Fischetti et al., 2004).  
As of 2010, HIV-2 can be divided into 8 different groups (A, B, C, D, E, F, G and H), with 
only one CRF (CRF01_AB) (Ibe et al., 2010) and a novel HIV-2 variant recently identified in 
the Ivory Coast (Ayouba et al., 2013). The majority of HIV-2 sequences in the database are 
groups A and B, which are circulating in the human population, while groups C to H represent 
only few detected infections. The geographical distribution of HIV-2 is less extensive than 
that of HIV-1. It is concentrated primarily to West Africa, although the prevalence of HIV-2 
is a growing concern in certain parts of Europe and in the South-Western region of India. 
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Figure1.12: Global spread of circulating recombinant forms of HIV-1. All currently identified CRFs 
are shown with arrows pointing to the geographical location where each CRF has been found 
(Figure from Hamelaar et al., 2013). 
 
1.4.2 Global distribution of HIV subtypes 
HIV-1 genetic subtypes are unevenly distributed in different geographical locations. 
According to recent studies, the most prevalent HIV-1 subtypes are subtypes A, B and C. 
Subtype C accounts for nearly half (48%) of all HIV-1 infections in 2004.2007, while 
subtypes A, B, D and G account for 12%, 11%, 2%, and 6%, respectively (Hemelaar et al., 
2011a).  The subtypes F, H, J, and K all together account for approximately 1% of infections. 
The circulating recombinant forms CRF02_AG and CRF01_AE are responsible for 8% and 
5% of cases respectively, and CRF03_AB for 0.1%. Other recombinants account for the 
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remaining 16% of infections. All recombinant forms (all CRFs and URFs) are responsible for 
over 20% of infections worldwide (Hemelaar et al., 2011a). The global distribution and 
prevalence of HIV-1 worldwide are shown in Figure 1.13A and 13B. This distribution reflects 
the present situation and might be susceptible to modifications in the next years. Subtype A 
viruses are predominant in Central and Eastern Africa (Kenya, Rwanda, Uganda, and 
Tanzania) and in Eastern European countries formerly constituting the Soviet Union. Subtype 
B, which is the most widely disseminated subtype, is predominant in North and Latin 
America, the Caribbean, Europe, and Australia. It is also common in several countries of 
Southeast Asia, North Africa, Middle East (Israel), and among South-African and Russian 
homosexual men. Subtype C is predominant in southern Africa, Ethiopia and India. Subtype 
D viruses are found principally in East Africa and to a lesser extent in West Africa. 
CRF01_AE and subtype B co-circulate in South-East Asia, whereas CRF02_AG, along with 
other recombinants, dominates in West and West Central Africa. In South America, the 
epidemic is a mixture of subtype B and BF recombinants, with a small proportion of subtype 
C infections. In East Asia subtypes B, C and BC recombinant strains dominate.  Central 
Africa harbors a complex mixture of rare subtypes (F, G, H, J and K) and recombinants, 
without any predominant strain. 
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Figure1.13: Global distribution and prevalence of HIV-1 subtypes and recombinant forms. 
A) Regional distribution of HIV subtypes and recombinants. The colors representing the different 
HIV-1 subtypes are indicated in the legend on the left-hand side of the figure. 
B) World global distribution. (Figure from Hamelaar et al., 2011). 
 
1.4.3 Mechanisms of genetic diversity 
The high genetic variability and rapid evolution of HIV are important factors in its worldwide 
spread. HIV genetic heterogeneity originates from the high mutation and recombination rates 
of the reverse transcriptase enzyme combined with a high turnover rate. This results in 
genetically diverse populations of viral species in each infected individual, referred as 
“quasispecies” (Eigen, 1993, Eigen, 1996), each with diversity comparable to that of the 
entire influenza population of any one year (Korber et al., 2001).  
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1.4.3.1 Mutations 
As for all RNA viruses, the inability of the reverse transcriptase (RT) to correct 
misincorporations leads to a high error rate. Most HIV mutations are introduced during 
reverse transcription stage of the viral life cycle. The most prominent source is the reverse 
transcriptase enzyme itself, which is error prone due to the lack of a proofreading capability. 
It does not contain a 3’ exonuclease activity capable of excising misincorporated nucleotides. 
The rapid viral turnover in an infected individual with the production of up to 10
10
 particles 
per day (Ho et al., 1995), and the poor fidelity of the replication process with the generation 
of 3 x 10
−5
 mutations per nucleotide per cycle (Mansky and Temin, 1995), indicate that on 
average 3 x 10
9 
mutations are generated each day in the viral population present in a patient. 
A more recent study indicates that the HIV-1 mutation rate is in fact around the retroviral 
average of 1.4 x 10
−5
 errors per base pair, per replication cycle (Abram et al., 2010). 
1.4.3.2 Recombination 
Detectable recombination of HIV may occur when a cell becomes infected with two or more 
genetically distinct HIV virions. These virions may come from the same subtype (intra-
subtype recombination) (Rousseau et al., 2007, Philpott et al., 2005) or from different 
subtypes (inter-subtype recombination) (Charpentier et al., 2006, Yirrell et al., 2002). Dual 
infection (similar to double infection) occurs when an individual is infected with strains 
derived from two different individuals. The dual HIV infections can be divided into co. and 
superinfections. Co-infection is defined as simultaneous infection with two heterologous 
strains before an immune response has developed and antibodies are detectable in the blood 
before seroconversion. Thus, co-infection would occur within the first month of infection. 
Superinfection is defined as infection with a second strain after the initial infection and the 
immune response to it has been established, after initial seroconversion. The HIV-1 
recombination rate was approximately two to three recombination events per genome per 
replication cycle, and crossovers or breakpoints were identified throughout the viral genome 
(Jetzt et al., 2000). A recent study found that recombination breakpoints are non-randomly 
distributed across the genomes of HIV-1 inter-subtype recombinants by analyzing the position 
of the breakpoints found in sequences of the Los Alamos Database (http://www.hiv.lanl.gov/) 
(Fan et al., 2007). Two recombination prone regions or “hot spots” were identified. They are 
located at the borders of the env gene around the first exon of tat, vpu and the beginning of 
env, and the second exon of tat, rev, and the 3’ end of env (Figure 1.14). However, comparing 
Chapter1: Introduction Page 29 
 
the recombination breakpoints across gp120 indicated that that the C2 region is also a hotspot 
for recombination (Baird et al., 2006, Galetto et al., 2004). 
 
 
 
 
 
 
 
 
 
Figure1.14:  The distribution of breakpoints across HIV-1 genome. The diagrammatic 
representation of HIV-1 genome is shown in upper panel. The bars and the number of breakpoints 
detected in sequences of the Los Alamos Database (http://www.hiv.lanl.gov/) are shown in lower 
panel. (Figure from Jun Fan et al. 2007) 
 
1.4.4 Consequences of HIV-1 genetic diversity 
1.4.4.1 Impacts of HIV-1 genetic diversity on transmission and disease progression 
Although earlier studies found an association between CRF01_AE and heterosexual 
transmission as well as between subtype B and intravenous drug use (Gao et al., 1996, Soto-
Ramirez et al., 1996), a more recent longitudinal study performed in Thailand found an 
increased probability of CRF01_AE transmission among IDUs compared with subtype B 
(Hudgens et al., 2002). A recent study performed in HIV-discordant couples in Uganda found 
that subtype A was associated with a significant higher rate of heterosexual transmission than 
subtype D (Kiwanuka et al., 2009). The rate of transmission may reflect differences in 
subtype-specific co-receptor tropism. The HIV strains capable of using CCR5 are more 
frequently transmitted than strains that use CXCR4, however CXCR4 viruses emerge later in 
infected patients and are associated with more rapid disease progression (Berger et al., 1998). 
It was found that HIV-1 subtype D used CXCR4 more frequently in early infection which 
may in part explain their reduced heterosexual transmissibility when compared to other 
genetic forms (Huang et al., 2007, Kaleebu et al., 2007, Kiwanuka et al., 2009) whereas 
subtype A mostly used CCR5 even in late infection. This may explain why HIV-1 subtype D-
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infected patients had more rapid progression that those infected with subtype A in Uganda, 
Kenya, and Tanzania. The percentage of CXCR4 viruses appears lower in subtype C than in 
subtype B, even when the viruses are obtained from patients with advanced AIDS (Cilliers et 
al., 2003). A previous study in Tanzania suggested that subtypes A, C and recombinants are 
more likely to be perinatally transmitted than subtype D (Renjifo et al., 2001), and that 
pregnant women infected with subtype C were more frequently susceptible to transmit HIV to 
their children than those infected with subtype B (Renjifo et al., 2003). 
HIV-1 subtype differences in disease progression have been studied in several cohorts. A 
retrospective cohort study (1996.2007) reported that Africans patients infected with HIV-1 
non-B subtypes (A, C, F.K, CRF01_AE, CRF02_AG,) had slower rates of disease progression 
compared to Haitians and Canadians infected with subtype B viruses (Keller et al., 2009). A 
study in Senegal reported that women infected with non-A subtypes were 8 times more likely 
to develop AIDS than those infected with subtype A (Kanki et al., 1999). A study of a Kenyan 
cohort showed that patients infected with subtype D had a higher mortality rate and a faster 
decline in CD4+ count than those infected with subtype A or C (Baeten et al., 2007). The 
propensity of subtype D to exhibit a greater degree of using dual co-receptor than other 
subtypes (Huang et al., 2007) may help to explain the observation that subtype D appears to 
be associated with a more rapid rate of disease progression than other subtypes. In contrast, 
no difference in disease progression was found between patients infected with subtypes B and 
CRF01_AE in Thailand (Amornkul et al., 1999) or subtypes CRF02_AG or other subtypes in 
Cameroon (Laurent et al., 2002). 
1.4.4.2 Impacts of HIV-1 genetic diversity on diagnostics  
HIV-1 fourth-generation  immunoassays are able to detect all known HIV-1 group M 
subtypes, group O and HIV-2 positive samples with 100% sensitivity and >98% specificity 
(Kwon et al., 2006). These assays provide an advantage for detection of infection during the 
window period prior to seroconversion since the diagnostic window may be reduced by an 
average of 5 days relative to an IgM-sensitive EIA (Fiebig et al., 2003, Weber et al., 1998). 
However, such advanced assays are often not available in resource limited countries where 
most new infections occur. In field situations with a high diversity of circulating HIV strains, 
such as in Cameroon, the performance of rapid diagnostic tests is much less satisfactory with 
sensitivities ranging from 94.1 to 100% and specificities ranging from 88.0% to 98.8%. In 
particular, group O infections are poorly detected (Aghokeng et al., 2009). PCR-based assays 
for viral load measurements also have difficulty detecting and reliably quantifying HIV-1 
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RNA when testing diverse genetic variants of HIV-1 from Africa, especially group O. 
Different assays also frequently yield discordant viral load results (Rouet et al., 2010). Group 
P infections may not be efficiently detected by the current HIV screening tests due to the 
absence of group P-specific reagents for antibody detection (Vallari et al., 2011). 
1.4.4.3 Impacts of HIV-1 genetic diversity on antiretroviral therapy 
The development of resistance to antiretroviral drugs continues to be an important problem in 
the treatment of HIV-infected individuals. Studies around the world have demonstrated that 
different group M subtypes have similar susceptibilities to currently used antiretroviral drugs, 
which were originally developed based on subtype B viruses (Kantor, 2006). Different HIV 
genetic forms carry in their genomes genetic signatures and polymorphisms that could alter 
the structure of viral proteins which are targeted by drugs, thus impairing ARV drug binding 
and efficacy. In general, several mutations are generally required for the virus to become 
resistant to protease inhibitors (PI), whereas a single amino acid substitution can induce 
resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTIs) (Beerenwinkel et 
al., 2005). The NNRTI resistance mutation V106M occurs in subtype C and CRF01_AE, but 
not in subtype B, and the protease inhibitor (PI) mutation L891V occurs in subtypes C, F and 
G, but not in B (Martinez-Cajas et al., 2009). Among non-B subtypes differences are also 
notable, as Nevirapine resistance mutations developed more frequently in subtype D than A in 
a mother-to-child transmission prevention study using single-dose Nevirapine (Eshleman et 
al., 2005). Of note, a high proportion of group O viruses are naturally resistant to NNRTIs due 
to the presence of the C181Y substitution in RT (Depatureaux et al., 2011). 
 
1.5 Neutralizing antibodies against HIV infection 
1.5.1 Antibody responses to HIV 
Following acute HIV infection an abundance of antibodies are elicited. Antibodies have the 
ability to inhibit HIV-1 infection through multiple pathways: they can bind cell-free virus and 
prevent the infection or they can complex with Fcδ receptor to block HIV-1 through effector 
cell mechanisms (Overbaugh and Morris, 2012). The progression of these antibodies include: 
i) binding antibodies that first develop within 8 days after plasma virus detection and initially 
exist as antigen–antibody complexes, followed a few days later by circulating anti-gp41 
antibodies, and further few weeks later with anti-gp120 antibodies (Tomaras et al., 2008); ii) 
non-neutralizing antibodies that act together with innate immune cells to kill off virus infected 
cells known as antibody dependent cell-mediated  cytotoxicity (ADCC) and antibody 
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dependent cell-mediated  viral inhibition (ADCVI) (Sarmay et al., 1992); iii) neutralizing 
antibodies (Nabs) (Figure 1.15). Neutralizing antibodies aim to block viral entry and 
subsequent infection by binding to exposed regions on the envelope, however, little or no role 
for these antibodies is known once HIV-1 has entered its target cell.  
1.5.1.1 Non-neutralizing antibodies (ADCC and ADCVI) 
Non-neutralizing antibodies can clear the virus by binding to the infected cells and initiate the 
recruitment of activated effectors cells, which in turn induces cytolysis or apoptosis of 
infected cells. ADDC is the result of the formation of a complex between the IgG Fab portion 
of the antibody with the viral protein on the cell surface and binding of the Fc portion to the 
Fc receptors of the antibody (Sarmay et al., 1992). Fc receptors are expressed on natural killer 
cells, monocytes, macrophages, dendritic cells and neutrophils (Sarmay et al., 1992). The 
binding to the Fc receptors can lead to release of antiviral cytokines (Russell and Ley, 2002), 
resulting to the killing of the infected target cell (Baum et al., 1996) (Figure 15B). ADCVI 
also involves the interaction between a target cell, ADCVI antibody and an effector cell. 
However, rather than causing cell death, ADCVI antibodies aim to reduce the viral output 
from infected target cells (Overbaugh and Morris, 2012) (Figure 1.15C).  
Vaccine studies in both humans and non-human primate model systems have brought some 
evidence that non-neutralizing antibodies may provide protection from infection (Mascola et 
al., 1999; Mascola et al., 2000; Barouch et al., 2012; Baba et al., 2000; Parren et al., 2001). In 
human vaccine studies, a correlation was observed between both antibody binding activity 
and ADCVI antibody activity and the incidence of HIV-1 infection in vaccine recipients in 
the Vaxgen Phase III efficacy trial (Gilbert et al., 2005, Forthal et al., 2007).  
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Figure1.15: Schematic representation of the mechanism of action of nAbs and antibodies that 
act through ADCC and ADCVI. (A) Antibody neutralization of cell-free virus. Neutralizing 
antibodies bind to HIV-1 envelope glycoproteins and block the interaction of viral particles with CD4 
and CCR5, essential receptors on target cells required for infection. (B) Antibody-dependent cellular 
cytotoxicity leads to the killing of infected cells. In the case of ADCC, a complex between the IgG Fab 
portion of antibody bound to envelope protein on the cell surface and the Fc portion to the Fc receptors 
on effector cells leads to lysis of the infected cell. (C) Antibody-dependent cell-mediated  virus 
inhibition. ADCVI measures the effects of ADCC-mediated  cell killing, which lead to reduced virus 
production, as well as virus inhibition by antiviral cytokines and other secondary effects of FcR-virus 
interactions such as phagocytosis (Figure from Overbaugh and Morris, 2012) 
 
1.5.1.2 Neutralizing antibodies (nAbs) 
 Autologous neutralizing antibodies 
In HIV-1 infection, nAbs  can block the virus-cell interaction by inhibiting the binding of 
virion to CD4 and co-receptors on the cell surface, therefore preventing conformational 
changes of the virus envelope that are required for subsequent steps in the virus life cycle. 
The earliest neutralizing antibodies can be detected within months of infection in most HIV-1 
infected individuals (Gray et al., 2007, Richman et al., 2003, Wei et al., 2003). Most HIV-1 
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infected individuals produce antibodies capable of inhibiting their own virus (autologous 
virus) and are known as autologous neutralizing antibodies (Arendrup et al., 1992, Moore et 
al., 1994, Moog et al., 1997, Pilgrim et al., 1997, Richman et al., 2003, Wei et al., 2003, Frost 
et al., 2005, Deeks et al., 2006, Gray et al., 2007). These antibodies target immunogenic 
exposed regions of the HIV-1 virion; however their neutralization capacity is transient due to 
viral mechanisms to escape antibody recognition (Arendrup et al., 1992, Richman et al., 
2003). The appearance of neutralization escape variants soon after the autologous response 
supports the notion that these antibodies exert immunological pressure on the virus (Wei et 
al., 2003, Richman et al., 2003, Deeks et al., 2006, Frost et al., 2005). Recent studies 
suggested that autologous antibody response primarily target variable regions rather than the 
conserved regions of the HIV-1 envelope, explaining the strain specificity of these antibodies 
(Moore et al., 2009a). The V1V2 region was therefore shown to be a frequent target of 
autologous nAbs in HIV-1 and Simian–Human Immunodeficiency Virus (SHIV) (Moore et 
al., 2008, Laird et al., 2008).  A study reported on the detection of autologous nAbs as early as 
52 days after detection of HIV-specific antibodies in acutely infected patients (Wei et al., 
2003). Gray et al, (2007) have evaluated autologous and heterologous neutralizing antibody 
responses in 14 HIV-1 subtype C acutely infected individuals (Gray et al., 2007). Envelope 
clones were used which were obtained within the first 2 months of infection. Their results 
revealed that potent autologous neutralizing antibodies are produced within 3 to 12 months 
post-infection with an increase in autologous antibody production observed within the first 6 
months (Gray et al., 2007). Interestingly, it was also noted that potent autologous 
neutralization correlated with shorter Env variable region lengths as well as the presence of 
fewer glycosylation sites especially in the V1V2 region of Env (Gray et al., 2007). Another 
study suggested that the C3V4 region, specifically the C3 α.2-helix is a major target of 
autologous neutralization antibodies in subtype C infections (Moore et al., 2008).  V4 does 
not appear to be a significant autologous nAb target, although changes in this region may 
mediate neutralization escape (Sato et al., 2008) while the role of V5 is less clear.  Studies on 
the control of superinfection have also revealed the role of autologous neutralizing antibodies. 
Basu et al (2012) have shown that superinfected individuals infected with subtype C mount 
low or undetectable autologous nAb responses prior to intra-subtype superinfection in 
contrast to singly-infected  matched controls who presented HIV-1.specific antibodies with 
very potent neutralizing features (Basu et al., 2012). Another study from Mayr et al (2012), 
reported evidences that patient  superinfected by discordant subtypes who exhibits broad 
nAbs against heterologous viruses, mount low autologous nAbs response against their original 
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discordant autologous viruses (Mayr et al., 2012). These results were discordant with the 
description of six untreated female sex workers who became superinfected despite a broad 
and potent nAbs responses prior to the infection with a second HIV-1 strain (Blish et al., 
2008). These superinfected individuals were able to mount autologous nAbs responses to their 
superinfecting variant following superinfection (Blish et al., 2008). 
 Heterologous neutralizing antibodies 
In contrast to the early autologous Nab responses, antibodies capable of neutralizing 
heterologous viruses (heterologous neutralization) develop later in infection and can be 
remarkably potent and cross reactive (Richman et al., 2003, Wei et al., 2003, Gray et al., 
2007). Only a small percentage of chronically infected patients can develop broadly cross-
reactive nAbs against multiple HIV-1 viruses (Braibant et al., 2006, Donners et al., 2002, 
Pilgrim et al., 1997, Moore et al., 1996, Moog et al., 1997, Simek et al., 2009, Gray et al., 
2011b). The reasons why some individuals develop broadly cross-reactive nAbs as well as 
why breadth develops so rarely is unclear but is related to the duration of infection and viral 
levels suggesting that years of persistent viral stimulation are necessary for their generation 
(Piantadosi et al., 2009b, Sather et al., 2009, Euler et al., 2010, Gray et al., 2011b). Broadly 
cross-reactive nAbs response was initially thought to be quite uncommon (Mascola and 
Montefiori, 2010), but recent studies have described the presence of broadly cross-reactive 
nAbs in different cohorts (Doria-Rose et al., 2009, Sather et al., 2009, Simek et al., 2009, 
Gray et al., 2009a). These have been important studies as they indicate that such sera and 
antibodies are not rare (Stamatatos et al., 2009, Gray et al., 2009a, Sather et al., 2009), 
providing evidence that the natural B cell response can generate broadly cross-reactive nAbs 
against HIV-1. This is obviously the type of antibody response that we would like to elicit 
with a preventative vaccine. 
1.5.2 Mechanisms of evasion from neutralizing antibodies 
HIV-1 has developed multiple escape mechanisms to avoid neutralization. Such mechanisms 
include the inaccessibility of relevant epitopes due to the trimeric structure of envelope, 
nucleotide substitutions, insertions and deletions, modification of envelope potential N-linked 
glycosylation sites (PNGS), (Mc Cann et al., 2005). HIV envelope is heavily glycosylated, 
with almost 50% of the total mass consisting of poorly or non-immunogenic glycans (Leonard 
et al., 1990) shielding antibody access to the epitope. It has been reported that changes in 
glycan packing yields viruses resistant to the autologous neutralizing antibody response (Wei 
et al., 2003, Wibmer et al., 2013). This neutralization escape mechanism is referred as an 
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“evolving glycan shield” (Wei et al., 2003). Moore et al. (2012) suggested that a change in 
glycan at amino acid 332 result in resistance to BnAb PGT128 (Moore et al., 2012). The 
trimeric nature of the envelope glycoprotein shields conserved regions, while exposing 
relative amorphous highly glycosylated loop structures. These regions tolerate high levels of 
variation and therefore can easily escape from neutralizing antibodies (Wyatt et al., 1998). 
Multiple studies have suggested that the V1/V2 loops cover conserved epitopes involved in 
the co-receptor binding site (Kwong et al., 2000), as deletion of these variable loops confers 
sensitivity to antibodies targeting this region (Sullivan et al., 1998, Wyatt et al., 1995). Van 
Gils et al (2011) have shown that an increase in the length of the V1V2 loop and the 
number of PNGS in that same region of the HIV-1 envelope glycoprotein is directly 
involved in the protection of HIV-1 against HIV-specific neutralizing  antibodies (van Gils 
et al., 2011). 
1.5.3 Broadly neutralizing antibodies (BnAbs) 
Until 2009, only a small number of first-generation BnAbs have been isolated from HIV-1 
subtype B infected individuals (Zolla-Pazner, 2004). These BnAbs neutralize many primary 
isolates from different genetic subtypes, indicating some conserved structures on the envelope 
glycoproteins. The mapping of the sera of the HIV-1 individuals exhibiting broadly 
neutralizing activity against different strains revealed five predominant neutralizing antibody 
specificities: a) the CD4 binding site on gp120; b) glycan-dependent epitopes on gp120 that 
are N332A sensitive; c) an epitope in the vicinity of the CD4.induced site; d) a quaternary 
epitope on gp120 that is sensitive to the loss of glycosylation at position N160; and e) the 
conserved gp41 membrane proximal external region (MPER) (Figure 1.16). Passive 
immunization of primates challenged with chimeric SHIV strains has shown that human 
BnAbs can protect against infection and are effective against intravenous (Baba et al., 2000, 
Mascola et al., 1999), oral (Hofmann-Lehmann et al., 2001) or intravaginal challenges 
(Mascola et al., 2000, Parren et al., 2001, Veazey et al., 2003).  
Since 2009, several second-generation  BnAbs have been identified with improve breadth and 
potency activity against several different HIV-1 strains (Hraber et al., 2013) (Figure 1.16). 
These new BnAbs were derived from donors infected with different HIV-1 subtypes and the 
success of this effort was based on the combination of three strategies: a) the selection of 
chronically infected individuals with potent and cross-subtype reactive serum antibodies; b) 
the use of novel selection of screening approaches; and c) the development of efficient 
methods to isolate human monoclonal antibodies (Corti and Lanzavecchia, 2013). 
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Figure1.16: Neutralizing monoclonal antibodies targeting HIV envelope. (Figure from McCoy and 
Weiss 2013 adapted from Burton and Weiss 2010) 
 
1.5.3.1 First-generation of HIV-1 broad neutralizing monoclonal antibodies 
 IgG1b12 (b12) 
Before 2009, the mAb with the best anti-HIV potency and breadth was b12 (Burton et al., 
1994). It was selected by phage display of an antibody library constructed from the bone 
marrow of an HIV-1 infected donor. B12 recognizes the highly conserved CD4 binding site 
on gp120 and acts as a competitive inhibitor of CD4 (Roben et al., 1994). B12 interacts with 
its epitope via its unique extended long complementarity-determining region (CDR3 loop) 
from the variable domain of its heavy chain (Roben et al., 1994) allowing it to access the CD4 
binding pocket (Saphire et al., 2001). Upon binding to its epitope, b12 induces little entropic 
and conformational changes suggesting a favourable fit into the CD4 binding site of gp120 
(Kwong et al., 2002). The mAb b12 neutralized approximately half of the virus panel tested 
by Binley et al (Binley et al., 2004) and is thus reasonably broad. 
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 2G12 
2G12 was selected from hybridomas of human peripheral blood B lymphocytes from HIV-1 
positive volunteers; it targets a conserved cluster of oligo-mannose glycans on gp120 (Trkola 
et al., 1996). Binding of 2G12 could be abolished when the N-linked carbohydrates in the C1, 
C2, C3, C4, and V4 were removed from gp120 (Trkola et al., 1996). Similar to b12, 2G12 
induces little conformational changes when bound to its epitope (Kwong et al., 2002). More 
recently, modifications in V1/V2 and V3 have been linked to 2G12 sensitivity (Chaillon et al., 
2011). Mutagenesis studies have implicated the glycans at positions 295, 332, 339, 386 and 
392 in gp120 as being the most critical for 2G12 binding (Sanders et al., 2002, Scanlan et al., 
2002). 2G12 was tested in a neutralization assay against pseudoviruses representing subtypes 
A, B, C, D, F, AC and CRF01_AE as well as 25 primary viral isolates in order to determine 
the neutralization breadth of the antibody (Binley et al., 2004). Results revealed that 2G12 
could effectively neutralize 41% of the tested viruses none of which were from subtype C or 
E (Binley et al., 2004). The fact that 2G12 does not exhibit cross neutralization against 
subtype C isolates may be due to the lack of a glycan at position 295 at the N-terminal base of 
the V3 loop in subtype C viruses (Binley et al., 2004).  
 2F5 and 4E10 
The two most studied mAbs 2F5 (Barbato et al., 2003) and 4E10 (Stiegler et al., 2001) 
recognizes two adjacent highly conserved epitopes in the extreme C-terminal of the gp41 
ectodomain, the MPER, and also have a lipid binding ability (Alam et al., 2009). This region 
is particularly attractive for vaccine design because it mediates the viral entry process and is 
highly conserved between viral strains. 
The 2F5 epitope has been mapped to the motif ELDKWA at the end of the HR2 region of 
gp41 (Muster et al., 1993), where the core residues D664, K665 and W666 are indispensable 
for antibody recognition (Zwick et al., 2005). 2F5 neutralized 67% of the isolates however 
shows poor neutralization capacity against subtype C isolates; possibly due to the fact that 
most subtype C viruses have a DSW motif instead of DKW (Purtscher et al., 1996, Stiegler et 
al., 2001). 
4E10 recognizes the epitope containing the NWFDIT motif. Mutagenesis experiments have 
demonstrated that the residues W672, F673 and W680 are indispensable for recognition by 
4E10 (Zwick et al., 2005). 4E10 exhibits potent cross-reactive neutralization activity against 
90 viruses from subtypes A, B, C, D, F, G, J and AC, AE, AG, BF and BG recombinants 
(Binley et al., 2004). 
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 Z13e1 
Z13 was isolated in 2001 from an antibody phage display library and was shown to recognize 
an epitope similar to that of 4E10 but with the ability to neutralize a limited set of primary 
viruses (Zwick et al., 2001). Recently, a high affinity variant of Z13 named Z13e1 was 
generated by mutagenesis and recognizes an epitope overlapping that of 2F5 and 4E10 
(WASLWNWFDITN). Z13e1 exhibited about 100.fold better affinity for the MPER as well 
as enhanced neutralization capacity against sensitive strains of HIV-1 (Nelson et al., 2007). 
 447.52D 
The anti-V3 neutralizing antibody 447.52D shows moderate neutralization breadth by 
interacting with a conserved GPGR motif in subtype B isolates via its long CDR H3 loop in a 
sequence independent manner (Conley et al., 1994). However, for CCR5.utilizing viruses, the 
V3 loop is poorly immunogenic before CD4 binding therefore 447.52D has limited 
neutralization breadth against these isolates (Lusso et al., 2005). Interestingly, 447.52D has 
been shown to neutralize 45% of subtype B viruses but only 7% of other subtypes (A, B, C, 
D, F, AC and AE as well as 25 primary viral isolates) (Binley et al., 2004). Neutralization of 
non-B subtypes largely depends on the presence of the GPGR motif (Binley et al., 2004).  
1.5.3.2 Second generation of HIV-1 broad neutralizing monoclonal antibodies 
Although much was learnt from the first-generation of mAbs described above, there was 
relatively limited breadth and potency, especially with respect to non-subtype B viruses, 
which account for the majority of HIV-1 infections. These mAbs are unable to completely 
eliminate viruses from infected individuals and the use of immunogens based on their 
epitopes has also failed to elicit broadly neutralizing immune responses (Mehandru et al., 
2007, Trkola et al., 2005). Therefore, novel approaches to isolate new BnAbs with more 
breadth and potency are needed. 
 PG9 and PG16 
Recently in 2009, PG9 and PG16 have been identified by the adaptation of single B cell 
cloning to a functional high-throughput screening of about 30,000 activated memory B cells 
from a subtype A-infected African donor (Walker et al., 2009). PG9 and PG16 neutralize 
between 70 and 80% strains of HIV tested (Walker et al., 2009) by binding preferentially to 
trimeric Env via the V1/V2 loops of the gp120 subunit (McLellan et al., 2011, Walker et al., 
2009). Mutagenesis analysis revealed that their epitopes are primarily located in the conserved 
regions of the V2 and 
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V3 loops of gp120 and the preferential binding to trimeric gp120 is due to gp120 subunit 
presentation in the context of trimeric viral spike rather than gp120 cross-linking (reviewed 
by Chen et al., 2012). 
 VRC01 and VRC02/VRC03  
In 2010, two novel CD4-binding sites mAbs were identified named as VRC01 and its somatic 
variants VRC02 and VRC03 (Zhou et al., 2010, Wu et al., 2010b). VRC01 and VRC02 were 
identified by isolating single mAb-producing B cells with an antigenically resurfaced HIV-1 
gp120 core protein (Wu et al., 2010b). Both antibodies neutralizes with high potency in vitro 
up to 90% of circulating HIV-1 strains tested (Wu et al., 2010b, Zhou et al., 2010, Li et al., 
2011). VRC03 showed less neutralization potency than VRC01 and VRC02, with the ability 
to neutralize 57% of HIV-1 diverse primary isolates, including subtypes A, B, C, D, G and 
CRF01_AE and CRF07_BC (Wu et al., 2010b). VRC01 binds to a highly conserved portion 
of the CD4 binding site. Interestingly there is a significant correlation to the residues on 
gp120 involved in CD4 binding as well as VRC01 binding (Zhou et al., 2010). This unique 
antibody partially mimics the CD4 molecule with 73% homology with the CD4 N-terminal 
domain (Zhou et al., 2010). An interesting feature of the VRC01 antibody is that it targets the 
outer domain of the CD4 binding site which is occluded by glycan shields (Zhou et al., 2010). 
The VRC01 light chain makes contact with the N-linked glycan at residue 276 on gp120; 
therefore VRC01 uses the glycan for binding rather than being occluded by it (Zhou et al., 
2010). 
 HJ16 
HJ16 is another mAb isolated in 2010, which recognize an epitope in the CD4-binding site 
(Corti et al., 2010). It competes with sCD4 and b12 in binding to gp120s, and exhibits potent 
and selective neutralization of Tier.2 viruses (reviewed by Chen et al., 2012). 
 PGT121.145 
The PGT121 antibody family was identified from African donor 17 of the IAVI Protocol G 
cohort (walker et al., 2011). It consists of three primary members (PGT121, PGT122 and 
PGT123), and additional antibodies from this donor described recently (125.131) (Pejchal et 
al., 2011). This family of BnAbs neutralizes 65–80% of HIV-1 isolates and are the most 
potent anti-HIV-1 BnAbs identified to date, with a median IC50 ranging between 0.03–0.05 
µg/mL (Walker et al., 2011). This family of antibodies competes with PG9/PG16 and 
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interacts with two glycans at positions N301 and N332, as well as with the base of the gp120 
V3 loop (Pejchal et al., 2011, Walker et al., 2011, Diskin et al., 2011). 
 NIH45.46 
NIH45.46 is a new CD4-binding site mAb identified in 2011(Diskin et al., 2011). It is a more 
potent clonal variant of VRC01 that was isolated from the same donor with substantial 
advances in terms of potency and breadth of the antibody. This antibody did not have a large 
aromatic residue to contact the hydrophobic pocket between the CD4 binding loop and the 
bridging sheet on Env, as does CD4 itself (Diskin et al., 2011). By mutating a phenylalanine 
into this position on NIH45.46, an extremely potent CD4bs mAb was generated which could 
provide protection against approximately 75% of circulating strains at levels as low as 
0.1μg/ml (Diskin et al., 2011). 
 10E8 
Recently, 10E8 was isolated from an HIV-1.infected individual with high neutralization titers 
(Huang et al., 2012). 10E8 is an anti-MPER mAb and is among the broadest and most potent 
of antibodies described so far, neutralizing 95% of viruses tested with a median IC50 of 0.35 
μg/ml. 10E8 lacks many of the characteristics previously thought to limit the usefulness of 
MPER-specific antibodies in vaccines or passive therapies, including lipid binding and auto-
reactivity (Huang et al., 2012). The crystal structure of 10E8, along with biochemical binding 
studies, demonstrates that the breadth of 10E8 is mediated by its unique mode of recognition 
of a structurally conserved site of vulnerability within the gp41 MPER (Huang et al., 2012). 
 
1.6 Vaccine development 
Most vaccines work by stimulating an antibody response against the disease of interest. These 
antibodies then allow the immune system of the individual to fight off the pathogen. 
Normally, the immune system only makes large amounts of antibodies after an infection has 
taken place. Vaccination allows the antibodies to be made before a person has even been 
exposed to the disease, so the body will be ready to protect itself when it is actually exposed. 
After 30 years of HIV-1 pandemic, no vaccine exists for clinical use to prevent HIV-1 
infection. The reasons are multiples and include the remarkable high HIV-1 diversity; and the 
host’s inability to mount antibodies to targets within conserved envelope regions that confer 
broad neutralization. Recent insights of ways that vaccines can potentially stimulate 
protective T- and B-cell immunity, the identification of new targets for BnAbs, and the 
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discovery of new mechanisms of host control of HIV-BnAbs induction offer renewed hope 
for the development of a well-tolerated and effective preventive HIV-1 vaccine (Haynes and 
McElrath, 2013).  
Traditional vaccine strategies have focused on live attenuated viruses, whole killed viruses 
and protein subunits (Baba et al., 1999, Learmont et al., 1999). These approaches have proven 
successful against other viruses such as the influenza virus but raise great safety concerns 
with regard to HIV-1 (Giri et al., 2004). More recent vaccine strategies have made use of gene 
delivery technologies such as plasmid DNA vaccines, recombinant viral vectors (attenuated or 
replication-incompetent viruses) such as adenoviruses (Priddy et al., 2008) or poxviruses 
(Harari et al., 2008). 
A vaccine trial by Merck made use of a candidate which comprised a recombinant adenovirus 
vector that expressed HIV-1 subtype B gag, pol and nef genes (Priddy et al., 2008). However 
participants with pre-existing antibodies against the adenovirus vector showed suppressed 
immune responses to the vaccine (Kostense et al., 2004). Phase II b clinical trial studies were 
subsequently initiated to evaluate 3000 subjects for HIV-1 specific cellular immune responses 
elicited by this vaccine regimen. The trial was co-funded by the National Institute of Allergy 
and infectious disease (NIAID) and Merck & co. This was known as the STEP study and was 
conducted in America, Caribbean and Australia (McElrath et al., 2008). Unexpectedly, this 
study was brought to an early end due to safety concerns. It was hypothesized that the 
recombinant adenovirus vector may have increased the acquisition of HIV-1 infection in some 
individuals (Sekaly, 2008, Watkins et al., 2008). The results of the trial have caused scientists 
to call for a re-examination of vaccine development strategies. 
The first efficacy trial (Vax004) began in 1998. The Vax004 trial was aimed at determining 
the efficacy of a recombinant bivalent subtype B gp120 vaccine (AIDSVAX) in preventing 
sexual transmission of HIV-1 in North America and the Netherlands, where subtype B 
infections are prevalent (Berman, 1998). The trial included 5108 men who have sex with men 
(MSM) and 309 high risk women. Although the AIDSVAX vaccine elicited strong antibody 
responses, it failed to protect against HIV-1 infection and had no effect on the viral loads of 
participants who acquired HIV-1 infection after vaccination (Gilbert et al., 2005). This same 
vaccine was retested in Thailand within a vaccine regimen called RV 144. The vaccine was 
named as "ALVAC.AIDSVAX B/E" that uses ALVAC.HIV from Aventis-Pasteur with a 
combination of genetic elements of several different HIV strains encapsulated in a harmless 
canary pox virus vector in addition to elements of the HIV strains circulating in Thailand 
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(subtype E) and in US (Subtype B). The latest results from the RV144 trial showed, for the 
first time, a statistically significant 30% protective efficacy (Rerks-Ngarm et al., 2009). It was 
reported that subjects in the study in which antibodies recognizes the V1V2 loop in the HIV 
envelope protein gp120 were 43% less likely to become infected (Rolland et al., 2012) but 
those who produced envelope specific IgA were 54% more likely to become infected. This 
suggests that an effective HIV-1 vaccine should include components that elicit responses in 
both arms of the immune system. In summary, the major strategies that are being pursued 
include several approaches for the induction of broad nAbs, the augmentation of the quality 
and the quantity of non-neutralizing V1V2 antibodies as seen in the RV144 immune 
correlates study, and the development of vaccine vectors that better represent critical T-cell 
epitopes and the viral diversity of circulating strains (Haynes and McElrath, 2013). 
 
1.7 Importance to study HIV-1 subtype G  
HIV-1 subtype G is responsible for an estimated 1,500,000 HIV-1 infections worldwide, 
making it the sixth most prevalent subtype of HIV-1, after subtypes A, B, C, CRF01_AE and 
CRF02_AG (Hemelaar et al., 2006). Subtype G is endemic in West and Central Africa 
(Figure 1.17). A few studies describe the prevalence of subtype G (30.54%) in Nigeria (Ajoge 
et al., 2012, McCutchan et al., 1999, Peeters et al., 2000, Agwale et al., 2002), in Cameroon 
(4.5.12%) (Brennan et al., 2008, Tongo et al., 2013, Teto et al., 2013, Ndembi et al., 2008), in 
Congo (21%) (Niama et al., 2006), in Central African Republic (11%) (Marechal et al., 2006), 
and Democratic Republic of Congo (10%) (Vidal et al., 2000). At lower prevalence, subtype 
G is also found in Spain (Thomson et al., 2001, Delgado et al., 2002), in Portugal (Esteves et 
al., 2002), and Cuba (Perez et al., 2006, Sierra et al., 2007). 
 
 
 
 
 
 
Figure 1.17: Distribution of HIV-1 subtype G in 2004.2007. (Figure from Hemelaar et al., 2001) 
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Segments of subtype G are present in 19 of the 43 (44%) classified CRFs in Los Alamos 
National Library (LANL) database (www.lanl.org). In Cameroon, the majority (84%) of HIV-
1 infection among blood donors were caused by CRFs and unique recombinant forms (URFs) 
and 80% of the recombinant strains containing segments of subtype G (Yamaguchi et al., 
2009).  
A great debate has recently risen on whether subtype G is a pure subtype or CRF. Abecasis et 
al (2007) proposed that subtype G is actually a recombinant derived from parental strains 
CRF02_AG, and subtype J, and that CRF02_AG is a non recombinant subtype (Abecasis et 
al., 2007). Since the different subtypes are assumed to have evolved independently, different 
genome regions are expected to have the same evolutionary history. However, this was not 
apparently the case for subtype G (Abecasis et al., 2007). The subtype G designation was 
based on a classification of partial genome sequences from gag, pol, and env regions 
(Robertson et al., 2000). This was a preliminary classification because without a complete 
genome sequence, inter-subtype recombination may not be recognized (Yamaguchi et al., 
2009). This was the case when analysis of six HIV-1 isolates from Saudi Arabia were 
designated as subtype G based on partial gag, pol and env sequences and found to be 
CRF25_cpx and CRF43_02G when the complete genome sequences were obtained 
(Yamaguchi et al., 2008). However, Yamaguchi et al (2009) reported recently five full length 
subtype G genome from Cameroon as pure subtype G based on the current classification of 
HIV-1 strains (Yamaguchi et al., 2009). 
 
1.8 Rationale of the study 
Antibody that neutralizes HIV is likely be effective in preventing establishment of new 
infections and thus may be a critical product of an effective prophylactic HIV vaccine. The 
study proposed for this thesis is designed to provide some of the basic knowledge that should 
be helpful in developing such a vaccine. In particular, a vaccine should be a global vaccine, 
effective against any of the major subtypes of HIV-1 found in the world today. 
HIV-1 subtype G accounts for 5% of HIV-1 infection, making it the sixth most prevalent 
subtype of HIV-1, after subtypes A, B, C, CRF01_AE and CRF02_AG (Hemelaar et al., 
2006). Subtype G is concentrated in West and Central Africa (Hemelaar et al., 2011a) with 
spread to European countries, primarily Spain and Portugal, presumably with immigration of 
infected individuals and small satellite subtype G epidemics have been documented in Cuba 
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and among Russian intravenous drug users. In addition, 80% of the recombinant strains 
circulating in Cameroon contain segments attributed to subtype G (Brennan et al., 2008). 
However, until recently, little research has been done on the neutralization sensitivity and 
vulnerabilities of subtype G viruses, particularly those that circulate in its main reservoir. 
Systematic analyses of a wide range of HIV-1 envelope sequences (Brown et al., 2005) and 
neutralization patterns (Brown et al., 2008, Seaman et al., 2010) have been performed. 
However, subtype G viruses are severely underrepresented in these works. Brown et al (2005) 
studied only two subtype G-associated sequences while Brown et al (2008) did not study the 
neutralization patterns of any subtype G viruses and Seaman et al (2010) evaluated the 
intrinsic neutralization resistance of only one putative subtype G virus. A recent study has one 
neutralization study of Subtype G viruses (Revilla et al., 2011). In this work, only two of the 
subtype G sequences were derived from individuals from West or Central Africa and no 
testing of intrinsic neutralization capacity was performed, which is critical for evaluating 
which viruses should be included in test panels for vaccine evaluation.  
Understanding the role of nAbs and the molecular characteristics of the subtype G HIV-1 
variants involved are important for the development of effective HIV/AIDS vaccine and 
passive immunization approaches to HIV-1. 
There is thus an urgent and important need to study subtype G envelope sequences and 
neutralization capacity of antibodies to subtype G envelope viruses. This will allow immunity 
to subtype G viruses to be evaluated, both in infected donors and those immunized with test 
vaccines in the future.  
That is why our study focused on both molecular characterization of subtype G viruses and 
the role of nAbs to subtype G HIV-1 viruses. We restricted our analysis to subtype G HIV-1 
variants circulating in Cameroon which accounts for the most predominant HIV-1 subtype 
circulating in Cameroon, with the hope that our work would benefit to the development of 
strategies for prevention of HIV-1 infection, especially in Cameroon. 
Objectives of the study 
The goal of this project was to generate and characterise HIV-1 subtype G envelope clones 
and to define the role of neutralizing antibodies to subtype G viruses expressing theses 
envelopes. The ultimate purpose for pursuing this project was to contribute to immunogen 
design of an effective HIV vaccine that elicits broadly neutralizing antibodies to prevent 
infection. 
Chapter1: Introduction Page 46 
 
 
This was achieved by the following specific objectives: 
Specific objective 1: To examine the molecular and functional characteristics of the HIV-1 
envelope glycoproteins of subtype G viral variants that are crucial to improving strategies to 
prevent HIV-1 transmission. 
Specific objective 2: To evaluate the neutralization sensitivity of subtype G viruses and the 
neutralizing capacities of antibodies induced by the viruses by determining the neutralization 
antibodies titers against autologous and heterologous HIV-1 viral isolates. 
Specific objective 3: To characterize the sensitivity of HIV-1 subtype G viral isolates against 
broadly neutralizing antibodies and HIV-1 entry inhibitors, to gain insight into the 
neutralization vulnerabilities of the subtype G viruses. 
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Genetic, functional and co-receptor properties of HIV-1 subtype 
G envelope genes circulating in Cameroon 
 
2.1 Abstract 
Background 
HIV-1 subtype G circulates mainly in West and Central Africa and infects an estimated 1.5 
million individuals. Characterization of subtype G strains has been very limited so far; it is 
not clear that the full diversity of subtype G is reflected in available sequences. There is a 
need to better understand the genetic and biological properties of HIV-1 subtype G isolates 
because 80% of the recombinant strains circulating in Cameroon contain segments attributed 
to subtype G. We characterized 47 full length envelope genes isolated from plasma RNA by 
single genome amplification (SGA) obtained from 8 HIV-1 subtype G-infected individuals. 
Five study participants were blood donors later determined to be HIV-infected and the 
remaining three were undergoing testing for antiretroviral drug resistance. 
Results  
Samples were identified as subtype G-infected by prior sequencing of segments of gag and 
nef genes or in pol genes, and all env sequences obtained clustered more closely with subtype 
G reference sequences than other reference sequences. The five blood donors were classified 
as likely to be recent infections (<6 months, n=3) and not-recent infection (n=2) using a BED 
assay. All sequences from each individual donor clustered together, suggesting infection 
derived from single or highly related viruses. Phylogenetic trees of viruses from three 
individuals showed structures suggestive of infection with distinct but related viruses with 
evidence of recent recombination within related sequences, although other explanations are 
possible. One donor’s sequences (12541) clustered in a subnode with CRF06_cpx sequences 
and sequences from Russia and Cameroon. Genetic distance between env sequences from 
isolates from the same donor (“within-donor genetic distance”) was uniformly high in 
samples from donors undergoing antiretroviral resistance testing. One sample from the blood 
donor group had unusually low within-donor genetic distance; equivalent to that seem in very 
recent infection (<90 days), and had unusually high V4 lengths. In general, our subtype G 
clones exhibit lower V1V2 and V4 region lengths compared to the well characterized subtype 
B. All envelope clones exhibits CCR5 co-receptor usage predicted by web PSSM and 
geno2pheno and confirmed in TZM-bl cells by inhibition of invasion of pseudoviruses with 
CCR5 binding inhibitor TAK-779.  
Chapter 2: Genetic, functional and co-receptor properties of HIV-1 subtype G envelope genes 
circulating in Cameroon Page 49 
 
Conclusion 
Although there are more than 100 subtype G env sequences in the database, some of our 
sequences showed relatively poor similarity to them. This suggests that the full extent of the 
diversity of Subtype G has not yet been described, and provides additional evidence for the 
hypothesis that subtype G itself may be very old. This study highlights the identification of 
apparent recombination events in some individuals likely due to infection with two highly 
related sequences from the same donor, or the existence of a recombination product, one of 
whose parents is present and the other which was not present in the sequences obtained. The 
majority of HIV-1 subtype G infections are caused by viruses that exclusively utilize CCR5 
co-receptor, as previously found in the literature for a small number of tested subtype G 
samples. These findings are likely to provide useful information for the design and the 
evaluation of HIV-1 vaccine and for a better understanding of the HIV-1 epidemic. 
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2.2 Introduction 
Cameroon is located in West Central Africa, the epicenter of the HIV epidemic, where many 
type and subtypes of HIV-1, as well as HIV-2, co-circulate (Peeters et al., 2003, Vergne et al., 
2003). Cameroon has one of the most genetically diverse HIV epidemics in the world and the 
widest variety of circulating recombinant forms (CRFs) of HIV-1 despite relatively low HIV 
prevalence (Takehisa et al., 1998, Machuca et al., 2007, Ndembi et al., 2008).  HIV-1 subtype 
G is responsible for an estimated 1,500,000 HIV-1 infections worldwide, making it the sixth 
most prevalent subtype of HIV-1 worldwide (Hemelaar et al., 2011a). Subtype G has a 
complex relationship with CRF02_AG, which was originally presumed to be a recombinant 
derived partly from subtype G (Abecasis et al., 2007).  CRF02_AG is one of the mostly 
commonly found subtypes in Cameroon (Agyingi et al., 2013, Vidal et al., 2013, Machuca et 
al., 2007), and 80% of the recombinant strains circulating in Cameroon contains segments 
attributed to subtype G (Brennan et al., 2008). Nonetheless, subtype G sequences and viruses 
are incompletely characterized. The env gene of HIV is the only target for an antibody-based 
vaccine. Due in part to the unique pressure of antibody-mediated immunity, it exhibits the 
highest degree of genetic variation due to recombination, mutation and escape from host 
immune response making challenging the development of a vaccine (Wei et al., 2003). 
Changes in response to immune pressure in env include changes in the length of variable 
loops, the number and position of glycosylation sites, and the net charge value due to amino 
acid substitutions (Burton et al., 2005, Moore et al., 2012, Wei et al., 2003). 
Several studies in well characterized subtypes such as subtype B and C env genes have shown 
that some of these changes may impact the neutralization phenotype and can also change the 
cellular tropism (Mascola and Montefiori, 2003, Reitter and Desrosiers, 1998, Bunnik et al., 
2008, Cao et al., 1997, Moore et al., 2009a, Rong et al., 2007b, Rong et al., 2009, Sagar et al., 
2006, van Gils et al., 2011, Cilliers et al., 2003, Briggs et al., 2000, Cann et al., 1992, 
Fouchier et al., 1992). In addition, in contrast to subtypes B and C, there are few studies of 
subtype G clones with respect to co-receptor use (Revilla et al., 2011, Tebit et al., 2002, 
Zhong et al., 2003, Brandful et al., 2007).  
In this study, the genetic properties of full length env from 8 individuals infected with HIV-1 
subtype G were investigated. Five were blood donors subsequently found to be HIV-
1.infected and three were individuals who submitted samples for antiretroviral resistance 
testing. The latter three were included because we do not expect antiretroviral drug resistance 
selection to exert pressure upon the env gene. In analyzing these samples, substantial diversity 
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was found in within-donor diversity, and thus presumably also in time since infection. Some 
of our samples include similarity to CRF06_cpx env sequences within the subtype G 
phylogenetic tree that nonetheless cluster better with subtype G reference sequences than any 
other available reference sequences showing that the HIV-1 subtype G database plausibly 
does not reflect the full diversity of HIV-1 env.  
 
2.3 Methods 
2.3.1 Study participants 
Anonymous blood samples found to be HIV-1.infected were obtained from Yaoundé Central 
Hospital Blood Service, Yaoundé, Cameroon (n=64) between December 2006 and August 
2007 and were subtyped by sequencing and phylogenetic analysis of full length sequences of 
gag and nef (Jacob et al., 2012, Tongo et al., 2013). Five samples (8%) contained subtype G 
sequences in both gag and nef and were included in the present study. An additional ninety-
seven samples from CIRCB Research Institute in Yaoundé were collected for antiretroviral 
resistance testing, presumably because they were failing therapy, and these donors were 
recruited for research studies at CIRCB, including the present study. Five were found to have 
subtype G sequences in the fragment of the pol gene analyzed for antiretroviral resistance, and 
three of those five were included in the current study. These three samples were collected 
between June 2009 and April 2010. CD4
+
 T cells counts and viral load were also measured. 
The latter three were included because we do not expect antiretroviral drug resistance 
selection to exert pressure upon the env gene. This study received approval from the CIRCB 
Ethics Committee and the Human Research Ethics committee of the University of Cape 
Town, Faculty of Health Sciences (REC NO: 107/2011). 
2.3.2 Viral RNA extraction and cDNA synthesis 
RNA was extracted from the plasma (250μl) using the QIAamp Viral RNA Mini Kit (Qiagen) 
according to the manufacturer’s instructions.  Complimentary DNA (cDNA) was synthesized 
from the entire extracted RNA using the SuperScript III Reverse Transcriptase (Invitrogen) 
according to the manufacturer’s instructions. Following the completion of the reverse 
transcription step, the reverse transcriptase was inactivated by incubation at 70°C for 15 
minutes followed by digestion of the RNA by RNase H (Invitrogen) for a digestion at 37°C 
for 20 minutes. The cDNA was therefore either used immediately for PCR or stored at -20°C 
until analysis.  
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2.3.3 Single genome analysis (SGA) 
Single genome analysis (Simmonds et al., 1990, Salazar-Gonzalez et al., 2008) is a method 
for amplifying single genomes within a multigenome population, such as the cDNA we 
synthesised from plasma. By diluting the cDNA we increase the likelihood that a PCR 
amplification will contain only a single genome from the population. This approach has been 
used extensively (Keele et al., 2008, Salazar-Gonzalez et al., 2009, Abrahams et al., 2009). 
Figure 2.1 illustrates the process of single genome amplification in order to achieve the 
desired dilution for viral quasispecies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure2. 1: Experimental overview of single genome analysis. Several dilutions of the cDNA 
solutions are subject to PCR amplification of the env gene. PCR products from dilutions >20% 
positive PCR reaction were excluded from the analysis. If for example the 1:50 dilution resulted in a 
<20% positive PCR reaction rate, for that particular participant, the 1:50 dilution of cDNA was then 
repeated in a larger number of wells. To further confirm single-genome amplification, the entire 
envelope gene was sequenced in forward and reverse directions and any sequences containing double 
peaks were excluded from the analysis (This figure was drawn for the thesis). 
 
Several dilutions of the cDNA solutions are subject to PCR amplification of the env gene. The 
least dilute sample with <20% of wells positive was then repeated in a larger number of wells. 
The cDNA dilution where less than 20% of reactions yield a positive PCR amplification 
product is likely to contain one single amplifiable cDNA template. Single genome analysis 
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was confirmed when a directly sequenced PCR product gave rise to a sequence with a single 
peak. 
2.3.4 Full length env PCR amplification and sequencing 
Two primer sets were tested for the 2.stage PCR used for the SGA-based amplifications. The 
first set has been used extensively to amplify envelopes from other subtypes (Abrahams et al., 
2009, Salazar-Gonzalez et al., 2008). The second set of primers was modified to reflect as 
best as possible the commonly found polymorphisms where these primers annealed in the 
database subtype G sequences available at the start of this project. Amplifications were 
performed using FastStart Taq DNA polymerase (Roche Diagnostics). Second round PCR 
products were run on a 0.8% agarose gel and visualized under UV light with UVP system 
(UVP, Upland, CA). Bands between 2500.3000 bp were marked to be positive for full length 
HIV-1 envelope. Before sequencing, post PCR clean-up was performed to each PCR products 
using either DNA clean and concentrator kit (Zymo Research) or the Wizard SV Gel and PCR 
clean-up system (Promega). Sequencing was done at the University of Stellenbosch core 
sequencing facility using a standard set of twelve overlapping primers to generate sequence 
encompassing the entire env open reading frame.  
2.3.5 Sequence analysis 
Full length env gene sequences were assembled and edited using Chromaspro in the software 
package Bioedit and first aligned by MUSCLE in the software MEGA 5 (Tamura et al., 
2007), followed by manual adjustment to optimize the alignment. All chromatograms were 
carefully inspected for sites of ambiguous sequences (double peaks), and those that displayed 
doubled peaks were excluded from further analysis. Sequences containing premature stop 
codons or frame shifts were also excluded. Reference sequences were obtained from the Los 
Alamos National Library (LANL) HIV sequence database (www.hiv.lanl.gov) and used to 
determine the HIV-1 subtype of all nucleotide sequences obtained from our patients together 
with  the REGA HIV Subtyping Tool Version 2.0 (http://www.bioafrica.net). Maximum 
likelihood phylogenetic trees were constructed from these sequences with 100 full maximum 
likelihood bootstrap replicates (implemented in PHYML(Guindon et al., 2005)), and using the 
maximum likelihood method implemented in MEGA 5. The reliability of the branching 
orders was tested by bootstrap analysis of 1,000 replicates when using MEGA 5. Potential N-
linked glycosylation sites (PNGS) were identified using the web-based program N-Glycosite 
(www.hiv.lanl.gov). For each patient, the pairwise DNA distances (genetic distance) were 
calculated using MEGA 5 and differences were visualized using highlighter plots generated 
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by Highlighter (www.hiv.lanl.gov). Consensus sequences were generated for each individual 
using consensus maker tool (www.hiv.lanl.gov). Recombination analysis was performed 
using an advanced recombination detection program (RDP4) (Martin et al., 2005)  to detect 
intra-patient recombination events in DNA sequences, and a bootstrap value equal to or 
greater than 70% was considered as significant. 
2.3.6 Co-receptor usage prediction and co-receptor usage assay 
The co-receptor usage of all env sequences was predicted based on V3 amino acid sequences 
using various approaches: the 11/25 rule which is taking into account the key residues 11 and 
25 and total net charge of V3 loop (De Jong et al., 1992, Fouchier et al., 1992), Geno2pheno  
which is the bioinformatics tool based on the statistical model support vector machines 
(SVM) (Lengauer et al., 2007), and WebPSSM which is a tool based on the statistical model 
position specific scoring matrix (PSSM) (Jensen et al., 2006). Co-receptor usage assay of the 
newly derived env pseudoviruses was determined in TZM-bl cells by using two blocking 
agents: TAK-779 (NIH HIV reagent repository), a CCR5 receptor antagonist, and AMD-3100 
(NIH HIV reagent repository), a CXCR4 antagonist and was adapted as previously reported 
(Fouda et al., 2013, Wang et al., 2013, Li et al., 2006b). 100 µl of freshly trypsinized TZM-bl 
cells were distributed into 96-well plates (10,000 cells/well in DMEM.10% FBS containing 
HEPES and 7.5 μg/ml of DEAE-dextran) and incubated for 1 hour with either 50 µl of TAK-
779 (3.3μM), AMD-3100 (430nM), a combination of the two reagents, or no inhibitor 
(control wells). 50 µl of Pseudoviruses were added to wells with the different treatments in 
duplicate. The volume of each pseudoviruses added (50 µl) was normalized by titration to 
50.000 relative luminescence units (RLU) which is directly proportional to the number of 
infectious virus particles present in the initial inoculums.  This standard protocol is followed 
by the National Institute for Communicable Disease (NICD) and by our laboratory 
(Montefiori, 2009). After 48 hours of incubation, luminescence was measured (Bright-Glo, 
Promega) and the fold drop in infectivity due to the addition of inhibitor was calculated. 
Wells containing co-receptor inhibitors were compared to control wells to determine if either 
agent led to a reduction in infectivity. Viruses known to use either CCR5 (III B) or CXCR4 
(Bal PS) were used as controls. 
Virus percentage neutralizations were determined by the following calculation  
 
 
Chapter 2: Genetic, functional and co-receptor properties of HIV-1 subtype G envelope genes 
circulating in Cameroon Page 55 
 
Difference in average RLU between virus control and sample             X 100%. 
Difference in average RLU between virus control and cell control 
 
2.4 Results 
2.4.1 Study participants 
The five blood bank samples were screened for longer duration of HIV-1 infection using the 
BED
TM
 HIV-1 incidence test kit (Parekh et al., 2011) (CALYPTE Biomedical, Portland, 
Oregon, USA) and the median BED value was 0.67 (IQR=0.26-1.2). The BED assay detects 
increasing levels of anti-HIV IgG after seroconversion and can be used for detecting recent 
infections (Parekh et al., 2011). The BED assay values > 0.8 were associated with being 
infected for more than 5 months, and BED assay values < 0.8 were associated with a recent 
infection. The BED assay was not an appropriate test for the remaining three samples because 
ART substantially affects antibody levels independently of time since infection (Binley et al., 
2000, Morris et al., 1998). All ART testing patients had viral loads, and the median viral loads 
and CD4+ T cell counts of study participants at the enrolment was 105796 Copies/ml (IQR= 
58305-242775) and 463 cells/µl (IQR= 225-463) respectively (Table 2.1).  
 
Table2. 1: Epidemiological  and clinical information of participants 
Unk= unknown; Samples under ART: 10056, 11439 and 12541.  
 
 
2.4.2 Primer sets 
 A previously used primer set, and a similar primer set we optimized for use in subtype G 
were tested on two samples (BS03 and BS51) (Figure 2.1). We found that the primer set 
modified to match known subtype G sequences (primer set 1) at the point at which the 
Sample 
ID 
Subtype  Age Sex Viral load 
(Copies/ml) 
CD4+ cell count 
(Cell/ul) 
BED 
Assay 
year of sample collection 
BS03 G Unk M 346,463 Unk 0.67 2007 
BS12 G 36 M 69,244 334 1.28 2007 
BS46 G 46 F 79,555 230 0.36 2007 
BS48 G 29 M 132,037 878 0.15 2007 
BS51 G 31 M 257,039 278 1.12 2007 
10056 G 36 F 54,658 225 ND 2009 
11439 G 39 F 15,000 216 ND 2009 
12541 G 7 F 199,982 463 ND 2010 
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primers are intended to anneal gave PCR products of the correct size. Subsequently, only the 
primer set optimized for subtype G (primer set 1) was used in this study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure2. 2: Example of a PCR gel showing a test of dilutions of cDNA (SGA) from one subtype 
G sample (BS03) using 2 sets of primers. Subtype G primers (primer set 1) and subtype C primers 
(primer set 2) are indicated on top of the figure. The expected size of a PCR product from HIV-1 
envelope is also indicated on the left of the figure (3kb). 
 
2.4.3 Phylogenetic analysis  
We analyzed in total 47 env sequences from which, 45 full length gp160 SGA env sequences 
generated from this study,  each from an independent limiting dilution RT.PCR followed by 
sequencing (range 4.8 for each of eight study participants), and an additional two env 
sequences generated previously (Tongo et al., 2013). To determine the subtype classification, 
a maximum likelihood phylogenetic tree was constructed including group M reference 
sequences from LANL database. Sequences were screened for recombination and all our env 
sequences showed no evidence of inter-subtype recombination, suggesting that they are all 
homogenously subtype G derived and any sequence derived from other subtypes is in a patch 
small enough to remain undetected. All sequences clustered into three major groups within 
the expected subtype G with 100 bootstrap values (Figure 2.2). Sequences from three 
individuals (BS48, BS46, and BS51) grouped with sequences predominantly from Nigeria 
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with few from Spain and Cameroon, sequences from three individuals (BS12, 10056, and 
11439) that fell into a cluster comprising only sequences from Cameroon, that themselves 
appears linked to a major cluster of most of the sequences collected in Europe and Cuba. 
Sequences from two other individuals (BS03 and 12541) clustered with reference virus from 
Cameroon, Kenya, Russia, and CRF06_cpx. Moreover, all env sequences from the 8 
participants clustered into respective individual monophyletic lineages suggestive of infection 
with a single subtype. 
2.4.4 DNA sequences divergences and highlighter plot analysis 
Intra-patient genetic distances varied substantially among the patients (Figure 2.3.A). The 
median intra-patient distance was unusually low in one patient, BS48, with values similar to 
those normally observed in the first 90 days following infection with a single viral variant 
(Keele et al., 2008). Consistent with a short time since infection, BS48 had the lowest BED 
assay value (Table 1).The median intra-patient distance was high (>1.5%) in 4 individuals; 
10056, 11439, BS51, and 12541 with 3.45% (IQR= 0.1-6.8%), 2.1% (IQR=1.3-2.9%), 1.7% 
(IQR= 0.6-3.4) and 3.3% (IQR=2.3-6.7%) respectively, indicating a likely long period of time 
since infection and/or infection with multiple variants. Consistent with a long time since 
infection, BS51 had a high BED assay value (Table 2.1). The other three individuals were 
infected long enough to be on antiretroviral treatment. 
Sequences from each single donor grouped together on the phylogenetic tree, suggesting that 
each donor was infected with one virus or closely related viruses (Figure 2.3.B-I). However, 
the tree structure of three donors (10056, 12541 and BS51) showed substantial structure with 
one sequence from each donor appearing on the tree as an outlier (Figure 2.3.B-D). Several 
possibilities could explain this observation, including infection with two highly related 
sequences from the same donor, or the existence of a recombination product, one of whose 
parents is present and the other which was not present in the sequences obtained. 
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Figure2. 3: Maximum likelihood tree indicating the phylogenetic relationships between 193 env 
sequences of HIV-1. The tree was constructed using 47 sequences generated in this study and HIV-1 
reference sequences available in LANL with 100 bootstrap replicates. Sequences from each individual 
are displayed with different colors. The tree was rooted using HIV-1 group O isolate. Solid and open 
circles indicate branches with greater than 70% and 50% bootstrap support, respectively. Country 
codes are as follow: Cameroon=CM, Nigeria=NG, Spain= ES, Gabon=GA, Portugal= PT, France= 
FR, Cuba= CU, Kenya= KE, Russia= RU, Ghana= GH, Senegal= SE and Belgium= BE.  
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Figure2. 4:  DNA genetic distances and highlighter analysis of the gp160 env sequences. (A) Box 
plots of DNA genetic distances of the gp160 env sequences obtained from each donor. The line within 
each box represents the median value for each group. The P value was calculated by the one-way 
ANOVA, and individual differences were calculated using Dunn’s multiple comparison test; *, 
P<0.05; **, P<0.01; ***, P<0.001. (B-D), Neighbor joining phylogenetic tree and highlighter analysis 
of individuals exhibiting one sequence that appears as an outlier and (E-I), Individuals with no 
multiple variant events. The ticks in the highlighter plot represent the following: A: green, T: red, G: 
yellow, C: light blue, Gaps: gray. 
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2.4.5 Lengths and potential N-linked glycosylation sites of the V1/V5 env sequences  
The degree of length polymorphism was analyzed in regions V1/V2, V3 and V4/V5. All 
sequences showed high conservation of the cysteine residues that form the V1, V2, V3 and 
V4 loops of gp120. Another consistent observation was the considerable length variations in 
V1/V2 and the combined V4/V5 loop lengths, whereas the V3 loop remains constant with 35 
amino acid residues and exhibits only few sequences variability with 2 sequences containing 
34 amino acids each (Figure 2.4.A-C). The V1/V2 which ranged from 49 to 73 (median= 62) 
amino acids, contains the largest number of residues and the highest degree of length 
variation (P<0.0001) compared to the combined V4/V5 ranging from 35 to 46 (median= 39) 
amino acids (P<0.0001). The patients 12541 and BS12 exhibits the lowest V1V2 length, 
whereas the patient 10056 was having the highest V1/V2 length (Figure 2.4.A).  
A similar intra-patient analysis was performed for the degree of variation in the number and 
location of potential N-linked glycosylation sites (PNGS). The number of PNGS in gp120 
range from 18.31 (mean= 26) and was more than the number in gp41 with a range of 2.5 
(mean= 5). The total number of PNGS in gp160 for all the 47 sequences range from 20 to 36 
(mean= 30.5) and was significantly different (P<0.0001) indicating a variation in the 
glycosylation pattern in viral quasispecies in these patients (Figure 2.4.D). The patient 10056 
had the greater number of total PNGS than the rest of patients in which, there were no 
statistically significant changes in the number of PNGS. Similarly, a significant difference 
was observed in the combined V4/V5 region (P<0.0009) (Figure 2.4.G), however no 
significance difference was found in the V1/V2 (P=0.6174) and V3 region (P=0.4464) (Figure 
2.4.E and F). One patient (BS12) had a lower distribution of PNGS in V1V2 as well as the 
combined V4V5 regions. Most of these glycosylation sites are located within the V1/V2 and 
the V4/V5 regions. Several sites were quite conserved; however, 5 PNGS in gp120 and 3 
PNGS in gp41 have showed 100% conservation in all our sequences. 
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Figure2. 5: Longitudinal analysis of changes in the length of gp160 and the number of PNGS. Each dot represents one envelope virus variant. (A-C), 
Comparison of the number of amino acid residues in the variable loops and (D-G), Comparison of the PNGS in the variable loops. The P value was calculated 
by the one-way ANOVA, and individual differences were calculated using Dunn’s multiple comparison test; *, P<0.05; **, P<0.01; ***, P<0.001. 
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2.4.6 Genetic comparison between subtype G with subtype B and C sequences 
Amino acid sequences generated in this study were used in aggregate named as “subtype 
G.agg” and compared to the well characterized subtypes C (n=206), subtype B (n=211) 
reference sequences, but also to subtype G (n=71) reference sequences (subtype G-db) 
available in LANL database (Table 2). The comparisons were focused on the gp120 length of 
amino acids and the number of PNGS since both factor seems to play a role in neutralization 
phenotype (Mascola and Montefiori, 2003, Reitter and Desrosiers, 1998, Bunnik et al., 2008, 
Cao et al., 1997, Moore et al., 2009b, Rong et al., 2007b, Rong et al., 2009, Sagar et al., 2006, 
van Gils et al., 2011). The comparison showed that difference in gp120 length between 
subtype G-agg and subtype B was significant (P<0.005) with a considerable size variation in 
the V1/V2 and V4 regions, however, V3 and V5 did not vary in length (Table 2.2). The 
median lengths of gp120 and V4 for subtype G-agg were shorter than for subtype B. Although 
a considerable length variation was observed in the V1/V2 and V4, there was no significant 
difference between subtype G-agg and subtype C. When subtype G-agg was compared to 
subtype G-db reference sequences there was no statistical difference between the two groups. 
Fewer PNGS were present in V1/V2, V3, V4 and V5 and no significant difference was found 
in the number of PNGS in gp120 length, V1/V2, and V3 between all groups. However, there 
were two statistical differences: one in the V4 region (P<0.05) between Subtype G-agg and 
subtype B and the other one in the V5 region (P<0.05) when we compared PNGS in the two 
subtype G groups (Table 2.2). Many PNGS were common in all subtypes. Taken together, we 
found that a significant difference was only found in gp120 length between sequences 
generated in this study and subtype B sequences resulting in a longer V1/V2 and V4 length of 
subtype B than subtype G.agg. These results can be explained by the fact that subtype B 
sequences obtained from LANL database derived mostly from chronic viruses and seems to 
have longer amino acid length compared to our sequences obtained from patients recently 
infected. 
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IQR median IQR median IQR median IQR median IQR median IQR median IQR median IQR median IQR median IQR median
G-agg 25-28 26 4-6 5 1-1 1 3-5 4 1-1 1 496-511 506 53-68 62 35-35 35 25-28 27 12-12 12
G-db 25-27 26 4-6 5 1-1 1 4-5 4 1-2 1 502-511 506 59-66 61 35-35 35 24-29 26 11-12 12
B-db 23-27 25 4-6 5 1-1 1 4-5 5 1-2 1 507-517 512 59-66 62 35-35 35 30-34 32 12-12 12
C-db 22-27 26 4-6 5 1-1 1 4-5 4 1-1 1 499-513 507 56-66 60 35-35 35 26-32 29 12-12 12
Comparison 
G-agg vs G-db
G-agg vs B-db
G-agg vs C-db
Number of PNGS
>0.05
>0.05
>0.05 >0.05 >0.05 <0.05
>0.05 >0.05 >0.05 >0.05
Subtype
Length of variable loops
gp120 V1/V2 V3 V4 V5 gp120
>0.05 >0.05
V1/V2 V3 V4 V5
P value
>0.05 >0.05 >0.05 >0.05 <0.05 >0.05 >0.05 >0.05
<0.05 >0.05 >0.05 >0.05 >0.05
<0.05 >0.05 >0.05 <0.05 >0.05
 
 
Table 2.2: Comparison of sequence lengths and PNGS between HIV-1 subtypes G, B and C gp120. 
G-agg, 47 subtype G sequences generated in this study and used in aggregate; G-db, 71 subtype G reference sequences from LANL database; B-db, 211 well-
characterized subtype B database sequences; C-db, 206 well-characterized subtype C database sequences. Bolded P values (P<0.05) are significant differences 
analyzed by one way ANOVA after Bonferroni’s correction. 
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2.4.7 V3 region analysis and Co-receptor usage 
The V3 region was analyzed in details since it is an important determinant of the co-receptor 
usage (Briggs et al., 2000, Cann et al., 1992, Fouchier et al., 1992, Rizzuto et al., 1998). The 
V3 region was found to be highly conserved with the crown motif GPGQ present in 41 out of 
42 sequences (Table 3). The GPGQ crown motif is known to be associated with CCR5 tropic 
in subtype C sequences (Cilliers et al., 2003). Another characteristic of the V3 loop associated 
with tropism determination is the property of amino acids at position 11 and 25 (Fouchier et 
al., 1992). No positively charged amino acid residues were found at positions 11 and 25. The 
neutral Serine and Glycine residues were present in most cases at position 11, whereas in 
most cases, an amino acid with a negatively charged side chain (E or D) was present at 
position 25. However, three sequences (12541.E11, 12541.D12, 12541.E2) had a deletion at 
position 25. The net charge value was calculated by subtracting the number of the negatively 
charged amino acids D and E from the number of positively charged amino acid R and K. The 
net charge value of the V3 loop was low and ranged from +2 to +6, which is in agreement 
with previous reports indicating that few numbers of positive charges in the V3 region is 
associated with CCR5 utilization (Cilliers et al., 2003). The R5 tropism genotypic predictions 
using WebPSSM and Geno2pheno based on the V3 region (Jensen et al., 2006, Sing et al., 
2007) were confirmed in vitro by comparing pseudoviruses titers using co-receptor inhibitors 
on TZM-bl cells. TZM-bl cells express the receptor CD4 and both the CCR5 and CXCR4 co-
receptors (Platt et al., 1998). Pseudoviruses expressing the R5 tropic IIIB and the X4 tropic 
BalPS were used as control. All 28 subtype G clones had a CCR5 tropism as determined by a 
reduction or absence of TZM-bl cells infection in the presence of the CCR5 inhibitor TAK-
779 (3.3 µM), but not in the presence of CXCR4 inhibitor AMD-3100 (430 nM) (Table 2.3). 
Borrego et al (2012) reported recently similar IC50 (2.6 nM) for one clinical isolate but a 
1000-fold higher IC90 (2.8 µM) (Borrego et al., 2012) which is more similar to our results. 
One of the limitations in this experiment is that we did not calculate the IC50 or IC90 of TAK-
779. However, the amount of virus added was the same for all viruses and the variation in 
sensitivity to TAK-779 may be related to the high genetic diversity of the envelope of these 
viruses that may affect the binding affinity of TAK-779. In addition, it is possible that CCR5 
use may evolve during the course of HIV-1 infection such that CCR5 variants isolated from 
our subtype G patients which had low levels of CD4+ T cells have reduced sensitivity to 
TAK-779. 
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Table 2.3: co-receptor usage properties of the HIV-1 subtype G envelope sequences.            
Clone ID  Subtype   Web 
PSSM 
Geno2 
pheno 
V3 net 
charge 
Amino 
acid 
(11/25)      
Crown 
motif 
Co-receptor assay (TZM-bl) 
  Fold drop 
infectivity with 
3.3uM TAK-
779 
Fold drop 
infectivity with 
430nM AMD-
3100 
Co-
receptor 
10056_C12 G CCR5 CCR5 4 GR GPGQ nd nd nd 
10056_C1 G CCR5 CCR5 4 GS GPGQ 5.3 NR CCR5 
10056_C6 G CCR5 CCR5 4 GS GPGQ nd nd nd 
10056_E6 G CXCR4 CCR5 6 SG GPGQ nd nd nd 
10056_F5 G CCR5 CCR5 4 GS GPGQ nd nd nd 
10056_E8 G CCR5 CCR5 4 GS GPGQ nd nd nd 
10056_F2 G CCR5 CCR5 4 GS  GPGQ 6.7 NR CCR5 
10056_D8 G CCR5 CCR5 4 GS GPGQ 6.7 NR CCR5 
11439_G7 G CCR5 CCR5 4 SE GPGQ nd nd nd 
11439_D4 G CCR5 CCR5 4 SE GPGQ 2.4 NR CCR5 
11439_H4 G CCR5 CCR5 4 SE GPGQ 4.3 NR CCR5 
11439_C5 G CCR5 CCR5 4 SE GPGQ 2.6 NR CCR5 
11439_F5 G CCR5 CCR5 4 GE  GPGQ nd nd nd 
11439_F6 G CCR5 CCR5 4 SE GPGQ nd nd nd 
12541_C12 G CCR5 CCR5 5 SA GPGQ 5.9 NR CCR5 
12541_B2 G CCR5 CCR5 5 SA GPGQ 12.5 NR CCR5 
12541_E11 G CCR5 CCR5 5 S- GPGQ nd nd nd 
12541_D12 G CCR5 CCR5 5 S- GPGQ nd nd nd 
12541_E2 G CCR5 CCR5 5 S- GPGQ nd nd nd 
12541_C11 G CCR5 CCR5 3 SD GPGR nd nd nd 
BS03_H3 G CCR5 CCR5 4 SE GPGQ 7.1 NR CCR5 
BS03_A1 G CCR5 CCR5 4 SE GPGQ nd nd nd 
BS03_G4 G CCR5 CCR5 4 SE GPGQ 5.3 NR CCR5 
BS03_E3 G CCR5 CCR5 4 SE GPGQ nd nd nd 
BS12_D9 G CCR5 CCR5 3 SD GPGQ 6.3 NR CCR5 
BS12_D2 G CCR5 CCR5 3 SD GPGQ 2.4 NR CCR5 
BS12_F6 G CCR5 CCR5 3 SD GPGQ nd nd nd 
BS12_A5 G CCR5 CCR5 2 SD GPGQ nd nd nd 
BS12_G8 G CCR5 CCR5 3 SD GPGQ 4.5 NR CCR5 
BS12_A6 G CCR5 CCR5 2 SD GPGQ 6.3 NR CCR5 
BS46_A2 G CCR5 CCR5 4 DA GPGQ nd nd nd 
BS46_E1 G CCR5 CCR5 3 DA GPGQ 16.7 NR CCR5 
BS46_mt G CCR5 CCR5 4 DA GPGQ nd nd nd 
BS46_H4 G CCR5 CCR5 4 DA GPGQ nd nd nd 
BS46_E2 G CCR5 CCR5 3 DA GPGQ 6.3 NR CCR5 
BS48_F5 G CCR5 CCR5 4 SE GPGQ 25.0 NR CCR5 
BS48_H10 G CCR5 CCR5 4 SE GPGQ 5.3 NR CCR5 
BS48_E1 G CCR5 CCR5 4 SE GPGQ 4.2 NR CCR5 
BS48_E4 G CCR5 CCR5 4 SE GPGQ 20.0 NR CCR5 
BS48_mt G CCR5 CCR5 4 SE GPGQ nd nd nd 
BS48_F1 G CCR5 CCR5 4 SE GPGQ 25.0 NR CCR5 
BS48_E3 G CCR5 CCR5 4 SE GPGQ 14.3 NR CCR5 
BS51_B5 G CCR5 CCR5 4 SA GPGQ 5.6 NR CCR5 
BS51_B6 G CCR5 CCR5 4 SA GPGQ 7.1 NR CCR5 
BS51_H2 G CCR5 CCR5 3 SE GPGQ 5.6 NR CCR5 
BS51_A3 G CCR5 CCR5 4 SA GPGQ 7.7 NR CCR5 
BS51_D4 G CCR5 CCR5 4 SA GPGQ nd nd nd 
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IIIB (CXCR4) B Controls NR 250 CXCR4 
BALPS 
(CCR5) 
B Controls 1.9 NR CCR5 
 ‘nd’= not determined, NR= No Reduction, fold drop infectivity shown is ratio of percentage 
neutralization of each virus to control virus. 
 
2.5 Discussion 
In this study, 47 full length sequences were analyzed from 8 individuals infected with HIV-1 
subtype G with the goal to investigate the genetic properties that are known to influence 
epitope exposure on the gp120 molecule and elucidate the co-receptor utilization by HIV-1 
subtype G viruses in Cameroon.  Phylogenetic analysis of the full length env has revealed that 
all these viruses belong to HIV-1 subtype G. env sequences were interspersed among all 
subtype G sequences showing a wide spectrum of diversity among our samples. In fact, 12541 
sequences branched from near the root of the subtype G subtree in a poorly populated branch 
containing some sequences related to a segment of CRF06_cpx. Sequences from within one 
sample were genetically related to each other, while samples were genetically distinct from 
each other. These results suggest that our samples capture a substantial amount of the 
diversity within the subtype G envelope sequences and are largely different from each other. 
These finding are therefore consistent with the results of a previous study on subtype G 
(Revilla et al., 2011).  
This study also showed that in 4 individuals, the viral population was heterogeneous with 
large genetic distances (>1.5%) indicating a likely long period of time since infection. The 
three individuals failing ART were almost certainly infected for much longer, suggesting a 
reason for the increased diversity. Individual analysis showed that 10056 had the most 
variable sequences (3.45%), followed by 12541 (3.3%), 11439 (2.1%) and the rest of patients 
(<2%). The maximum values are based largely on one outlier, and this outlier may have been 
derived from a related virus. So, the maximum might be more related to how far apart the two 
viruses were than how long the person was infected. Four individuals had homogeneous viral 
sequences, with a much shorter genetic distance (<1.5%), suggesting a restricted viral 
evolution in those individuals. Consistent with a recent infection, one individual (BS48) 
exhibits the lowest intra-patient genetic distance with values similar to those normally 
observed in the first 90 days following infection with a single viral variant (Keele et al., 2008) 
The length of amino acids and the N-linked glycosylation of the HIV-1 envelope are among 
the mechanisms used by the virus to evade antibody recognition, possibly by shielding 
underlying epitopes of envelope from antibodies recognition (Gray et al., 2007, Pinter et al., 
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2004). Since several PNGS are relatively constant across HIV-1 subtypes, there is a great 
interest in developing a carbohydrate based antigen in order to elicit a humoral immune 
response. Previous studies have shown that viruses with shorter V1V2 lengths are preferably 
transmitted in some subtypes (Chohan et al., 2005, Derdeyn et al., 2004). We examined and 
statistically analyzed the difference in length of variable loops and the number of PNGS of 
the isolated envelope genes and found a variation in the glycosylation sites and variable loop 
lengths in the 8 patients. The V1V2 lengths from patients infected for < 6 months (BS03, 
BS46, and BS48) were not significantly shorter when compared to patients infected for > 6 
months (BS12, BS51). The V1V2 and V4V5 had the most length variation within and 
between participants, whereas the V3 length was constant. This variation in length appears 
similar to previously observed in subtype C (Coetzer et al., 2007). 
Several studies have reported that viruses from acute infection have shorter variable loops and 
fewer glycosylation sites than viruses from chronic infection (Kwiek et al., 2008, Russell et 
al., 2011, Derdeyn et al., 2004). Li et al. (2006) suggested that increased exposure of epitopes 
on the shorter, less-glycosylated gp120 of newly transmitted subtype C viruses could result in 
enhanced immunogenicity, greater antigenicity or both. This interpretation is based on 
evidence that difference in the length of variable loops and number and position of PNGS on 
gp120 may contribute to different neutralization properties (Li et al., 2006a). Results of the 
analysis among our subtype G samples showed no relationship between time since infection 
and length of variable region and glycosylation sites. Some patients (12541) known to be 
infected for a long period of time exhibits a relatively short V1V2 and V4V5 length. In 
addition, BS48 from the blood donor group had unusually low within-donor genetic distance; 
equivalent to that seem in very recent infection (<90 days), and had unusually high V4 
lengths. This might be a feature of many subtype G envelope compared to subtype B and C. 
However, due to the small sample size, this analysis may not have a strong power and should 
be taken with caution. Therefore, a larger number of subtype G gp120 sequences from acutely 
and chronically infected individuals will be needed to resolve whether or not viruses from 
acute infection have unique feature in the context of subtype G. 
The gp120 regions of envelopes from subtype C acute viruses have been reported to be 
shorter and less glycosylated compared to subtype C chronic viruses (Derdeyn et al., 2004). 
However, these differences are not seen in subtype B (Chohan et al., 2005). Subtypes B and C 
are the most extensively studied and well characterized HIV-1 subtypes and the majority of 
the sequences available from LANL database are from chronic patients. A similar analysis 
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was performed in this study by comparing subtype G sequences generated in this study 
(subtype G.agg) to subtype G, B and C gp120 in the LANL database, known to contain in 
majority sequences from chronic viruses. A general distinguishing feature was the shorter of 
gp120 and V4 length on subtype G-agg compared to subtype B. Furthermore, although the 
number of PNGS site on gp120 was not significantly different, subtype B had more PNGS 
site in the V4 region. These findings are similar to those of recent studies where the gp120 of 
subtype C and A expands and add loop sequences and PNGS over the course of infection 
(Chohan et al., 2005, Sagar et al., 2006, Derdeyn et al., 2004). A significant difference in the 
PNGS number in the V5 region was also found by analyzing our patient collectively compare 
to Subtype G obtained from the database (Subtype G-db, whereas, there were no difference 
compare to subtype C-db. 
The env sequences were also tested for the co-receptor usage in TZM-bl cells and we 
determined that all our env clones were CCR5 tropic, which is consistent with previous 
studies on subtype G suggesting the use of CCR5 by the majority of viruses (Revilla et al., 
2011, Tebit et al., 2002, Zhong et al., 2003, Brandful et al., 2007). It was surprising that four 
viruses BS12.D2, 11439.C5, 11439.D4, and BalPS) had 3.4 fold less reduction in infectivity 
in the presence of such a high concentration of TAK-779 (3.3µM). Baba et al, (1999) reported 
that TAK-779 inhibited the replication of CCR5 clinical isolates as well as laboratory strains 
at a concentration of 1.6-3.7nM, which is less than the concentration we used to inhibit these 
HIV-1 subtype G viruses. The variability in the sensitivity to TAK-779 of these CCR5 viruses 
may not be due to alternative co-receptor usage but rather differential CCR5 binding and to 
the extreme heterogeneity of the HIV-1 envelope glycoproteins (gp120 and gp41) that may 
affect the susceptibility of variant HIV-1 strains (Torre et al., 2000).  
In HIV-1 subtype G, there is little information on the genetic characteristics of the V3 loops 
that determine the tropism. The V3 sequences were therefore analyzed and found that almost 
all isolates had the GPGQ crown motif with a low net positive charge value. The V3 loops of 
R5 viruses generally have lower net positive charge than those of X4 (Jiang, 1997, Huang et 
al., 2005, Fouchier et al., 1992). 
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2.6 Conclusion 
In conclusion, this study characterizes extensively the genotypic properties of HIV-1 subtype 
G circulating in Cameroon. This study shows that the heterogeneity of env diversity and 
evolution among our study participants differs with HIV-1 disease course (HIV-1 naïve and 
HAART patients). This study also highlights the identification of apparent recombination 
events in some individuals. Subtype G envelope gene exhibit lower gp120, and V4 length 
compared to the well characterized subtype B, and the majority of infection are caused by 
viruses that exclusively utilizes CCR5 co-receptor. These findings are likely to provide useful 
information for the design and the evaluation of HIV-1 vaccine and for a better understanding 
of the HIV-1 epidemic                                   . 
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Characterization of neutralization antibody responses in 
HIV-1 subtype G infected patients in Cameroon 
 
3.1 Abstract 
Background 
The high genetic diversity of HIV-1 is a great obstacle for development of an effective 
vaccine against this pathogen. HIV-1 subtype G accounts for 5% of HIV-1 infection 
worldwide, centered on West and Central. However, immunity to viruses of this subtype, 
particularly strains that circulate in its main reservoir, Central and West Africa have been 
understudied. In this study, we characterized the neutralization capacities of 7 subtype G-
infected plasma samples, including their ability to neutralize 28 pseudoviruses obtained from 
the same seven samples. Five study participants were blood donors later determined to be 
HIV-infected and the remaining two were undergoing testing for antiretroviral drug 
resistance. 
Results 
The neutralization sensitivity of subtype G pseudoviruses to autologous neutralization (own 
plasma), and plasma pools was characterized using full length envelope clones to generate 
pseudoviruses for infection studies. Our data showed that autologous neutralization was 
generally low to undetectable among out study participants HIV-1 subtype G infected 
individuals, as observed previously for samples from other subtypes. However, strikingly, all 
four BS12.derived viruses exhibited substantial sensitivity to neutralization by their own 
plasma (geometric mean ID50= 564).  
The ability of subtype G plasma to neutralize a panel of 14 HIV-1 env pseudoviruses was 
evaluated. The panel includes representatives of subtypes A, B, C, and CRF02_AG which 
were from tier 2 (moderately resistant viruses) to tier 3 (highly resistant viruses). Three of the 
samples were from patients undergoing testing for antiretroviral resistance, and thus may have 
antiretroviral drugs in their blood plasma despite having detectable viral loads. However, 
plasma from two of these three patients failed to neutralize negative control pseudovirus 
(Murine Leukemia Virus envelope, MLV) or most other viruses tested, suggesting that levels 
of antiretroviral drugs in these two samples were too low to interfere with the neutralization 
assay. It may be that these donors were not taking their antiretroviral. The third sample 
showed evidence suggesting that antiretroviral drugs were present in the plasma, and this 
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sample was excluded from further analysis in the neutralization studies. Blood plasma from 
two out of the remaining seven study participants, including BS12, neutralized more than half 
of panel virus tested at >50% neutralization at a dilution of 1/50, indicating at least limited 
neutralization breadth in these two samples. Interestingly, BS12 serum, the samples that 
showed a substantial potent autologous activity, also neutralized 3/5 of the tier 3 isolates from 
the panel viruses (278-50 and 257-31 not neutralized; 33-7, 253-11, and PV0.4 neutralized). 
Mapping of the epitope targeted by neutralizing antibodies in BS12 plasma indicated that the 
dominant neutralizing antibody for virus CAP45.2.00.G3 in sample BS12 targeted the PG9/16 
site. This site is the target in the V2 and V3 regions of the broadly neutralizing monoclonal 
antibodies PG9 and PG16. BS12 plasma also exhibited substantial neutralization of an HIV-2 
chimeric virus displaying the MPER of 253-11, a CRF02_AG virus, although we did not 
examine if these anti-MPER antibodies are capable of neutralizing HIV-1 viruses by 
recognizing MPER.  
Conclusion 
Our data showed that one sample, BS12, was unusual in that the plasma sample itself 
neutralized viruses derived from sequences found in the same sample. Our data suggest that in 
study participant BS12 plasma, the V1V2, and MPER regions are the main immunodominant 
regions of the envelope targeted by neutralizing antibodies, indicating that its autologous 
neutralization and its limited neutralization breadth may be dictated by a limited number of 
target epitopes. We believe that a subset of these HIV-1 viral variants may be used for 
screening of HIV-1 vaccine candidate to assure that evaluation of vaccine-induced antibody 
includes some of the substantial diversity ground in subtype G. 
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3.2 Introduction 
In 2011, UNAIDS and WHO estimated that there were 34 million people living with HIV, 
and  over 2.5 million new infections with 69% of these new infections occurring in Sub-
Saharan Africa (UNAIDS, 2012, WHO, 2013). An effective vaccine that prevents HIV-1 
transmission is urgently needed. It is likely that an effective vaccine will need to include a 
component that induces neutralizing antibodies against a broad range of HIV-1 strains 
(Burton et al., 2012). Studies in nonhuman primates have shown that passively transferred 
neutralizing antibodies (nAbs) can protect against HIV-1 infection when present at the time of 
exposure (Barouch et al., 2012, Baba et al., 2000, Mascola et al., 1999, Mascola et al., 2000, 
Parren et al., 2001). Designing an effective vaccine has so far been unsuccessful, presumably 
due to the high sequence variability of the envelope glycoproteins (Env) (Burton et al., 2004), 
the shielding of critical neutralizing epitopes by N-linked glycans (Kwong et al., 2002) and 
the considerable evolution of the antigen binding site of antibodies that appears to be required 
for the production of neutralization breadth (Burton et al., 2012). Some HIV-1 individuals 
mount a strong autologous neutralization response within a few months to one year of initial 
infection (Li et al., 2006b, Richman et al., 2003, Wei et al., 2003, Gray et al., 2007). 
Antibodies capable of neutralizing heterologous viruses tend to develop later in infection; but, 
only a small proportion of chronically infected patients can develop broadly cross-reactive 
nAbs against multiple HIV-1 viruses (Braibant et al., 2006, Donners et al., 2002, Simek et al., 
2009, Gray et al., 2011a). 
A number of new candidate immunogens have been identified and it is important that the 
vaccine-induced responses be examined against different HIV-1 variants, including those 
circulating in endemic areas. It has been recommended that separate panels of well 
characterized viruses be developed for each major HIV-1 subtypes (Mascola et al., 2005). The 
availability and standard use of these reference subtypes should allow the acquisition of 
standardized measurements of the neutralizing antibody responses so that advancement in 
immunogen design can be identified (Li et al., 2005). 
HIV-1 subtype G is the sixth most prevalent subtype of HIV-1 after subtypes A, B, C, 
CRF01_AE and CRF02_AG (Hemelaar et al., 2006). Subtype G is concentrated in West and 
Central Africa (Hemelaar et al., 2011b) however; very limited information is available on the 
neutralization properties of HIV-1 subtype G viruses. Systematic analysis of a wide range of 
HIV-1 envelope sequences (Brown et al., 2005) and neutralization patterns (Brown et al., 
2008, Seaman et al., 2010) have been performed. However, subtype G viruses are severely 
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underrepresented in these works. Brown et al (2005) studied only two subtype G-associated 
sequences while Brown et al (2008) did not study the neutralization patterns of any subtype G 
viruses and Seaman et al (2010) evaluated the intrinsic neutralization resistance of only one 
putative subtype G virus. Only a recent study has one neutralization study of Subtype G 
viruses been published (Revilla et al., 2011). In this work, only two of the subtype G 
sequences were derived from individuals from West or Central Africa and no testing of 
autologous and heterologous neutralization capacity was performed, which is critical for 
evaluating which viruses should be included in test panels for vaccine evaluation and 
understanding to what extent particular immunogen design techniques are likely to cover 
subtype G viruses.  
This study describes the characterization of the autologous and heterologous neutralization 
antibody response of viral envelopes generated from seven HIV-1 subtypes G infected 
individuals from Cameroon using conventional assays. We also examined the specificity of 
neutralizing antibodies in a patient exhibiting good autologous and heterologous 
neutralization capacity to understand how such antibodies might contribute to neutralization 
breadth. 
 
3.3 Methods 
3.3.1 Study participants and plasma samples 
Study participants and plasma samples used in this study are described in details in chapter 
2.3.1 of this thesis. 
The plasma samples were tested against viruses individually or as a pool containing an equal 
mixture of individual plasma samples from the same subtype. Three pools of plasma were 
made: The subtype C pool (South Africa; n= 68) from our laboratory study cohort in 
Khayelitsha Site B clinic, the CRF02_AG pool (Cameroon; n=12) (Jacob et al., 2012), and the 
subtype G pool (Cameroon; n=8) from our study samples (Tongo et al., 2013). All plasma 
samples were heat inactivated for 1 hour at 56⁰C before use as a source of antibodies in the 
neutralization assay. This study received approval from the CIRCB Ethics Committee and the 
Human Research Ethics committee of the University of Cape Town, Faculty of Health 
Sciences (REC NO: 107/2011). 
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3.3.2 Cell lines 
The TZM-bl cells were obtained from Drs. J Kappes and X Wu through the NIH AIDS 
Research Reagent Reference Program (ARRRP). These cells were derived from HeLa cell 
clone and expresses CD4, CCR5 and CXCR4 (Platt et al., 1998). TZM-bl cells contain two 
reporter genes: the luciferase and the Escherichia coli β-galactosidase under the control of the 
HIV-1 LTR promoter (Wei et al., 2002). The 293T cells used for transfection were obtained 
from Dr. A Rice through the ARRRP.  
3.3.3 Virus envelope panel and chimeric viruses   
A panel of 14 reference HIV-1 env pseudoviruses comprising representatives of different 
subtypes (A, B, C, and CRF02_AG) was used in the heterologous neutralization assays. The 
panel of pseudoviruses was chosen based on subtype diversity, neutralization resistance 
(Seaman et al., 2010, Blish et al., 2009, Jacob et al., 2012) and geographic diversity of origin. 
All tier designations are as per Seaman et al (Seaman et al., 2010). The cloned envelope 
constructs used and their subtypes in parenthesis were: Q168.a2 (A), QG984 (A), QH343 (A), 
Q461.e2 (A), TRO11 (B), RHPA (B), REJO (B), SC 4226 (B), ZM249 (C), CAP45 (B), 
255.34 (CRF02_AG), 33-7 (CRF02_AG), 278-50 (CRF02_AG), 253-11 (CRF02_AG) and 
were all obtained from ARRRP. The Murine Leukemia Virus (MLV) was provided by Dr. 
Lynn Morris, NICD, Johannesburg, South Africa. Samples were tested against MLV as a 
negative control. The 7312A parent HIV-2 construct and all HIV-2/HIV-1 chimeric constructs 
containing HIV-1 MPER sequences (C1, C1C) (Gray et al., 2007) (except 253-11 MPER) 
were provided by Dr. George Shaw, University of Pennsylvania, Philadelphia, USA. The 253-
11 MPER construct was produced by mutagenesis from HIV-2 C1 by Rajesh Jacob in our 
laboratory using the Stratagene QuikChange II XL Site-Directed Mutagenesis Kit (Stratagene, 
La Jolla, USA). 
3.3.4 Cloning of envelope genes, pseudoviruses production and titration 
The cDNA extracted from the infected individual plasma samples were used to amplify the 
full-length env gene using the single genome amplification (SGA) assay as previously 
described (Salazar-Gonzalez et al., 2008). Briefly, the approximately 3kb PCR products 
generated using the HIV-1 subtype G specific PCR primers or the general primers  were 
cloned into pcDNA3.1D/V5.His.TOPO vector (Invitrogen, Carlsbad, CA, USA) and bacterial 
colonies screened by PCR for insertion and correct orientation using T7 and BGH primers. 
Pseudoviruses were made by cotransfecting 293 T cells with 4 µg of  a chosen plasmid with 
an envelope insert with 8 µg of SG3∆env HIV genome plasmid using X-tremeGENE 9 DNA 
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transfection reagent (Roche Diagnostics, Basel, Switzerland) as previously described 
(Montefiori, 2009). 48 and 72 hours after transfection, the culture supernatant containing 
pseudoviruses was harvested, ﬁltered, aliquoted, and stored at .80°C. The dilution of 
supernatant needed to obtain 50,000 relative light units (RLU) of readout for each 
pseudoviruses was determined by infection in TZM-bl as described (Montefiori, 2009).  
3.3.5 Neutralization assay 
TZM-bl-based neutralization by patient plasma or plasma pools were assessed as described 
(Montefiori, 2009). Patient plasma samples were evaluated for neutralization antibody activity 
against patient derived pseudoviruses (autologous neutralization). Testing against a virus 
panel for measuring neutralization breadth/capacity was performed by estimating the ID50 as 
described in section 3.3.6 below. Otherwise, serial two-fold dilutions of plasma were 
distributed in duplicate in 96-well ﬂat-bottom plates (Costar) in a total volume of 100 µl per 
well and pre-incubated with 50 µl of pseudoviruses for one hour. Freshly trypsinized TZM-bl 
cells were then added (10,000 cells/well in Dulbecco’s modiﬁed Eagle’s medium [DMEM] 
10% fetal bovine serum [FBS] containing HEPES and 7.5 µg/ml of DEAE-dextran). After 48 
hours of incubation at 37°C, 100 μl of cells/well were transferred to 96.wells black solid plate 
(Costar) and the luminescence measured using the Bright-Glo™ luciferase substrate 
(Promega, Madison, USA) and measured on a VERITAS microplate luminometer (Turner 
BioSystems). The 50% inhibitory dilution (ID50) was measured as the plasma dilution that 
cause a 50% reduction in relative luminescence units (RLU) compared to the level in the virus 
control wells after subtraction of cell control RLU. The ID50 was calculated from testing 
neutralization for at least four dilutions of plasma using curve fit functions in Prism version 5 
(GraphPad, La Jolla, USA). The neutralization score for each virus and for each plasma 
sample was defined as the geometric mean of all of the ID50 values for that virus or plasma 
sample.    
3.3.6 Estimation of ID50 for each serum/virus pair and its validation 
For the purpose of estimating neutralization breadth, an ID50 was predicted from percentage 
neutralization (measured at 1/100 serum dilution) based on a linear regression analysis 
developed by others in my laboratory that was performed on a subpopulation (n=240; 
“training set”) of the sample/virus combinations with known percentage neutralization of 
serum (at 1:100 dilution) and measured ID50 values. The effect of percentage neutralization 
was modeled both linearly and non-linearly. Based on R
2
,
 
we measured the goodness of fit of 
the corresponding models and chose a linear model (Jacob et al., 2012). The equation was 
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used to predict the ID50 from % neutralization at 1/100 serum dilution. The calculated 
relationship is: ln (predicted ID50) =1.303 + 0.060962 * % neutralization @ 1/100. The 
serum/virus pairs in the training set included sample/virus combinations from previous studies 
in the laboratory (Jacob et al., 2012). The 1/100 serum dilution was the only dilution tested 
for all pooled of sera. 
The model was validated on a separate subset of sample/virus combinations (“test set”) with 
known percentage neutralization of serum (at 1:100 dilution) and measured ID50 values 
(n=234) from others in our laboratory. The predicted ID50 values derived from the percentage 
neutralization for the “test set” correlated well with the corresponding measured ID50 values 
(R
2
=0.67) (Jacob et al., 2012). 
3.3.7 Statistical analysis  
ID50 titers for both autologous and heterologous neutralization responses were performed 
using the nonlinear regression (curve fit) function in GraphPad prism 5 software programme 
(GraphPad, La Jolla, USA). Correlations were measured by Spearman’s rank test in GraphPad 
5. Correlations with p-value ≤0.05 were considered as statistically significant. 
 
3.4 Results 
3.4.1 Study participants 
The five blood bank samples and the three initial samples from patients undergoing testing for 
antiretroviral resistance were screened against the negative control pseudovirus MLV. Plasma 
from the blood bank samples and two of the three patients failing ART failed to neutralize 
MLV suggesting that levels of antiretroviral drugs in these two samples were too low to 
interfere with the neutralization assay. It may be that these donors were not taking their 
antiretroviral. One donor (11439) neutralized MLV and may have antiretroviral drugs in the 
plasma, and was excluded in the neutralization studies. 
3.4.2 Variations in autologous neutralization sensitivity between study participants 
The sensitivity to autologous neutralization of subtype G viral variants was studied from eight 
patients by testing the ability of each participant’s plasma sample to neutralize their envelope 
variants. A total of 28 pseudoviruses (ranging from 2 to 6 per participant) were tested against 
their respective plasma. Figure 3.1 shows that the neutralizing antibody response varied in 
magnitude for all the eight subjects. Evidence for neutralization by autologous plasma was 
detected in 6 out of 7 patients (Figure 3.1). The sensitivity of different viral variants to 
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autologous neutralization within the same patient varied among participants. The neutralizing 
antibody response was not detectable in two patients (BS03 and BS51) and three patients 
(12541, BS46, and BS48) had a low AnAbs activity. Interestingly, two patients (10056 and 
BS12) developed autologous neutralization activity against all their respective viruses. This is 
best illustrated in one of these two participants (BS12), in which all four BS12.derived viruses 
exhibited substantial sensitivity to neutralization by their own plasma (geometric mean ID50= 
564) which is approximately four-fold higher than the neutralization potency of 
10056.derived viruses (geometric mean ID50=142). These results suggest an effective 
neutralizing antibody pressure which is mounted against the HIV-1 viruses of these 
participants, although this pressure is not enough for the effective control of the infection. 
Unfortunately, BS12 was an anonymous blood donor and it is not possible to obtain further 
samples to trace the effect of this high level of neutralizing antibody upon subsequent 
evolution of the HIV population in this individual. 
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Figure3. 1: Neutralization of subtype G viral isolates by autologous plasma. The patient ID and 
the pseudoviruses tested are shown to the left and the patient plasma tested is indicated at the top. The 
neutralization titer is also shown as the plasma dilution that causes the inhibition of 50% of virus 
infection when the virus is neutralized by the participant’s plasma. The highest titer (>300) is shown in 
red as indicated at the right of the figure. The grey box indicated that <50% neutralization was 
observed at 1:50 which was the highest concentration of plasma tested, and the value of 50 was 
assigned. 
3.4.3 Neutralization activity of plasma pools 
The ability of various plasma pool samples to neutralize viruses expressing HIV-1 subtype G 
envelopes was next assessed. Three different panels of HIV-1 plasma pools were used for 
neutralization assays. The subtype C pool (South Africa), subtype G pool (Cameroon) and 
CRF02_AG pool (Cameroon) were made using equal amount of plasma from at least eight 
HIV-1 infected individuals in order to provide a desired sample diversity of the antibody 
repertoire present in each individual plasma sample. As depicted in figure 2, most of these 
viruses shared similar level of sensitivity to neutralization by the various plasma pools, but 
Sample 
ID
Virus
Autologous  
plasma ID50
10056.C1 228
10056.D8 150
10056.F2 84
12541.B2 103
12541.C12 <50
BS03.G4 <50
BS03.H3 <50
BS12.A6 555
BS12.D2 754
BS12.D9 608
BS12.G8 632
BS46.A2 <50
BS46.E1 185
BS46.E2 215
BS46.H4 52
BS48.E1 <50
BS48.E3 131
BS48.E4 <50
BS48.F1 127
BS48.F5 <50
BS48.H10 85
BS51.A3 <50
BS51.B5 <50
BS51.B6 <50
BS51.H2 <50
BS48
BS51
10056
12541
BS03
BS12
BS46
300-999
100-299
50-99
<50
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some exhibit either a highly sensitive or highly resistant phenotype. This finding is consistent 
with previous reports from Seaman et al, (2010) and Shang et al, (2011) (Seaman et al., 2010, 
Shang et al., 2011), where variable degrees of sensitivity to neutralization were also found 
among panel of viruses against different subtype-specific plasma. This finding suggests that 
viral sensitivity to plasma neutralization seems dependent more on viral characteristics than 
on the type of plasma used. The overall potencies of these plasma pools were ranked in the 
following order: subtype C (ID50 1:285) > subtype G (ID50 1:151) > CRF02_AG (ID50 1:90). 
Potency of the subtype C pool was significantly higher than that of the CRF02_AG pool 
(P<0.001) and subtype G pool (P<0.009). The most parsimonious explanation could be the 
fact that samples from subtype C pool were selected from patients with moderate 
neutralization activity against a panel of 24 different HIV-1 viruses tested in another study in 
our laboratory (R.A.Jacob unpublished data), while the subtype G sample were not selected 
based upon neutralization activity. Differences in potency was also significant for the subtype 
G pool compared to CRF02_AG (P<0.0001), suggesting that CRF02_AG pool used in this 
study, which was also used in a previous study (Jacob et al., 2012) did not contain high levels 
of heterologous neutralizing antibody, including antibody specific for subtype G viruses.  
However, there was no significant correlation between neutralization activity of subtype G 
pool and the autologous neutralization activity (P=0.16), suggesting that the subtype G pool 
used in this study still contain nAbs present in the autologous plasma even at a lower 
concentration.  
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Figure3. 2: Neutralization of subtype G viral isolates by pool of plasma. The patient ID and the 
pseudoviruses tested are shown on the left and the plasma pools tested are indicated at the top. Plasma 
pool were made using equal amount of plasma from HIV-1 infected individuals in order to provide a 
desired sample diversity of the antibody repertoire present in each individual plasma sample such as 
subtype C (n=68), CRF02_AG (n=12), and subtype G (n=8). The neutralization titer is also shown as 
the plasma dilution that causes the inhibition of 50% of virus infection when the virus is neutralized by 
the plasma pools. The highest titer (>1000) is shown in red as indicated at the bottom of the figure. 
The grey box indicated that <50% neutralization was observed at 1:50 which was the highest dilution 
of plasma tested. 
 
3.4.3 Subtype G Env autologous neutralization (ID50 titers) does not correlate with the 
length and N-linked glycosylation site of the variable loops 
Several recent studies in subtype C have demonstrated an inverse association between the 
neutralization sensitivity and length of variable loops (V1V2) and number of potential N-
linked glycosylation sites (PNGS) (Rong et al., 2009, Gray et al., 2007, Sagar et al., 2006, 
Rong et al., 2007a, Pinter et al., 2004). Gray et al (2007) reported that the magnitude of nAbs 
responses was associated with shorter V1V5 envelope length and fewer glycosylation sites, 
Sample ID Virus C pool AG pool G pool Virus GMT
10056.C1 346 62 95 127
10056.D8 285 59 111 123
10056.F2 61 <50 66 63
12541.B2 200 110 198 163
12541.C12 578 105 174 220
BS03.G4 465 100 221 218
BS03.H3 <50 100 221 149
BS12.A6 397 118 228 220
BS12.D2 869 174 361 379
BS12.D9 338 116 257 216
BS12.G8 872 76 118 199
BS46.A2 481 136 225 245
BS46.E1 286 95 360 214
BS46.E2 509 98 246 230
BS46.H4 313 97 249 197
BS48.E1 746 210 914 523
BS48.E3 546 97 315 255
BS48.E4 540 111 51 145
BS48.F1 490 161 236 265
BS48.F5 191 54 <50 101
BS48.H10 660 182 668 431
BS51.A3 713 122 196 258
BS51.B5 332 102 160 176
BS51.B6 403 95 157 182
BS51.H2 547 82 151 189
Serum GMT 410 105 203
BS46
BS48
BS51
10056
12541
BS03
BS12
>1000
300-999
100-299
50-99
<50
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particularly in the V1V2 region (Gray et al., 2011a). In addition, Rong et al (2007) reported 
that the V1V2 lengths have affects on autologous neutralization sensitivity in patient derived 
subtype C envelopes (Rong et al., 2009). We therefore analyzed whether the length of 
variable loops and the number of potential N-linked glycosylation sites (PNGS) in all 7 
subtype G-infected patient viruses was correlated with autologous neutralization titers using 
the Spearman rank correlation test. Figure 3.3.A, 3.B, and 3.C shows that there were no 
significant correlations between the amino acid lengths of V1V2, V1V5 and C3V5 with 
autologous neutralization titers (p=0.93, p=0.61, and p=0.21 respectively). The same analysis 
was extended for the PNGS, and again, there were no significant correlations with autologous 
neutralization titers (p=0.75, 0.93, and 0.88 respectively) (Figure 3.3.D-F). 
 
 
Figure3. 3: Correlations between the length of V1.V2, V1.V5, and C3.V5 of envelope and 
autologous neutralization titer. The autologous neutralization titer for each of the 8 study participant 
was plotted against the length of the V1V2 (A), V1V5 (B), C3V5 (C) regions or the number of PNGS 
in the V1V2 (D), V1V5 (E), C3V5 (F) regions. The Spearman correlation coefficient (r), the p-values 
and a line fit with 95% confidence interval are shown. r values and p-values are shown. The 
correlation was significant when p<0.05. 
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3.4.4 Cross-neutralizing activity HIV-1 Subtype G plasma samples 
The heterologous neutralizing activity of subtype G plasma has not been previously reported. 
Plasma samples from HIV-1 subtype G infected individuals studied here was therefore 
evaluated on whether they could neutralize a panel of 14 pseudoviruses chosen upon subtype 
diversity and neutralization resistance (Seaman et al., 2010, Blish et al., 2009). The virus 
panel included four subtype A, four subtype B, two subtype C and four CRF02_AG. The 
plasma were evaluated by a “geometric mean titer” that was the geometric mean of all the 
percentage neutralization values for that serum against all panel viruses that neutralized at 
1/100 dilution. The Proportion of viruses neutralized was calculated by the number of viruses 
neutralized by each plasma sample divided by the total number of viruses tested. 
Blood plasma from two out of the seven study participants neutralized more than half of panel 
virus tested at >50% neutralization at a dilution of 1/50, indicating at least limited 
neutralization breadth in these two samples. One participant 10056 was excluded from further 
analysis in the neutralization studies because of evidence suggesting the presence 
antiretroviral drug in the plasma. Interestingly, the other participant BS12 neutralized 2 tier 3 
viruses (33-7 and 253-11) (figure. 3.4.A). We therefore tested BS12 blood plasma with all tier 
five panel viruses available in the laboratory. We found that BS12 plasma neutralized 3/5 of 
the tier 3 isolates from the panel viruses (278-50 and 257-31 not neutralized; 33-7, 253-11, 
and PV0.4 neutralized) (figure. 3.4 B). 
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Figure3. 4: Heterologous neutralization capacity of participant’s plasma. A) Neutralization 
capacity of subtype G plasma against a panel of reference HIV-1 pseudoviruses chosen for subtype 
diversity and neutralization resistance, including subtypes A, B, C, and CRF02_AG. The participant’s 
plasma analyzed is shown to the left and virus panel tested is indicated at the top. The percent 
neutralization of the indicated pseudovirus by the indicated plasma at a screening dilution of 1/100 is 
also shown.  The highest percent neutralization value (>90) is shown in red as indicated on the top of 
the figure. The grey box indicated that <50 percent neutralization was observed at a screening dilution 
of 1/100. Samples were tested against Murine Leukemia Virus (MLV) as a negative control and 
against the highly neutralization-sensitive subtype B SF162.2 as a positive control. unk, tier unknown; 
virus not analyzed in Seaman et al (Seaman et al., 2010). B) Neutralization of BS12 plasma against a 
panel of five tier 3 reference HIV-1 pseudoviruses known to be highly resistant to neutralization. The 
tier 3 viruses include four CRF02_AG (33-7, 278-50, 253-11, and 257-31) and one subtype B (PV0.4) 
viruses. The ID50 titer is plotted vertically and plasma dilutions are shown on the horizontal axis.  
 
>90
70-89
50-69
<50
A 
B 
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3.4.5 Correlation of neutralization breadth with CD4+ T cell counts and viral loads 
There are many previous studies that showed an inverse relationship between CD4+ T cell 
counts and neutralization breadth, and a positive correlation with viral loads (Euler et al., 
2010, Gray et al., 2011a, Piantadosi et al., 2009b, Sather et al., 2009). In order to assess the 
relationship between neutralization and clinical disease markers in our study participants, we 
correlated the participant’s viral loads and CD4+ T cell counts to geometric mean titers 
(GMT). These analyses revealed as shown in figures 3.5A and 3.5B, there were no significant 
correlations between CD4+ T cell counts or viral loads and the geometric mean titers. One of 
the caveats of this study was the small sample size, which means that we may not have had 
sufficient statistical power to find this correlation in our samples.   
 
 
Figure3. 5: Correlation of geometric mean titer (Neutralization breadth) with CD4+ T cell 
counts and Viral loads (A&B). Spearman r values and p-values are shown. Each dot represents a 
single individual. 
 
3.4.6 Mapping of the antibody specificity in broadly neutralizing plasma 
One of the great interests in the antibody vaccine development is the target of broadly 
neutralizing antibodies. One patient in our study (BS12), which was ART naïve and that 
showed a substantial potent autologous activity as well as a good breadth of neutralization 
against a panel of different viruses (subtypes A, B, C, and CRF02_AG), was further 
investigated. A recent study by Walker et al, (2010) elucidated a number of key sites targeted 
by individuals with neutralization breadth. The sites included N160, L165 in V2 region and 
B A 
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N332 glycan in C3 region (Walker et al., 2010). To assess the presence of this type of 
antibodies in BS12 infected plasma, we tested mutants viruses containing single point 
mutation introduced in V2 (N160A, T162A, K169E) for PG9/PG16-like epitopes, in C3 
(N332A) for 2G12-like epitopes, into CAP45.2.00.G3, CAP255, Du156.12, and Q23.17 
compared to wild type virus and tested for loss of neutralization sensitivity against BS12 
plasma. We also tested for anti-MPER activity using three HIV-2 chimeric viruses containing 
HIV-1 MPER fragments: C1 containing subtype B (Yu2 sequence) MPER, C1C a consensus 
subtype C MPER, and 253-11 containing CRF02_AG MPER from 253-11 virus. 
As shown in Table 3.1.A, there was a 9.3 fold drop in neutralization titer compared to the 
wild type neutralization titer when BS12 plasma was tested against the CAP45 K169E 
mutant. This suggested that the dominant neutralizing antibody for virus CAP45.2.00.G3 in 
sample BS12 targeted the PG9/PG16 site. This site is the target in the V2 and V3 regions of 
the monoclonal antibodies PG9 and PG16. In addition, BS12 plasma also exhibited 
substantial neutralization of an HIV-2 chimeric virus displaying the MPER of 253-11, a 
CRF02_AG virus (Table 3.1.B), although we did not examine if these anti-MPER antibodies 
are capable of neutralizing HIV-1 viruses by recognizing MPER. Taken together, these results 
suggested that BS12 most likely has PG9/PG16.site antibodies, and that these antibodies were 
responsible for most of the neutralization activity against virus CAP45.2.00.G3, and the 
sample also contained detectable anti-MPER antibodies. However, we could not follow the 
evolution of the virus in response to these antibodies because this study participant was an 
anonymous blood donor. 
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Table 3.1: Mapping data to define antibody specificities found in plasma sample BS12. 
 
Parent virus 
and mutation 
ID50 
(parent) 
ID50 
(mutant) 
Fold 
reduction 
mutation 
ratio
 a
 
Target 
tested 
CAP45 N160A 1127 437 2.6 PG9/16 site 
CAP45 T162A 1127 442 2.5 PG9/16 site 
CAP45 K169E 1127 121 9.3 PG9/16 site 
CAP255 N332A 4764 2997 1.6 PGT/2G12 
site 
Q23.17 N332A 1528 650 2.3 PGT/2G12 
site 
Q23.17 N160K 1528 2978 0.5  PG9/16 site 
Du156 N332A 592 990 0.6 PGT site 
 
 
Parent virus 
and mutation 
ID50 
(parent) 
ID50 
(mutant) 
Fold effect 
neutralization 
of MPER HIV-
2 chimera 
b
 
Target 
tested 
C1 50 59 1.2 MPER 
C1C 50 197 3.9 MPER 
253-11 50 3882 78 MPER 
a
 Calculated as wild type IC50/mutant IC50 for the plasma. 
b
 Calculated as HIV-2 MPER chimera 
IC50/HIV-2 IC50 (7312A) for the plasma and ID50>1000 is an indicator of anti-MPER activity (Gray et 
al., 2007; Gray et al., 2011). Changes in titer of >3.fold are shown in bold. 
 
3.5 Discussion 
As HIV-1 continue to spread and initiate new infections especially in high endemic areas, 
understanding the specificities of neutralizing antibodies developed in HIV-1 infected 
individuals may be important in identifying possible targets for an effective HIV-1 vaccine.  
Some recent studies in subtype C, B, and few from other subtypes have suggested that the 
contemporaneous viruses tend to be less sensitive to neutralization by contemporaneous 
plasma (Li et al., 2006a, Moore et al., 2009b, Rong et al., 2009, Richman et al., 2003, Frost et 
al., 2005). We therefore undertook this study with the goal of characterizing neutralizing 
antibody patterns in the context of HIV-1 subtype G, one of the most circulating strains in 
West Africa. The ultimate goal of this study was to create a well characterize panel of subtype 
G gp160 reference clones to facilitate the evaluation of vaccine-elicited neutralization 
antibody responses.  
A 
B 
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We found that nAbs responses against contemporaneous autologous virus was generally low 
in the majority of viruses, including viruses from recently infected individuals (individuals 
with BED value <0.8) and individuals with longer infection (ART failing individuals and 
individuals with BED value >0.8). This results are not surprising because previous studies 
with untreated primary HIV-1 infections have reported that, nAbs responses against 
contemporaneous autologous viruses were generally lower than the responses against earlier 
viruses (Richman et al., 2003, Gray et al., 2011a, Rong et al., 2009, Moog et al., 1997). 
However, in one apparently long-term HIV-1 infected individual (BED assay>0.8), BS12 
exhibits a substantial potent AnAbs activity against all four isolated contemporaneous viruses. 
Although low levels (ID50<200) of neutralizing titers to contemporaneous autologous virus 
were observed in the majority of the participants, neutralizing titers varied between and within 
individuals. The most possible explanation may be that some viruses that we isolated just 
arose, and then we would expect no neutralization (Moog et al., 1997), or perhaps some are 
on the way out from antibody pressure that has been there for a while because the autologous 
neutralization might be high (Rong et al., 2009).  
Our study has demonstrated that many subtype G viral variants exhibit a variable level of 
sensitivity to neutralization by the various plasma pools, with a small proportion of viruses 
showing a more sensitive or resistant phenotype. This finding is consistent with Seaman et al, 
(2010) in which a rank order approach was used to classify viral neutralization sensitivity to 
pooled plasma into three-tier (Seaman et al., 2010). The neutralization activity observed 
between the HIV-1 subtype G viruses and subtype G plasma pool (subtype-specific 
neutralization) (Seaman et al., 2010, Brown et al., 2008, Jacob et al., 2012) was less potent as 
viral variants were more sensitive to subtype C pool than subtype G pool. The most 
parsimonious explanation is that the subtype C samples were selected for good neutralizers, 
while the subtype G and CRF02_AG were not. Therefore, subtype C viruses used in this 
study had high levels of heterologous neutralizing antibody, including antibodies specific for 
subtype G and CRF02_AG. We also observed a within-subtype neutralization with our 
subtype G infected plasma samples that neutralizes subtype G viruses better than CF02_AG 
indicating the sensitivity of subtype G viruses to subtype G specific neutralizing antibodies. 
Furthermore, the sensitivity of one virus to a particular plasma pool was often observed to 
other plasma pools suggesting that the neutralization was dependent on the virus 
characteristics rather than the type of plasma pool used.  
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Previous studies have reported that the antibody response increase in potency over time, 
capable of neutralizing heterologous HIV-1 variants (Moore et al., 1996, Moog et al., 1997, 
Donners et al., 2002, Binley et al., 2008, Piantadosi et al., 2009a, Sather et al., 2009, Simek et 
al., 2009, Gray et al., 2011a). Our results show that nAbs in plasma from long-term HIV-1 
infection is associated with BnAbs responses against heterologous viruses than are plasma 
from recently infected individuals. BED assay value of 1.28 identified BS12 as a long-term 
HIV-1 individual, and 10056 is a patient under ART, therefore with a long-term HIV-1 
infection.  Blood plasma from the two (10056 and BS12) out of seven (29%) study 
participants, neutralized more than 50% of panel virus tested at ID50>50, indicating at least 
limited neutralization breadth in these two samples. This frequency agrees to those previously 
described in other studies reporting up to 30% of samples with this activity (Doria-Rose et al., 
2009, Euler et al., 2010, Gray et al., 2009b, Piantadosi et al., 2009b). One of the two plasma 
samples remaining from patients failing ART (10056) showed broad neutralization activity 
against almost 50% of panel reference viruses that covered HIV-1 subtype A, B, C and 
CRF02_AG, which is consistent with the results from Medina-Ramirez, (2011) done in HIV-1 
subtype B infected patients under ART, where there was broadly neutralizing antibody 
activity despite undetectable viral loads (Medina-Ramirez et al., 2011). Therefore, the good 
neutralizing antibodies in the patient 10056 could be a consequence of improve B cell 
function associated with antiretroviral treatment. On the other hand, it is possible that the 
good neutralizing antibodies in the patient BS12, which is a naive infected patient with a 
long-term HIV-1 infection, could be the fact that maturation of neutralizing antibodies in this 
patient is very efficient. 
In this study we did not see any significant correlation between in one hand, the autologous 
neutralization titer and the length and PNGS in V1V2, V1V5 and C3V5 regions, and in 
another hand the neutralization breadth and the markers of disease progression (CD4+ T-cell 
counts and viral loads) among our HIV-1 subtype G infected individuals. Gray and colleagues 
(2011) found a significant correlation between the CD4 T-cell count and viral loads with 
neutralization breadth at six months post-infection only and not at later time points (Gray et 
al., 2011). The small sample size has severely limited our statistical power to address those 
issues. 
Previous studies have shown that V1V2 and C3 regions are the main targets of autologous 
neutralizing antibodies in subtype C (Moore et al., 2009b, Rong et al., 2009, Moore et al., 
2008, Lynch et al., 2011). The fine mapping of the plasma from the participant BS12 who 
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displayed potent autologous neutralization and broadly Cross-neutralizing antibodies 
indicated that nAbs recognized the lysine (K) in position 169 in the V2 and V3 regions, 
indicating possible quaternary epitopes that are targeted by PG9/PG16.site antibodies. In 
addition, the same participant had antibodies against the MPER in the gp41 region, indicating 
that the high autologous neutralization and the relatively high neutralization breadth may be 
dictated by antibodies directed at more than one epitope. However, we could not establish 
whether these antibodies were present early in the infection or whether they evolved, as the 
patient was a blood donor and plasma sample availability at different time point was a 
limitation. Despite this limitation and based on our data we propose that in BS12 HIV-1 
subtype G infected plasma, the  V1V2, and MPER regions are the main immune-dominant 
region of the envelope targeted by neutralizing antibodies. 
Certain limitations of our study deserve to be mentioned. Firstly, we only tested a limited 
number of viral clones derived from the SGA amplicons from each patient, it is hard to be 
sure that these samples are not biased compared to the population of HIV-1 in each individual 
that we tested. Secondly, we do not know the time since initial HIV-1 infection of any of the 
individuals that we studied, although, the low diversity in BS48 suggests a very recent time 
since infection. Thirdly, our sample size was too small, making this study underpowered 
regarding the significance of different correlations analyzed in this study. Fourthly, the 
unavailability of plasma samples at different time point was one of our major 
disappointments. Therefore, it was difficult to follow-up the immunological data and the 
evolution of immune response in these participants, particularly BS12, the one that we found 
to have very high neutralization against contemporaneous viral isolates. 
 
3.6 Conclusion 
In summary, this study provides the first characterization of neutralization phenotype in HIV-
1 subtype G viral variants using a set of HIV-1 infected individual plasma, plasma pools from 
different subtypes, and a panel of 14 different viruses. Our data showed that one sample, 
BS12, was unusual in that the plasma sample itself neutralized viruses derived from 
sequences found in the same sample. Our data suggest that in study participant BS12 plasma, 
the V1V2, and MPER regions are the main immune-dominant region of the envelope targeted 
by neutralizing antibodies. We believe that a subset of these HIV-1 viral variants may be used 
for screening of HIV-1 vaccine candidate. Last, our characterization of these viruses added 
detailed information about subtype G, which is historically understudied. 
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HIV-1 subtype G envelope variants have similar sensitivity to new 
generation of anti-CD4-binding site and anti-MPER broadly 
neutralizing monoclonal antibodies, but sensitivity to inhibitors of 
viral entry varies 
 
4.1 Abstract 
Background 
HIV-1 subtype G is the sixth most prevalent subtype and infects approximately 1.5 million 
individuals worldwide, especially in West and Central Africa. The development of 
neutralizing antibody-based vaccine against HIV-1 may need to be effective against different 
subtypes that are transmitted globally. One of the main components of this effort has been the 
identification and characterization of broadly neutralizing antibodies (BnAbs). In this study, 
we assessed the neutralization breadth and potency of a panel of eleven (11) first and second-
generation of BnAbs against 26 HIV-1 subtype G viruses generated from 8 HIV-1 infected 
individuals. The sensitivity of these viruses against soluble CD4 (sCD4), TAK-779, a CCR5 
inhibitor, and T20, a fusion inhibitor was also evaluated. 
Results 
We found that subtype G viruses were highly sensitive to the CD4-binding site monoclonal 
antibodies (mAbs) NIH45–46G54W and VRC01 as well as MPER mAb 10E8, neutralizing all 
26 viral variants. In addition, subtype G viruses showed sensitivity to 4E10 which was able to 
neutralized 25 of 27 (92%) of viruses and median IC50 of 0.42ug/ml.  These viruses were 
more sensitive to 4E10 than a large panel of worldwide viruses published last year 
(IC50=1.93ug/ml) and of all subtype G viruses with published sensitivity to 4E10 (median IC50 
=17ug/ml). However, neutralization by the mAbs b12, 2G12, Z13e1 was generally poor, 
while 2F5, PG16, PG9 and VRC03 have moderate activity neutralizing 42%, 65%, 27%, and 
50% of viral variants respectively. Subtype G viruses were highly sensitive to TAK-779 and 
T20 but exhibit more variable sensitivity to sCD4, a phenotype that have been observed 
frequently among freshly isolated viruses because sensitivity to sCD4 protein is thought to be 
associated with exposure of the CD4 binding site. 
Conclusion 
NIH45–46G54W, VRC01 and 10E8 which are directed against the CD4-binding site and the 
MPER region showed significant activity against HIV-1 subtype G viral isolates. These 
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results confirm the broadly neutralizing activities of NIH45–46G54W, VRC01, 10E8 and 4E10 
across group M and reveal the resistance of most subtype G viruses to mAbs 2G12, b12, and 
Z13e1. Despite the mapping hit in BS12 plasma for PG9/PG16 site antibodies against 
CAP45.2.00.G3 described in chapter 3 of this thesis, BS12 derived viruses were not highly 
sensitive to neutralization against PG9 and PG16 and it is not clear if these viruses are 
neutralized by the autologous plasma sample by recognition of this site. In particular, these 
viruses were not more sensitive to PG9 and PG16 compared to other viruses. This group of 
subtype G viruses could also be useful for screening T20 and CCR5 inhibitors that are being 
tested as potential microbicides in regions where HIV-1 subtype G predominate. In that 
regard, the relative sensitivity of the viruses examined here to T20 and CCR5 inhibitors is 
encouraging, because freshly isolated viruses are representatives of circulating viruses that are 
the critical targets for such interventions.  This characterization is important and should feed 
into the design of immunogens for HIV-1 vaccine, particularly as a global vaccine will be 
used in regions where HIV-1 subtype G and related recombinant forms predominate. 
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4.2 Introduction 
Multiples studies have demonstrated the potential of HIV-1 broad neutralizing antibodies to 
protect against HIV-1 infection using nonhuman primate models (Burton et al., 2012, Baba et 
al., 2000, Mascola et al., 1999, Mascola et al., 2000, Parren et al., 2001). However, one of the 
greatest obstacles for the development of an effective HIV-1 vaccine is the high sequence 
variability of HIV-1 isolates. An important component for the development of HIV-1 vaccine 
is the identification and characterization of neutralization antibody specificities that are 
effective against the majority of circulating HIV-1 strains, particularly those common in Sub-
Saharan Africa such as subtype G, in order to use their epitope for immunogen design 
(Burton, 2002). Several studies have shown that HIV-1.specific neutralizing antibodies and 
inhibitors of HIV-1 entry used as microbicides can also prevent infection when used as a 
microbicide in a non-human primate model (Veazey et al., 2003, Veazey et al., 2005). 
Until 2009, only a small number of  BnAbs isolated from HIV-1 subtype B infected 
individuals have been identified and known to potently neutralize different HIV-1 viral 
isolates: b12 recognizes the CD4 binding site (Burton et al., 1994), 2G12 targets a conserved 
cluster of oligo-mannose glycans on gp120 (Trkola et al., 1996), and mAbs 2F5 (Barbato et 
al., 2003), 4E10 (Stiegler et al., 2001) and Z13e1 (Zwick et al., 2001) recognizes three 
adjacent epitopes in the membrane-proximal external region (MPER) of gp41 . These mAbs 
have limited activity in non-B subtypes, with the exception of 4E10 which neutralizes most 
strains with low to moderate potency (Gray et al., 2006).  Therefore, there was an urgent and 
important need to isolate new BnAbs from non-subtype B infected individuals. Since 2009, 
several new BnAbs have been identified with improved breadth and potency activity against 
several different HIV-1 strains and are gaining more attention, although any of these BnAbs 
would be desirable to induce with HIV-1 vaccine (Hraber et al., 2013). These new BnAbs 
were derived from donors infected with different HIV-1 subtypes: subtype A (PG9 and 
PG16), subtype B (VRC01, VRC02, and VRC03, NIH45–46G54W) and subtype C (HJ16 and 
PGT) (Tomaras et al., 2011). The success of this effort was based on the combination of three 
strategies: a) the selection of chronically infected individuals with potent and cross-subtype 
reactive serum antibodies; b) the use of novel selection of screening approaches; and c) the 
development of efficient methods to isolate human monoclonal antibodies (Corti and 
Lanzavecchia, 2013). PG9 and PG16 recognize a quaternary epitope involving the V1V2 and 
V3 loop of the gp120 (Walker et al., 2009, Doores and Burton, 2010) MAbs VRC01, 
NIH45.45W which is an engineered form of NIH45.46, a clonal variant of VRC01, and HJ16 
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recognize the CD4 binding site (Zhou et al., 2010, Wu et al., 2010a, Corti et al., 2010), while 
the mAb 10E8 recognize the MPER in the gp41 region (Huang et al., 2012). 
HIV-1 subtype G is the sixth most prevalent subtype of HIV-1 after subtypes A, B, C, 
CRF01_AE and CRF02_AG (Hemelaar et al., 2006). Subtype G circulates mainly in West 
and Central Africa (Hemelaar et al., 2011a) however; very limited information is available on 
the neutralization properties of HIV-1 subtype G viruses. To date, no study of which we are 
aware have study the sensitivity of subtype G viruses to new generation of BnAbs. Revilla et 
al, (2011) studied the sensitivity of subtype G against the first generation of mAbs b12, 2F5, 
4E10 and 2G12 (Revilla et al., 2011).  It is unclear how effective new generations of BnAbs 
are specifically against HIV-1 subtype G viruses. Therefore a better understanding of a 
relative breadth and potency of these new BnAbs against HIV-1 subtype G viruses will allow 
the evaluation of the neutralization phenotype of subtype G viral variants. 
In this study, we determined differences in neutralization sensitivity of HIV-1 viral variants 
generated from 8 HIV-1 subtype G infected individuals from Cameroon using TZM-bl 
neutralization assay against eleven BnAbs and three entry inhibitors: soluble CD4 (sCD4), 
TAK-779, a CCR5 inhibitor, and T20, a fusion inhibitor . We sought to determine what 
BnAbs had the highest potency and broadest coverage against our panel of HIV-1 subtype G 
viruses.  
 
4.3 Methods 
4.3.1 Study participants, plasma samples, entry inhibitors, and monoclonal antibodies 
Study participants and plasma samples used in this study are described in section 2.3.1 of this 
thesis. 
The human monoclonal antibodies 2F5, 4E10, 2G12, IgG1b12, PG9, PG16, VRC01, VRC03, 
Z13e1, NIH45–46G54W, and 10e8, the  soluble human CD4 (sCD4-183), the CCR5 inhibitor 
TAK-779, the fusion inhibitor T20 were all obtained from the AIDS Research and Reference 
Reagent Program, Division of AIDS, NIAID, NIH (ARRRP). The pSG3∆env HIV-1 plasmid 
was also obtained from Drs. J. Kappes and Xiaoyun Wu through ARRRP. 
4.3.2 Cell lines 
The TZM-bl cells were obtained from Drs. J Kappes and X Wu through the ARRRP. These 
cells were derived from HeLa cell clone and expresses CD4, CCR5 and CXCR4 (Platt et al., 
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1998). TZM-bl cells contain two reporter genes: the luciferase and the Escherichia coli 
β.galactosidase under the control of the HIV-1 LTR promoter (Wei et al., 2002). The 293T 
cells used for transfection were obtained from Dr. A Rice through the ARRRP.  
4.3.3 HIV-1 env gene single genome amplification, cloning, and pseudoviruses 
production  
The cDNA extracted from the infected individual plasma samples were used to amplify the 
full-length env gene using the single genome amplification (SGA) assay as previously 
described (Keele et al., 2008). Briefly, the 3kb PCR products generated using one of two sets 
of primers (as described in section 2.3.4 methods in chapter 2)  were cloned into 
pcDNA3.1D/V5.His.TOPO vector (Invitrogen, Carlsbad, CA, USA) and bacterial colonies 
screened by PCR for insertion and correct orientation using T7 and BGH primers and plasmid 
were sequenced and compared to SGA PCR products. Pseudoviruses were made by 
cotransfecting 293 T cells with 4 µg of each cloned viral envelopes with 8 µg of SG3∆env 
HIV genome plasmid using X-tremeGENE 9 DNA transfection reagent (Roche Diagnostics, 
Basel, Switzerland) as previously described (Montefiori, 2009). 48 and 72 hours after 
transfection, the culture supernatant containing pseudoviruses was harvested, ﬁltered, 
aliquoted, and stored at .80°C. The TCID50 for each pseudoviruses was determined by 
infection in TZM-bl as described (Montefiori, 2009).  
4.3.4 Neutralization assay 
Neutralization by mAbs, T20, and sCD4 were assessed as described (Montefiori, 2009). The 
monoclonal antibodies were used at a maximum concentration of 20µg/ml. briefly; serial two-
fold dilutions of the appropriate inhibitor in Dulbecco’s modiﬁed Eagle’s medium (DMEM) 
were pre-incubated in duplicate in 96-well ﬂat-bottom plates (Costar) with pseudovirus in a 
total volume of 150 µl per well for one hour. Freshly trypsinized TZM-bl cells were then 
added (10,000 cells/well in [DMEM] 10% fetal bovine serum [FBS] containing HEPES and 
7.5 µg/ml of DEAE-dextran). Inhibition of HIV-1 infection by TAK-779 was assessed by 
adding the inhibitor to TZM-bl cells for 1 hour prior to the addition of pseudovirus stocks. 
After 48 hours of incubation at 37°C, 100μl of cells/well were transferred to 96.wells black 
solid plate (Costar) and the luminescence measured using the Bright-Glo™ luciferase 
substrate (Promega, Madison, USA) and measured on a VERITAS MicroPlate Luminometer 
(Turner BioSystems).  
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Percentage neutralizations were determined by the following calculation 
 
  Difference in average RLU between virus control and sample             X 100%. 
  Difference in average RLU between virus control and cell control 
 
ID50 values were calculated from curve fits to titration data using Prism 5.0 (Graphpad, La 
Jolla, USA) 
4.3.5 Statistical analysis  
IC50 titers for various monoclonal antibodies neutralization responses were calculated using 
the nonlinear regression (curve fit) function in GraphPad prism 5 software programme 
(GraphPad, La Jolla, USA). Comparisons between level of neutralization and other variables 
were measured by the Spearman’s rank test in GraphPad 5. Correlations with p-value ≤0.05 
were considered as statistically significant. 
4.4 Results 
4.4.1 Neutralization sensitivity of HIV-1 subtype G viral variants to BnmAbs 
A total of 26 pseudoviruses (ranging from 2 to 6 per participant) were tested against 11 
BnmAbs. This includes the older set of BnAbs (first generation) that generally have lower 
potency and breadth but are still considered broadly neutralizing 2G12, 2F5, b12, 4E10 and 
Z13e1, as well as some of the more potent recently isolated BnAbs (second generation) such 
as PG9, PG16, VRC01, VRC03, NIH45–46G54W, and 10E8.  
There was a variation in the neutralizing activities of the BnAbs against subtype G viruses, 
with IC50 values ranging from 0.01 µg/ml to resistant (>20 µg/ml) (Figure 4.1.A). Subtype G 
viruses were highly sensitive to the CD4-binding site monoclonal antibodies (mAbs) NIH45–
46
G54W
 and VRC01 as well as MPER mAb 10E8, neutralizing all (100%) viral variants with a 
geometric mean IC50 of 0.07, 0.11, and 0.20µg/ml respectively. In addition, subtype G 
viruses showed sensitivity to 4E10 which was able to neutralized 25 of 27 (92%) of viruses 
and median IC50 of 0.42ug/ml. These viruses were more sensitive to 4E10 than a large panel 
of worldwide viruses published recently (IC50=1.93ug/ml) (Huang et al., 2012) and of all 
subtype G viruses with published sensitivity to 4E10 (median IC50 =17ug/ml) (Revilla et al., 
2011, Binley et al., 2004, Huang et al., 2005). The activity of BnAb PG9 was relatively low 
27%, with a geometric mean of 13.28µg/ml. However, PG16 and VRC03 have moderate 
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breadth and potency neutralizing 65% and 50% with geometric mean IC50 of 2.10 and 
13.25µg/ml respectively. Despite the mapping hit in BS12 plasma for PG9/PG16 site 
antibodies against CAP45.2.00.G3 described in chapter 3 of this thesis, BS12 derived viruses 
were not highly sensitive to neutralization against PG9 and PG16. Moreover, these viruses 
were not more sensitive to PG9 and PG16 compared to other viruses. All viral variants were 
sensitive to at least three of the BnAbs tested, and none were neutralized by all eleven BnAbs 
tested; however, one virus (BS12.D9) was neutralized by 10 of the 11 (91%) BnAbs tested 
including b12 and 2G12 and was only resistant to mAb VRC03. It was also resistant to the 
soluble CD4. 
The majority of subtype G viruses were resistant to b12, 2G12, and Z13e1 with respectively 
11%, 19%, and 19% neutralization activity at highest concentration tested 30µg/ml 
(Geometric mean IC50 of 19.40, 20.86, and 17.29µg/ml respectively). 2F5 and 4E10 showed 
moderate and high neutralization activities with 43% and 92% respectively with geometric 
mean IC50 of 7.63 and 0.57µg/ml respectively (Figure 4.B). Last, virus 12541.B2 was the 
most resistant virus and was resistant to 8 of 11 BnAbs tested, while BS12.D9 was the most 
sensitive and was neutralized by 10 of 11 BnAbs tested.  
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
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Patient ID Clones ID 2G12 2F5 4E10 10E8 Z13e1 PG9 PG16 VRC01 VRC03 NIH45-46 B12 sCD4
10056.C1 >20 >20 0.18 0.81 >20 >20 3.7 <1.87 1.8 0.03 >20 >20
10056.F2 >20 <1.25 <0.62 <0.15 >20 >20 >20 <19 <18.5 1.2 >20 >20
10058.D8 17 13 0.03 0.004 >20 >20 1.25 0.02 <1.87 0.01 >20 >20
11439.C5 >20 <2.5 <2.5 0.44 >20 >20 >20 0.8 >20 0.13 1.21 0.25
11439.D4 >20 0.44 >20 0.36 >20 >20 >20 4.02 >20 0.35 >20 >20
11439.H4 >20 1.15 <2.5 0.37 >20 >20 0.009 0.72 >20 0.27 >20 >20
12541.B2 >20 >20 >20 0.05 >20 >20 >20 0.06 >20 0.02 >20 10.5
12541.C12 19 >20 0.23 0.21 >20 >20 5.8 0.04 12.7 0.03 >20 4.72
BS03.G4 >20 >20 0.32 0.2 13 >20 >20 0.07 13.45 0.07 5.2 >20
BS03.H3 >20 >20 0.39 0.22 >20 >20 >20 0.07 18.76 0.05 >20 >20
BS12.A6 18.01 >20 0.42 0.27 >20 >20 >20 0.07 >20 0.07 >20 >20
BS12.D2 >20 >20 0.12 0.05 >20 12.5 <0.15 0.04 5.2 0.07 >20 15.5
BS12.D9 <2.5 <2.5 1.5 0.83 6.18 20 1.16 <0.15 >20 0.09 3.4 >20
BS12.G8 >20 >20 0.55 0.56 >20 >20 >20 0.09 >20 0.07 >20 3.8
BS46.E1 >20 2.8 13.26 7.9 >20 16 0.02 0.06 3.68 0.06 >20 2.5
BS46.E2 >20 >20 0.28 0.12 >20 >20 5.28 0.03 9.75 0.04 >20 17.1
BS48.E1 >20 >20 0.36 0.18 >20 >20 6.9 0.07 >20 0.07 >20 15.8
BS48.E3 >20 14.5 0.8 0.19 >20 6.2 <0.15 0.05 >20 0.08 >20 >20
BS48.E4 12.1 0.52 0.49 0.09 >20 1.3 <0.15 0.05 >20 0.06 >20 2.5
BS48.F1 >20 0.78 0.41 0.1 0.3 0.009 0.08 0.06 >20 0.07 >20 0.9
BS48.F5 >20 0.9 0.76 0.19 >20 1.5 <0.15 0.05 >20 0.05 >20 >20
BS48.H10 >20 >20 0.29 0.24 2.74 >20 >20 <0.15 >20 0.07 >20 13.5
BS51.A3 >20 >20 0.66 0.31 >20 >20 8.1 0.07 14.76 0.03 >20 >20
BS51.B5 >20 >20 0.05 0.03 10.12 >20 0.72 0.07 3.22 0.07 >20 >20
BS51.B6 >20 >20 0.43 0.62 >20 >20 3.76 0.07 13.5 0.02 >20 17.4
BS51.H2 >20 >20 0.31 0.3 >20 >20 7.5 0.07 15.6 0.07 >20 >20
Anti-CD4 binding site mAbsAnti-MPER mAbs
BS51
BS48
10056
11439
12541
BS03
BS12
BS46
>20
10-20
2.5-10
0.1-2.5
<0.1
B 
B 
A 
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Figure4. 1: Neutralization sensitivity of HIV-1 subtype G viruses against broadly monoclonal 
antibodies. A) The patient ID, and viruses analyzed are shown to the left. Each row shows the virus 
name, and the concentration that is required to achieve 50% neutralization [IC50 (µg/ml)] for the 
mAbs tested. The red shading indicates more potent neutralization, as indicated below the figure. Gray 
shading indicates that 50% neutralization was not achieved at highest concentration of mAb tested (20 
µg/ml). B) Summary of neutralization breadth and potency of BnAbs against subtype G viral isolates. 
The percentage of viruses neutralized is indicated for each BnAb on the top of the graph. 
 
 
4.4.2 Clustering analysis of the neutralization activities of BnAbs against HIV-1 subtype 
G variants 
We generated heat maps to study the hierarchical clustering patterns of neutralization by 
BnAbs and to group viruses with similar neutralization sensitivity to BnAbs (Figure 4.2). The 
dendrogram at the top of the figure shows three distinct clusters of BnAbs, with those on the 
left being more broad and potent. The second cluster showed moderate neutralization activity 
and the third cluster a low neutralization activity. The dendrogram on the left shows two 
groups of viruses identified based on their sensitivity to BnAbs. Viruses generally clustered 
by their overall neutralization sensitivities. Four of the BS48 samples cluster together in the 
cluster of six viruses at the bottom (Figure 4.2), but two (BS48.E1 and BS48.H10) clustered 
with the resistant viruses. Interestingly, BS48 is the sample that looks like it was taken within 
30 days of seroconversion as described previously (Keele et al., 2008). Bar et al., (2012) 
suggested that the low ID50 titers at this stage are associated with antibody-mediated selection 
pressure. Indeed, despite the low autologous ID50 titer (ID50 from <50 to 1:131), the BS48 
patient can produce neutralizing antibody responses as early as within 30 days of 
seroconversion. Selection at this early stage has been observed in other infected individuals in 
which early antibody can select for virus escape, even at very low ID50 (Bar et al., 2012). 
4.4.3 Analysis of epitope sequences recognized by BnAbs 
The epitope sequences recognized by BnAbs were analyzed, since mutagenesis studies have 
revealed that mutations in the BnAbs epitopes can affect the neutralization phenotype (Blish 
et al., 2008, Zwick et al., 2005, Moore et al., 2011, Tomaras et al., 2011). 
Because 2G12 failed to neutralize the majority of viral variants, we investigate whether these 
viruses lacked the PNGS at position 295, 332, 339, 386, and 392 required for neutralization 
(Sanders et al., 2002, Trkola et al., 1996, Scanlan et al., 2002). As shown in Table 1, all 
viruses lacked one or more potential N-linked glycosylation sites (PNGS) at these positions, 
which is likely to explain their resistance to 2G12.  
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Figure4. 2: Hierarchical clustering of mAbs (bottom) and subtype G viruses (right). A heatmap 
of IC50 values for each virus-mAb combination is shown, with darker shading indicating increasing 
potency, as indicated on the top. The yellow indicates that 50% of neutralization was not achieved at 
the highest concentration of mAb tested (20 µg/ml). The heatmap was generated using hierarchical 
clustering and Euclidean distance method and the log10 values of the IC50 neutralization data for each 
viruses and nAbs that are displayed on the horizontal axes (www.hiv.lanl.gov). 
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2F5 recognize the core epitope ELDKWA at the MPER region with LDKW residues (at 
positions 664-667) being critical for binding and neutralization activity (Zwick et al., 2005, 
Tian et al., 2002) and amino acid mutation at Lys.665 appeared to be the key determinant of 
resistance (Binley et al., 2004).  
Among the fourteen 2F5 resistant viruses, 10 had mutations at the LDKWA motif consistent 
with their phenotypic resistance (Table 4.1). Four maintained the LDKWA motif, although all 
were resistant.  
4E10 binds to the core epitope NWFDIT (at positions 671-676), located at the C terminus of 
the 2F5 epitope. Mutagenesis studies have shown that mutations at residues Trp-672, Phe-
673, and Trp-680 are critical for binding and result in resistance to neutralization by 4E10 
(Zwick et al., 2005). Analysis of epitope sequences of the two 4E10 resistant viruses revealed 
that none had mutation at these three key residues, however substitutions at positions 671, 
674, and 676 may contribute to their resistance to 4E10. In addition, it has been documented 
that many viruses that contain the amino acids that correspond to the full epitope may be 
resistant (Zwick et al., 2005, Binley et al., 2004), and therefore must be reasons other than 
changing of the epitope sequence that may result in 4E10 resistance. In fact, Sun Zy et al, 
(2008) have reported that residues Trp-672 and Phe-673 are connected via a short hinge to a 
flat C-terminal helical segment (at position 675-683). This meta-stable L-shaped structure is 
immersed in viral membrane and, therefore, less accessible to immune attack (Sun et al., 
2008). b12 targets the CD4 binding site on gp120 (Burton et al., 1994). Site-directed  
mutagenesis have shown that gp120 amino acid substitutions D185N, N276A, S364H, 
S365A, P369L, and T373R reduced the susceptibility or resulted to neutralization resistance 
to b12 (Mo et al., 1997, Pantophlet et al., 2003, Duenas-Decamp et al., 2008).  All clones 
contained one or more mutations known to impact b12 activity at residues 369, 185, and 364 
which may explain their overall resistance to b12.` 
PG9 and PG16 recognize a quaternary epitope involving the V1V2 and V3 loop of the gp120 
(Walker et al., 2009, Doores and Burton, 2010). As reported previously by walker et al, 
(2009), the absence of the key residues at positions 156 and 160 in the V2 region is associated 
with resistance to neutralization to both PG9 and PG16 (Walker et al., 2009). Only one virus 
(11439.D4) did not have the N160 residue normally required for recognition of PG9. More 
mutations were observed at position 158, 169, and 181 which may account for the 
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neutralization resistance of some variants to PG9 (Walker et al., 2009, Tomaras et al., 2011, 
Moore et al., 2011). Few variants were resistant to PG16. PG16-resistant viruses were likely 
the result of substitutions K305R and I309F. It is striking that resistance to PG9 and PG16 
appeared distinct among our viruses. This effect was large enough that PG9 and PG16 appear 
in distinct cluster in the hierarchical clustering in Figure 4.2.  
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Table 4.1: Amino acid sequences in positions of BnAb epitopes important for binding or neutralization 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All positions correspond to the HXB2 envelope protein. Amino acid positions correspond to sites for which mutations have been shown to affect the 
neutralization phenotype
Virus clade
295 332 339 386 392 156 158 159 160 162 169 173 176 181 299 305 307 309 317 318 185 276 364 365 369 662 663 664 665 666 667 671 672 673 674 675 676 680
N N N N N N S F N S/T K* Y F I P K I I F V D N S S P E L D K W A N W F D I T W
10056.C1 G . T . . . . . . . . . . . . . R . . . Y G . . . L A . . . . . S . . . . S .
10056.D8 G . T . . . . . . . . . . . . . R . . . Y G . . . L A . . . . . S . . . . S .
10056.F2 G . T . . . . . . . . . . . . . R . . . Y G . . . L A . . . . . S . . . . S .
11439.C5 G . . K . . . . . . . . . . . . . . . . Y E . . . L A . . . . . . . . . . S .
11439.D4 G . . K . . . . . K . . . . . . . . . . Y E . . . L A . . . . . . . . . . S .
11439.H4 G . . K . . . . . . . . . . . . . . . . Y E . . . L A . . . . . . . . . . S .
12541.B2 G K . S D . . T . . . . . . L . . . F . Y . . . . L A . . Q . . S . . S . S .
12541.C12 G K . S D . . T . . . . . . L . . . F . Y . . . . L A . . Q . . S . . S . S .
BS03.G4 G I . K . . . . . . . R . . . . . . F . Y . . . . I A . . . . T S . . . . S .
BS03.H3 G I . K . . . . . . . R . . . . . . F . Y . . . . I A . E . . T S . . . . S .
BS12.A6 G . . D . . . . . . . R . . . . . . . . Y . . . A L A W . . . . S . . . . S .
BS12.D2 G . . D . . . . . . . R . . . . . . . . Y . . . A L A W . . . . S . . . . S .
BS12.D9 G . . D D . . . . . . R . . . . . . . . Y . . . A L A W . . . . S . . . . S .
BS12.G8 G . . D . . . . . . . R . . . . R . . . Y . . . A L A W . . . . S . . . . S .
BS46.E1 G . . T . . . . . . . . . . V . . . . . Y . . . T L A . . . . . T . . . . S .
BS46.E2 G . . T . . . . . . . . . . V . . . . . Y . . . T L A . . . . . . . . . . S .
BS48.E1 G . D Y D . . . . . . . . . V . . . . . Y . . T A L A . . . . . . . . . . . .
BS48.E3 G . . Y D . . . . . . . . . V . . . . . Y . . T A L A . . . . . . . . . . . .
BS48.E4 G . . Y D . . . . . . . . . V . . . . . Y . . T A L A . . . . . . .. . . . . .
BS48.F1 G . D Y D . . . . . . . . . V . . . . . Y . . T A L A . . . . . . . . . . . .
BS48.F5 G . D Y D . . . . . . . . . V . . . . . Y . . T A L A . . . . . . . . . . . .
BS48.H10 G . D Y D . . . . . . . . . V . . . . . Y . . T T L A . . . . . . . . . . . .
BS51.A3 G . . . Y . . . . . . . . . V . . . . . Y . . . A L A . . . . T . . . S . S .
BS51.B5 G . . . Y . . . . . . . . . V . . . . . Y . . . A L A . . . . T . . . S . S .
BS51.B6 G . . . Y . . . . . . . . . V . . . . . Y . . . A L A . . . . T . . . S . S .
BS51.H2 G . K . . . . . . . . . . . V . . . . . Y . . . T L S . . . . . . . . S . S .
2F5: ELDKWA(HXB2) 4E10: NWFDIT(HXB2)PG9/PG16(HXB2) b12(HXB2)2G12(HXB2) PG16(HXB2)
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4.4.4 Sensitivity of subtype G viruses to HIV-1 entry inhibitors 
The sensitivity of subtype G viral variants was further evaluated against three HIV-1 entry 
inhibitors (Figure 4.3). The inhibitors used were sCD4, T20 a fusion inhibitor, and TAK-779 
a CCR5 antagonist. As depicted in figure 4, Subtype G viruses were highly sensitive to TAK-
779 (based upon the fold drop in infectivity with the drug added) and T20 (geometric mean 
IC50 of 1.44 µg/ml) but exhibit more variable sensitivity to sCD4, a phenotype that have been 
observed frequently among freshly isolated viruses because sensitivity to sCD4 protein is 
thought to be associated with exposure of the CD4 binding site. Soluble CD4 neutralizes 12 of 
26 (46%) of viral variants, while no neutralization activity against viruses generated from 
10056 and BS03 individuals was observed at highest concentration tested (IC50 of 20 µg/ml). 
The susceptibility to T20 and TAK-779 was similar for almost all variants did not vary 
substantially among the different viral variants. 
 
Chapter 4: HIV-1 subtype G envelope variants have similar sensitivity to new generation of anti-
CD4 binding site and anti-MPER broadly neutralizing monoclonal antibodies, but sensitivity to 
inhibitors of viral entry varies Page 107 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure4. 3: Sensitivity of HIV-1 subtype G viruses to entry inhibitors. The patient ID, and viruses 
analyzed are shown to the left. Each row shows the virus name, and the concentration that is required 
to achieve 50% neutralization [IC50 (µg/ml)] for the entry inhibitor tested. Viruses were obtained as 
described previously (Montefiori et al., 2009) and entry inhibitors was detemined using pseudovirus 
infection of TZMbl cells. We couldn’t determine IC50 for TAK-779 due to substrate limitations and 
TAK-779 values represent the fold drop infectivity used in the coreceptor assay by comparing 
percentage neutralization in well containing co-receptor inhibitors to control wells to determine if 
either agent led to a reduction of infectivity.  The red shading indicates more potent neutralization, as 
indicated below the figure. Gray shading indicates that 50% neutralization was not achieved at highest 
concentration of mAb tested (20 µg/ml).   
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Patient ID Clones ID T20 sCD4
Fold drop 
infectivity 
with 3.3uM 
TAK-779
10056.C1 1.07 >20 5.3
10056.F2 <0.31 >20 6.7
10058.D8 0.14 >20 6.7
11439.C5 0.04 0.25 2.6
11439.D4 0.09 >20 2.4
11439.H4 0.07 >20 4.3
12541.B2 0.18 10.5 12.5
12541.C12 0.006 4.72 5.9
BS03.G4 1.05 >20 5.3
BS03.H3 1.04 >20 7.1
BS12.A6 0.49 >20 6.3
BS12.D2 0.1 15.5 2.4
BS12.D9 1.5 >20 6.3
BS12.G8 0.9 3.8 4.5
BS46.E1 0.06 2.5 16.7
BS46.E2 0.66 17.1 6.3
BS48.E1 0.74 15.8 4.2
BS48.E3 0.09 >20 14.3
BS48.E4 0.06 2.5 20
BS48.F1 0.05 0.9 25
BS48.F5 0.07 >20 25
BS48.H10 0.53 13.5 5.3
BS51.A3 0.7 >20 7.7
BS51.B5 0.49 >20 5.6
BS51.B6 0.57 17.44 7.1
BS51.H2 0.56 >20 5.6
BS48
BS51
10056
11439
12541
BS03
BS12
BS46
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4.5 Discussion 
This study was aimed to characterize the sensitivity of subtype G viruses generated from 8 
infected individuals in Cameroon against Bnabs and inhibitors of viral entry. Subtype G is a 
HIV-1 subtype circulating mostly in West and Central Africa. Several new BnAbs with great 
breadth and potency have been identified, but their neutralization profile against subtype G 
viruses from a West and Central African country has not been defined. We analysed the 
neutralization profile of 26 HIV-1 subtype G envelope variants, against 11 BnAbs targeting 
different epitopes and HIV-1 entry inhibitors.  
Most subtype G variants displays high sensitivity profile to BnAbs tested. NIH45–46G54W, 
VRC01, and 10E8 which are directed against the CD4-binding site and the MPER region 
showed a remarkable combination of breadth and potency. Interestingly, we observed that the 
neutralization sensitivity to these three BnAbs results in 100% coverage of subtype G variants 
tested. Most subtype G viruses were also highly sensitive to 4E10 (92% coverage). These 
results are similar to the pattern of neutralization observed using these BnAbs in recent 
studies (Hraber et al., 2013, Mabuka et al., 2013, Euler et al., 2011, Goo et al., 2012), and 
confirm that these BnAbs may be among the most effective against different circulating HIV-
1 variants. 
Many subtype G viruses were resistant to one or more BnAbs, including those recently 
identified such as PG9 and VRC03, known to possess a remarkable breadth and potency 
against different HIV-1 strains. Most subtype G viruses were resistant to b12, 2G12, and 
Z13e1 up to a concentration of 20 µg/ml, and exhibit a moderate sensitivity against 2F5, and 
PG16. The resistance profiles found for the subtype G viruses described here are similar to 
two previous reported studies using 15 plasmids expressing subtype G Env libraries (Walker 
et al., 2009, Revilla et al., 2011).  Those studies showed the resistance of subtype G to mAbs 
B12 and 2G12, high frequency neutralization by 2F5, 4E10, PG9 and PG16 although, in 
contrast to Walker study, the susceptibility of our viruses showed low frequency to mAb PG9. 
We were somewhat surprise that although the mapping of BS12 plasma indicated that the 
dominant neutralizing antibody for virus CAP45.2.00.G3 in sample BS12 targeted the PG9/16 
site, these viruses were not unusually sensitive to the PG9 and PG16 monoclonal antibodies 
themselves. We expected BS12.derived viruses to be better neutralized by the mAbs PG9 and 
PG16. Therefore some resistance to PG9 and PG16 may be more common among subtype G 
viruses. However, having antibodies that target the PG9/PG16 site does not necessarily mean 
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they bind it the same way that PG9 or PG16 do. It is possible that the autologous antibodies 
recognize the site differently and thus can see the BS12 viruses even though the PG9 and 
PG16 cannot. 
The relatively poor neutralization by the mAbs b12, Z13e1, and 2G12 was not surprising, it is 
known that some of the subtypes A, C, and the few G viruses previously characterized  
circulating in Sub-Saharan Africa, display limited sensitivity to first-generation antibodies 
such as b12 and 2G12 (Revilla et al., 2011, Walker et al., 2009, Wu et al., 2010a, Blish et al., 
2007). Our results point to subtype G as showing a wide resistance to four of the five first 
generation BnAbs raised against subtype B used in this study with only 4E10 which target the 
MPER in the gp41 region, being able to neutralize 92% of the viruses. 
It was interesting to evaluate how conserved the epitopes targeted by these BnAbs were 
among HIV-1 subtype G. It is clear that, while substitutions in the conserved core epitopes 
can predict neutralization resistance, the presence of the correct core sequence cannot predict 
neutralization (Binley et al., 2004). We found that viruses that are resistant to these BnAbs are 
largely involved in mutations at residues known to be critical for mAb binding and 
neutralization. However, some BnAbs-resistant viruses had mutations to the core epitope, 
though other BnAbs-resistant maintained the core epitope (Table 1), a phenomenon reported 
previously by several authors (Binley et al., 2004, Blish et al., 2009, Blish et al., 2007, Zwick 
et al., 2001). This was observed for example in PG9-resistant viruses in which five of the 
nineteen resistant viruses maintained the core epitope. Strikingly, this resistance to PG9 was 
not reflected in similar resistance to PG16. This provides additional evidence that 
conformational changes controlled by sequences not in the core epitope may influence the 
resistance phenotype in these viruses, as suggested previously (Revilla et al., 2011). 
We further characterized the sensitivity of these subtype G viruses to HIV-1 entry inhibitors 
since no study of which we are aware have been reported. All subtype G viruses were highly 
sensitive to T20, the fusion inhibitor, and TAK-779, a CCR5 inhibitor. These results 
correlated with previous reported studies with subtype C viruses (Cilliers et al., 2004, Blish et 
al., 2007, Kishko et al., 2011). Although some subtype G virus were sensitive to sCD4, most 
were resistant and thus apparently lack the b12 epitope or is not accessible to b12 nAbs, a 
phenotype that has been reported by previous studies with many subtype A viruses (Blish et 
al., 2007) and some subtype B viruses (Reeves et al., 2002). Sensitivity to sCD4 protein is 
thought to be associated with the exposure of the CD4 binding site (Pugach et al., 2004).   
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4.6 Conclusion 
In summary, this study highlights the fact that it may be possible to neutralize HIV-1 subtype 
G viral variants with the recently identified BnAbs targeting the CD4 binding site such as 
NIH45–46G54W and VRC01, and the anti MPER BnAb 10E8. Our results point to HIV-1 
subtype G as showing a wide resistance to four of the five first generation BnAbs raised 
against subtype B used in this study with only 4E10 which target the MPER in the gp41 
region, being able to neutralize the majority of the viruses. This group of subtype G viruses 
could also be useful for screening T20 and CCR5 inhibitors that are being tested as potential 
microbicides in regions where HIV-1 subtype G predominate. In that regard, the relative 
sensitivity of the viruses examined here to T20 and CCR5 inhibitors is encouraging, although 
the partial resistance of several of our viruses to TAK-779 may indicate that drug pressure 
will select more resistant viruses quickly from the partially resistant ones. We believe that 
these results will facilitate in inclusion of subtype G viruses in test panels to evaluate 
responses to candidate vaccines and in choices needed for the design of immunogens for HIV-
1 vaccine in regions where HIV-1 subtype G predominate. 
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Conclusion and perspectives 
HIV-1 subtype G accounts for 5% of HIV-1 infection worldwide, centered on West and 
Central Africa. It has also spread to several European countries, Cuba and is found among 
Russian intravenous drug users. Subtype G presumably spread outside West Africa with 
migration of infected individuals.  In addition, 80% of the recombinant strains circulating 
worldwide contain segments attributed to subtype G (Brennan et al., 2008).  However, 
historically, much of HIV-1 vaccine research and immunogen design to date has focused on 
subtype B, largely due to the ease of availability of this subtype in the high income countries 
of North America and Europe where most basic studies on HIV-1 immunogen design were 
done. Therefore there is urgency, despite the challenges of developing an HIV-1 vaccine, to 
study these understudied subtypes such as subtype G in order to develop a globally relevant 
vaccine. During the course of this study, we characterized the genetic properties of subtype G 
env sequences and evaluated the neutralization sensitivity and vulnerabilities of HIV-1 
subtype G viruses. 
In the first part of this work, we analyzed in total 47 env sequences, 45 of which I isolated by 
single genome analysis (SGA) PCR and two of which were isolated by colleagues (Tongo et 
al., 2013). Our samples were chosen based upon subtype analysis of gag and nef genes 
(Tongo et al., 2013) or of pol genes (not shown). Although recombinants were possible, 
phylogenetic analysis of the full length env has revealed that all virus sequences belong to 
HIV-1 subtype G. 12541-derived sequences branched from near the root of the subtype G 
subtree in a poorly populated branch containing some sequences related to a segment of 
CRF06_cpx. However, the 12541 sequences did not contain the J-like sequences at the 3’ end 
of env normally expected in CRF06_cpx and the sequences without the J-like region did not 
cluster within CRF06_cpx sequences, suggesting that these 12541 sequences are within 
subtype G and not CRF06_cpx.  This suggests that the full extent of the diversity of Subtype 
G has not yet been described, and provides additional evidence for the hypothesis that subtype 
G itself may be older than has been calculated (Abecasis et al., 2009). We did not find any 
significant difference between the V1V2 lengths from patients likely to be infected for < 6 
months (BS03, BS46, and BS48, based upon BED assay results (Parekh et al., 2011) with 
patients likely to be infected for > 6 months (BS12, BS51). The V1V2 and V4V5 had the 
most length variation within and between participants, whereas the V3 length was constant. 
This variation in length appears similar to previously observed in subtype C (Coetzer et al., 
2007). This study also illustrated the fact that all of our HIV-1 subtype G infections are 
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caused by viruses that exclusively utilizes CCR5 co-receptor. However, we found that three 
of our subtype G viruses (BS12.D2, 11439.C5, and 11439.D4) had only a 2.3 fold less 
reduction in infectivity in the presence of a high concentration of TAK-779 inhibitor (3.3µM). 
Although this may suggest use of another receptor, all viruses were resistant to the CXCR4 
inhibitor. The variability in the sensitivity to TAK-779 of these CCR5 viruses may not be due 
to the extreme heterogeneity of the HIV-1 envelope glycoproteins (gp120 and gp41) that may 
affect the susceptibility of variant HIV-1 strains (Torre et al., 2000). CCR5 inhibitors have an 
antiviral effect in people who are predominantly infected with HIV that is adapted to using 
the CCR5 receptor, typically patients with higher CD4 counts (Torre et al., 2000). 
Unfortunately, we did not calculate IC50 so our results are not comparable with those others. 
We next characterized the neutralization sensitivity of subtype G viruses and the neutralizing 
capacities of antibodies induced by the viruses. However, a number of interesting findings 
were apparent. Firstly, as expected, we found that nAbs responses against contemporaneous 
autologous virus was generally low in either individuals with longer infection or recently 
infected individuals. We understand this using the following scenario: Within a few months of 
HIV-1 infection, nAbs against the autologous virus develop. In response to the immune 
pressure nAbs exert on the virus, escape mutants appear. Over the course of  acute to chronic 
infection the immune response matures, as a consequence, nAbs from a specific  time point 
are able to neutralize  early autologous virus but generally not contemporaneous circulating 
viruses (Richman et al., 2003, Gray et al., 2011a, Rong et al., 2009, Moog et al., 1997). 
However, BS12 exhibits a substantial potent autologous nAbs activity against 
contemporaneous viruses. This has also been observed in at least one study (Rong et al., 
2009).  Secondly, the sensitivity to neutralization by the various plasma pools varied, and 
viral variants were more sensitive to subtype C pool than subtype G pool suggesting that the 
neutralization was dependent on the virus characteristics or the neutralization potency of the 
serum/plasma pool, rather than the subtype infecting the serum/plasma pool used. Thirdly, 
blood plasma from two study participants neutralized more than 50% of panel virus tested at a 
low threshold of ID50>50, indicating at least limited neutralization breadth in these two 
samples. In addition, BS12 serum, the sample that showed a substantial potent autologous 
activity, also neutralized 3/5 of the tier 3 isolates from the panel viruses, suggesting 
substantial heterologous neutralizing activity in this plasma sample. Fourthly, mapping of 
BS12 plasma, the sample that display a potent autologous and heterologous neutralization 
capacities suggests that nAbs likely recognized epitopes overlapping the quaternary epitopes 
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targeted by PG9/PG16.site antibodies (Moore et al., 2011, Gray et al., 2011b). In addition, the 
same participant had antibodies against the MPER in the gp41 region. Antibodies to other 
epitopes were not found, suggesting that the breadth and the high level of autologous 
neutralization may be dictated by a limited number of target epitopes. In subtype C infection, 
the V1V2 and C3 regions are the immunodominant regions commonly targeted by autologous 
neutralizing antibodies particularly during the early stage of infection (Moore et al., 2008, 
Moore et al., 2009a, Rong et al., 2009, Lynch et al., 2011). Our results do indicate that the 
V1V2 and MPER regions are the immunodominant regions and the focus of the nAb 
responses resulting in broadly Cross-neutralizing antibodies in the plasma sample from the 
study participant BS12. Unfortunately, BS12 was an anonymous blood donor and follow up 
samples cannot be obtained to observe the effect of this high autologous neutralization on viral 
dynamics. 
We further characterized the sensitivity of HIV-1 subtype G viruses to eleven first and 
second-generation of BnAbs and three HIV-1 entry inhibitors. We found that subtype G 
viruses were highly sensitive to the CD4-binding site mAbs NIH45–46G54W and VRC01 as 
well as MPER mAb 10E8, neutralizing all (100%) viral variants. In addition, subtype G 
viruses showed sensitivity to 4E10 which was able to neutralized 92% of viruses.  These 
viruses were more sensitive to 4E10 than a large panel of worldwide viruses published last 
year and of all subtype G viruses with published sensitivity to 4E10. Our results point to 
subtype G as showing a wide resistance to four of the five first generation BnAbs raised 
against subtype B used in this study with only 4E10 which target the MPER in the gp41 
region, being able to neutralize 92% of the viruses. The relatively poor neutralization by the 
mAbs B12, Z13e1, and 2G12 was not surprising, it is known that several other subtypes 
display limited sensitivity to first-generation antibodies such as b12 and 2G12 (Revilla et al., 
2011, Walker et al., 2009, Wu et al., 2010a, Blish et al., 2007). We generated heat maps to 
study the hierarchical clustering patterns of neutralization by BnAbs and to group viruses with 
similar neutralization sensitivity to BnAbs. Four of the BS48 samples cluster together in the 
cluster of six viruses at the bottom of the heat map, but two (BS48.E1 and BS48.H10) 
clustered with the resistant viruses. Interestingly, BS48 is the sample that looks like it was 
taken within 30 days of seroconversion as described previously (Keele et al., 2008). This 
results suggests that despite the low autologous ID50 titer (ID50 from <50 to 1:131), the BS48 
patient may already be producing escape variants to autologous antibody that we can only 
Chapter 5: Conclusion and perspectives  Page 115 
observe by a shift in their sensitivity to neutralization. Selection at this early stage has been 
observed in other infected individuals (Bar et al., 2012).  
Subtype G viruses were highly sensitive to TAK-779 and T20 but exhibit more variable 
sensitivity to sCD4, a phenotype that have been observed frequently among freshly isolated 
viruses because sensitivity to sCD4 protein is thought to be associated with exposure of the 
CD4 binding site. 
Taken together, our characterization of these viruses added detailed information about 
subtype G, which is historically understudied. The results obtained in this thesis have 
contributed toward additional understanding of the genetic properties, co-receptor usage and 
vulnerabilities of HIV-1 subtype G against nAbs, new generation of human BnAbs, and entry 
inhibitors. 
Based on these results, the following are recommended: 
1- The characterization of full length sequences of HIV-1 subtype G generated by single 
genome analysis (SGA) in order to better characterize the origin of subtype G. 
2- A study with a large sample size with a proper follow-up should be explored. This 
type of study will be valuable for the characterization of antibodies, understanding of 
the characteristics of escape variants among subtype G-infected individuals and 
hopefully the definition and the discovery of new target immunogens. 
3- Investigate the contribution of antibody dependant cell-mediated  cytotoxicity 
(ADCC) and antibody dependent cell-mediated  viral inhibition (ADCVI) in 
controlling or attenuating HIV-1 subtype G progression, since B-cells producing 
BnAbs may have to compete with non-neutralizing antibodies to immunodominant 
epitopes and perhaps with non-neutralizing antibodies to the same epitope (Alam et 
al., 2008). 
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Appendices 
Appendix A: RNA extraction 
The QIAamp Viral RNA Mini Kit (Qiagen, Dusseldorf, Germany) was used according to the 
protocol as written in the manufacturer‘s handbook. 
1- 560µl of prepared buffer AVL containing Carrier RNA was pipetted into a 1.5 ml micro 
centrifuge tube. 
2- 140µl of plasma was added, mixed by pulse vortexing for 15 seconds. 
3- Thereafter, the mixture was incubated at room temperature (RT) for 10 minutes. 
4- This was brief centrifuged to remove drops from the inside of the lid. 
5- 560µl of 96.100 % ethanol was added to the tubes, pulse.vortexed for 15 seconds and brief 
centrifuged. 
6- 630µl of the resulting solution was applied to QIAamp spin column in a 2ml collection 
tube without wetting the rim and centrifuged at 6000 x g; 8000 rpm for 1 minute. The spin 
column was placed into a clean 2ml collection tube and tube containing the filtrate was 
discarded. 
7- The QIAamp spin column was carefully opened and step 6 repeated. 
8- 500µl of buffer AWI was added and centrifugation performed at 6000 x g; 8000 rpm for 1 
minute. The column was placed into another clean 2ml collection tube and the filtrate was 
discarded. 
9- 500µl of buffer AW2 was added and centrifuged at full speed 20 000 x g; 14 000 rpm for 3 
minutes. Spin column was placed into a clean 2ml collection tube and centrifuged at full 
speed for 1 minute. 
10- The QIAamp spin column was placed into a clean 1.5ml micro centrifuge tube and 50µl 
of elution buffer AVE was added, incubated for 1 minute at room temperature and then 
centrifuged at 6000 x g; 8000 rpm for 1 minute.  
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Appendix B: Reverse transcription and cDNA synthesis 
The Superscript III Reverse Transcriptase (Invitrogen, Carlsbad, USA) was used in order to 
generate the cDNA through reverse transcription (components of the kit included: SSIII RT 
(200 U/μl), 5X First-Strand Buffer, 0.1 M DTT.) and 10 mM dNTP (Fermentas, Canada). 
This procedure was performed in a RNA.only clean room. The condensate from the previous 
step was spin down briefly, after the heat incubation steps.  
The following components were added into a 0.2 ml RNase-free tube for each cDNA 
synthesis as depicted in table B.1. 
Table B.1 Mastermix for the cDNA synthesis 
 
 
 
 
 
The tubes were placed in a thermo-cycler at 65°C for 3.5 minutes, removed and placed on ice 
for 1 minute. The following components were added from the kit to the mix from above 
according to the method depicted in table B.2. 
Table B.2 Mastermix for the cDNA synthesis 
 
 
 
 
 
The reaction mixture was then gently mixed and left to incubate at 50°C for 1 hour and then 
increased to 55°C for 1 hour. Inactivation of the SSIII RT was achieved by heating at 70°C 
for 15 min. To each tube, 1μl of RNase H was added and left to incubate at 37°C for 20 
minutes. 
Reagent Volume (µl)/tube 
Sterile water 8.75 
Oligodt primer (20µM) 1.25 
dNTP (10mM each) 5 
RNA template 50 
Final volume/tube 65 
Reagent from kit (SSIII 
RT) 
Volume 
(µl)/tube 
Stock from 
kit 
Final dilution 
5x Buffer 20 5x 1x 
DTT 5 100mM 5 
RNaseOUT 5 40U/µl 2 
SSIII RT 5 200U/µl 10 
Final volume/tube 35     
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Appendix C: First round amplification PCR reaction 
Serial dilutions of cDNA were performed to obtain 20% positivity as illustrated above in 
figure 2.1. PCR reaction was made for one-100 reactions (94 tests + 2 negative controls) as 
depicted in table C.1. 
Table C.1 Mastermix for the first round PCR 
 
Once the correct cDNA dilution was determined through the dilution, 1μl of diluted cDNA 
was added into each well containing the 19μl of the master mix and mixing was achieved by 
pipetting up and down. The plate was placed in a thermal cycler and run with following PCR 
parameters: 94ºC for 2 minutes followed by 35 PCR cycles of 94ºC for 15 sec - denaturation, 
55ºC for 30 sec - annealing, and 68ºC for 4 minutes – elongation with a final extension of 
68ºC for 15 minutes and held at 4°C upon completion. 
From all positive wells, the amplicons from the first round were stored at -20°C for future 
envelope cloning once the second round products were resolved, visualized and confirmed 
using gel electrophoresis. 
Appendix D: Second round (Nested) PCR reaction 
PCR reaction mixture was prepared for one-100 reactions (94 tests + 2 controls) as depicted 
in table D.1. 
Table D.1 Mastermix for the second round PCR 
Reagent Volume (µl)/tube X100 reactions (µl) 
DEPC H20 15 1500 
10X Buffer 2 200 
MgCl2 0.8 80 
Reagent Volume (µl)/tube X100 reactions (µl) 
DEPC H20 15 1500 
10X Buffer 2 200 
MgCl2 0.8 80 
dNTP 0.4 40 
Taq (Faststart Taq DNA polymerase) 0.4 40 
Primer: OFM19 (20µM) 0.2 20 
Primer: VIF1.10W (20µM) 0.2 20 
Final volume 19 1900 
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dNTP 0.4 40 
Taq (Faststart Taq DNA polymerase) 0.4 40 
Primer: ENVA (20µM) 0.2 20 
Primer: ENVN.7R10T17W19T (20µM) 0.2 20 
Final volume 19 1900 
 
19μl of the master mix was pipetted into each well of a 96-well plate and 1μl from each of the 
first round PCR reaction samples was added to the corresponding well of the nested PCR 
plate. Mixing was achieved by pipetting up and down. The 96 well plate was placed in a 
thermal cycler and PCR performed with the following cycling parameters: 94ºC for 2 minutes 
followed by 45 PCR cycles of 94ºC for 15 sec - denaturation, 55ºC for 30 sec - annealing, and 
68ºC for 4 minutes – elongation with a final extension of 68ºC for 15 minutes and held at 4°C 
upon completion. 
Appendix E: Table of primers used for PCR reactions 
Primer name Primer sequence HXB2 position 
VIF1.10W GGGTTTATTWCAGGGACAGCAGAG 4900→4923 
OFM19 GCACTCAAGGCAAGCTTTATTGAGGCTTA 519←547 
ENV.A GGCTTAGGCATCTCCTATGGCAGGAAGAA 5954→5982 
ENVN.7R10T17W19T CTGCCARTCTGGGAAGWATCCTTGTGT 9171←9145 
→ denotes a forward primer. ← denotes a reverse primer.  
 
Appendix F: Table of primers used to sequence HIV-1 subtype G Env 
gp160 
Primer name Primer sequence HXB2 position 
EF00 GGGAAAGAGCAGAAGACAGTGGCAATGA 6204→6228 
For14 TATGGGACCAAAGCCTAAAGCCATGTG 6556→6582 
For16 TTTAATTGTGGAGGAGAATTTTTCTA 7350→7375 
EF170 AGCAGGAAGCACTATGGG  7799→7816 
EF200 GGGATAACATGACCTGGATGCAGTGGG 8095→8118 
EF260  TTCAGCTACCACCGATTGAGAGACT 8523→8544 
EF175 TTTAGCATCTGATGCACAGAATAG 6378←6398 
Rev15 CTGCCATTTAACAGCAGTTGAGTTGA 6990←7015 
EF115 AGAAAAATTCTCCTCTACAATTAA 7351←7371 
EF55 GCCCCAGACCGTGAGTTGCAACATATG 7914←7940 
EF15 CTTGCTCTCCACCTTCTTCTTC 8424←8445 
Rev19 ACTTTTTGACCACTTGCCACCCAT  8797←8820 
 → denotes a forward primer. ← denotes a reverse primer.  
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Appendix G: Post PCR clean-up 
Before sending samples for sequencing, post PCR clean-up was performed to each PCR 
products using either DNA clean and concentrator kit (Zymo Research) or the Wizard SV Gel 
and PCR clean-up system (Promega) according to the protocol as written in the 
manufacturer‘s handbook. 
1- An equal volume of Membrane Binding Solution was added to the PCR amplification. 
2- The Minicolumn was inserted into 2 ml collection tube. 
3- Therefore, the prepared PCR product was transferred to the Minicolumn assembly and 
incubated at room temperature for 1 minute. 
4- This was centrifuged at 16 000 x g for 1 minute. The flow through was discarded and 
the Minicolumn was reinserted into collection tube. 
5- 700µl of membrane wash solution (containing ethanol) was added into Minicolumn 
and centrifuged at16 000 x g for 1 minute. The flow through was discarded and the 
Minicolumn was reinserted into collection tube. 
6- The step 5 was repeated with 500µl of membrane wash solution and centrifuged at16 
000 x g for 5 minutes. 
7- The flow through was discarded and the column assembly was recentrifuged for 1 
minute with microcentrifuge lid open (or off) to allow evaporation of any residual 
ethanol. 
8- The minicolumn was transferred to a clean 1.5 ml microcentrifuge tube, and 50µl of 
nuclease.free water was added to the minicolumn, incubated for 1 minute at room 
temperature and then centrifuged at 16000 x g for 1 minute.  
9- The DNA was stored at 4ºC or -20ºC. 
Appendix H: Directional cloning using pcDNA3.1 Expression Vector 
PCR fragments, generated using EnvA-rx and ENVN.7R10T17W19T primers, were cloned 
into the pCDNA 3.1/V5.His TOPO vector (Invitrogen, Carlsbad, USA) into One Shot 
TOP10 Chemically-Competent cells (Invitrogen, Carlsbad, USA) and bacterial colonies 
were screened by PCR for insertion and correct orientation using T7 and BGH (supplied in 
the pcDNA 3.1/V5.His TOPO expression kit).  
Cloning procedure 
Appendices Page 146 
Sterile tubes were chilled on ice in order to be adequately chilled for downstream cloning. 
The cloning reaction mastermix consisted of the following as depicted in table H.1. 
Table H.1 Mastermix for ligation of PCR product into pcDNA3.1 Expression Vector 
Reagent Volume (µl)/tube 
Sterile water add to a final volume of 5 
Salt 1 
pcDNA3.1/V5.His TOPO Vector 1 
DNA 0.5 to 4 
Final volume/tube 6 
 
This reaction was mixed gently and incubated for 5 min at room temperature. Tubes were 
placed on ice for 10 minutes and One Shot TOP10 Chemically-Competent cells were thawed 
on ice for 10 minutes. Thereafter, 2µl of the cloning reaction above was added into the tubes 
containing One Shot TOP10 Chemically-Competent cells and left to incubate for 30 minutes. 
Cells were then heat shocked for 30 seconds at 42°C in a water-bath without shaking. The 
tubes containing the cells were then placed on ice for 2 minutes and to each tube of cells, 250 
μl of SOC medium (from the pcDNA 3.1 kit) was added. The tubes were then shaken for 1 
hour at 220 rpm at 32°C in a shaking incubator. Hundred.150μl of bacteria cells were then 
spread on Luria Bertani (LB) agar plates containing 100µg/ml Ampicillin (Sigma) and 
incubated overnight at 32°C. To screen for the presence of inserted env gene, 10 colonies 
were picked randomly for each sample and added into 5 ml of LB broth medium with 100 
µg/ml ampicillin in an individual 14 ml polypropylene round-bottom tube (BD Falcon) and 
incubated in a shaking incubator at 200 rpm overnight at 32°C. Bacteria were lysed and 
minipreps of plasmid DNA were prepared using GeneJet plasmid Miniprep Kit (Thermo 
Scientific) according to the manufacturer’s instructions. A PCR was therefore set up at a final 
volume of 20 µl to identify the plasmid containing the insert using 1 µl of plasmid DNA (100 
ng/µl), T7 (5’-TAATACGACTCACTATAGGG-3’), and BGH 
(5’.TAGAAGGCACAGTCGAGG.3’), both primers found on the vector and provided with 
the kit. The PCR conditions were as follows: 94ºC for 5 minutes followed by  35 PCR cycles 
of 94ºC for 30 sec - denaturation, 51ºC for 30 sec - annealing, and 72ºC for 3 minutes – 
elongation with a final extension of  72ºC for 10 minutes  and  held at 4°C upon completion. 
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Table H.2 Mastermix for colony PCR 
Reagent Volume (µl)/tube 
DEPC H20 9.96 
10X Buffer 1.25 
MgCl2 1 
dNTP 0.2 
Primer: T7 0.013 
Primer: BGH 0.013 
Faststart Taq DNA polymerase 0.038 
Final volume 12.5 
 
PCR products were run on a 0.8% Agarose gel electrophoresis and a visualization of a band at 
3kb was considered as positive clone. To confirm the presence of the insert in the plasmid, a 
restriction digestion with BamH1 and Xho1 (New England Biolabs) was also performed as 
depicted in table H.3. Plasmids with fragments of the correct size after restriction digestion 
were sequenced to conﬁrm sequence identity to the original env amplicon. A bacterial stock 
of each positive clone was made and kept at .80°C and the plasmid DNA was kept at -20°C 
until further analysis. 
Table H.3 Restriction enzyme digestion using BanH1 and Xho1 
Reagent Volume (µl)/tube 
Sterile water 16 
Xho1(New England Biolabs, Ipswich, USA) 1 
BamH1(New England Biolabs, Ipswich, USA) 1 
DNA  
10X Fastdigest Buffer  2 
Final volume 30 
 
 
 
